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1.1 Introduction
*
 
The de novo design of peptides and peptidomimetics with a defined conformation is an 
important question in biology and chemistry.1,2 To provide answers, general principles 
that guide the design must be developed. In case of proteins and peptides their 
biological response relays on the interaction of a part of the accessible three-
dimensional surface with a complimentary surface of the binding partner.3,4,5 The 
peptide backbone serves as a scaffold for the presentation of the amino acid side chain 
functional groups involved in the interaction, but the oligoamide backbone can also 
participate. The various functional groups, if properly arranged in space, can perform an 
enormous number of chemical functions which are the basis of all biological processes 
and life. In the case of de novo design of peptide and protein backbone conformations, 
structural constraints are used to limit their flexibility. One very successful approach, 
among others,6 is the introduction of two substitutents at the α position of an α-amino 
acid. 
Cα-Tetrasubstituted α-amino acids are non-proteinogenic modified amino acids, in 
which the hydrogen atom at the α-position of α-amino acids is replaced by an alkyl or 
aryl substituent. Cα-Tetrasubstituted α-amino acids play an important role in the de novo 
design of peptides and peptidomimetics with enhanced properties, because they possess 
a stereochemically stable quaternary carbon center which results, after incorporation 
into peptides, in a significant conformational bias. The orientation of the aromatic ring 
of an amino acid residue can also be restricted by these modifications. Another 
advantage of Cα-tetrasubstitution is the enhanced lipophilicity of the peptide molecule, 
which may be of importance to cross the blood-brain barrier or other membranes.  
A larger peptide can show several different equilibrium conformations in solution, 
which differ in their biological activity. To lock the peptide in one specific 
conformation, it is necessary to bias or constrain the peptide to prefer a particular 
backbone conformation. Sterically constrained Cα-tetrasubstituted α-amino acid can 
achieve this task.  
A number of notable successes have been reported, where small peptide fragments were 
used as antigens for eliciting immune responses to protein epitopes. However, the 
overall approach suffers from the fact that the peptide antigens are conformationally 
                                                 
*
 This introduction is part of a published review, see: Maity, P.; König, B. Pept. Sci. 2008, 
90, 8-27.   
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flexible and cause a wider range of antibodies to be raised against the peptide. This 
leads to an inefficient immune response. Again, conformationally constrained peptide 
fragments can help to overcome these drawbacks. Another use of chiral Cα -
tetrasubstituted α-amino acids is their application as valuable building blocks in organic 
synthesis and as core structure of catalysts for asymmetric bond formation reactions.  
Therefore, numerous attempts to the synthesis of Cα-tetrasubstituted amino acids have 
been performed, many of which involve an optical resolution of the racemic form.7 
Recent efforts mainly focus on asymmetric transformations based on the alkylation of 
enolates from bislactones,8 oxazinones,9 imidazolidinones10 and other procedures.11 
These methods have been documented by Seebach12 and Cativiela13 in their excellent 
reviews. 
In cyclic Cα -tetrasubstituted α-amino acids (Figure 1), to which the focus of this 
introduction is limited, both α-substituents are covalently connected. The ring 
introduces steric constraints into the amino acid residue and changes in the chemical 
reactivity of the pendant functional groups, e.g., a reduced rate of hydrolysis of a 
peptide or an ester group. 
 
X
H2N CO2H
n
n = 1- 5
X = CH2, NH, O, S
 
 
Figure 1. General representation of cyclic Cα-tetrasubstituted α-amino acids. 
 
In this introduction we focus exclusively on the synthesis and use of Cα-tetrasubstituted 
cyclic α-amino acids as structure determining and inducing elements. The survey will 
cover the recent synthetic approaches to prepare such amino acids. Cativiela´s13 earlier 
review covers acyclic and cyclic Cα-tetrasubstituted α-amino acids, but in the past seven 
years several new synthetic routes have been reported. Toniolo et al.14 discussed the 
effect of Cα-tetrasubstituted cyclic α-amino acids within their paper on conformation 
control by the Thorpe-Ingold effect. We cover in this introduction recent examples of 
conformationally stable turn structures of short peptides induced by Cα-tetrasubstituted 
cyclic α-amino acids and discuss typical examples of the ring size of the Cα-
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tetrasubstituted cyclic α-amino acids beginning with three-membered rings, continuing 
with four, five, six membered rings and finally ring structures larger than six-membered. 
 
1.2. Cyclopropane amino acids15 
1.2.1. Synthesis 
The cyclopropane motif is a valuable structure in enantioselective synthesis16 with 
representation in more than 4000 natural products and 100 therapeutic agents. 
Cyclopropane amino acids are found to inhibit amino acid processing enzymes of 
medical interest, by various mechanisms. They also have potential as conformation 
restriction moieties in bioactive peptides causing the stabilization of a peptide towards 
enzyme cleavage. The presence of a strained electrophilic cyclopropane ring may lead 
to covalent attachment of the peptide to an enzyme active site leading to enzyme 
inhibition. If conformational effects of the cyclopropane amino acid on a peptide are 
understood, active site mapping becomes possible. 
Each ring mono-substituted cyclopropane α-amino acids analog exists in diastereomeric 
E and Z-forms (Figure 2) in which the characteristic functionality at the β-carbon atom 
of the specific amino acid is cis to the carboxyl or to the amino function, respectively. 
 
NH2
COOH
R
H
NH2
COOH
H
R
Z-isomer E-isomer
 
 
Figure 2. Isomers of monosubstituted cyclopropane α-amino acids. 
 
Cyclopropane amino acids were first isolated from cider apples and perry pears by 
Burroughs17 and identified as an intermediate in the biosynthesis of ethylene.18 During 
the past two decades several new synthetic approaches for the synthesis of cyclopropane 
amino acids have been reported.13,14 One of the earliest and most straightforward 
synthetic methods used the alkylation of a glycine derivative or its congener with 
ethylene dibromide or its equivalent.19 Scheme 1 depicts the first preparation of a 
cyclopropane amino acid. 
Section 1. Introduction                                                                                                  4 
 
R
CO2R'
R
CO2R'
NH2
CO2R'
R = NC, N=CR2
R' = Me, Et
(i) (ii)
(i) BrCH2CH2Br/Base
(ii) HCl/H2O
 
 
Scheme 1. An early preparation of cyclopropane amino acids. 
 
The first approach for an asymmetric synthesis of cyclopropane amino acids was 
described by Pirrung20 in 1986 that involves the synthesis of both enantiomers of allo-
norcoronamic acid (cis-methyl-Acc). In the following review we focus on cyclopropane 
amino acids, which were used to induce turn structures when introduced in short 
peptides and refer the interested reader for the recent asymmetric synthesis of other 
cyclopropane amino acids to the review of Cativiela.13 
Pirrung21 and Burgess 22 described the diastereoselective synthesis of homo analogues 
of serine, methionine, leucine and others (Scheme 2) starting from enantiomerically 
pure (R/S)-epichlorohydrine or (R/S)-glycidyl triflate as the 1,2-dielectrophile and 
different malonate esters in the presence of sodium hydride.  
 
O R
CO2R'
CO2R'
Base O
H CO2R'
O
H CO2R'
NH2
H CO2R'
O O
3
2
R''
NH2
CO2R'H
R''
4
5
R = Cl
       OTf
R' = Me, t-Bu
R'' = OH, CN, OBn, SMe, NH2, N3,
           CONH2
1
 
 
Scheme 2. Synthesis of cyclopropane amino esters 4 and 5.  
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The resulting lactones (2, 3) were treated with methanolic ammonia to yield amides, 
which were converted by subsequent reactions into the desired cyclopropane amino 
esters 4 and 5. 
Enantiomerically pure D- and L-valine23 are useful starting materials for the synthesis of 
all four stereoisomers of 1-amino-2-isopropylcyclopropanecarboxylic acid. A cyclic 
sulphate (6), prepared from L-valine in a four-step procedure, reacts with dimethyl 
malonate or diethyl gluconate, to afford the key intermediates for the synthesis of (R, S) 
- and (S, S)- leucine surrogates followed by standard transformations (Scheme 3). 
Enantiomers of the target structures can be obtained starting from D-valine. 
 
O O
S
O O
CO2Me
CO2Me
NaH
CO2Et
CO2Et
NaH
CO2Me
CO2Me
CO2Et
CO2Et
7
9
CO2Me
NH2
8
NH2
CO2Et
10
6
 
 
Scheme 3 Synthesis of stereoisomers of 1-amino -2-isopropylcyclopropanecarboxylic 
acid esters 8 and 10. 
 
The cyclic sulphate (12) obtained from (1R, 2R)-1,2-diphenyl-1,2-ethanediol (11) reacts 
with diethylglutaconate, which can be conveniently elaborated to afford (1S, 2S)-1-
amino-2, 3-diphenylcyclopropanecarboxylic acid 13 (Scheme 4).24 
 
Ph
Ph
OH
HO
i) SOCl2
ii) RuCl3/NaIO4
S
O
O
Ph
Ph
O
O
Ph
H CO2H
NH2
H Ph
12 1311
 
Scheme 4. Synthesis of 1-amino-2, 3-diphenylcyclopropanecarboxylic acid 13. 
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Cyclic chiral glycine equivalents usually give rise to better selectivities in asymmetric 
reactions. Bis-lactim ethers described by Schöllkopf are well known chiral intermediates 
for the asymmetric synthesis of amino acids. Bis–lactim ethers derived from L-valine 
and glycine or L-tert-leucine and glycine have been used as starting materials in the 
synthesis of (1R, 2R)-allo-coronamic acid (16) (Scheme 5). 
 
N
N OCH3
H3CO H
R
N
N OCH3
H3CO H
R
CH2Cl
ClH2C
n-BuLi
ClH2C H
NH2
CO2H
Et
H
14 15
16
R = i-Pr, i-Bu
 
Scheme 5. Synthesis of (1R, 2R)-allo-coronamic acid 16. 
 
Williams et al.25 described the first asymmetric synthesis of 2-substituted 1-amino 
cyclopropane carboxylic acids using double bond cyclopropanation of a chiral 
didehydroamino acid derivative (17). The intermediates (18) were then transformed into 
the desired 2-substituted 1-amino cyclopropane carboxylic acids 19 (Scheme 6). 
N
Boc
O
O
R
H
Ph
Ph
S
O
NEt2
CH2Ph
N
Boc
O
O
R
H
Ph
Ph
NH2
CO2H
R
H
191817
R = CH3 (de, 100%), Et (de, 100%),
n-Pr (de, 100%), Ph (de, 100%)
 
Scheme 6. Synthesis of 2-substituted 1-amino cyclopropanecarboxylic acids 19. 
 
A detailed study using rhodium (II) N-(p-tert-butylbenzenesulfonyl) prolinate as a 
catalyst determined the key factors that control the enantioselectivity. The study 
concluded that the level of asymmetric induction is strongly enhanced by the use of non-
polar solvents, while increasing the size of the ester on the carbenoid results in a 
significant drop in enantioselectivity. Even better selectivity is observed when rhodium 
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(II) N-(p-dodecylbenzene sulfonyl) prolinate is used as a catalyst at -78ºC. The product 
21 was converted into the desired amino acid 22 in subsequent steps (Scheme 7). 
 
N2
CO2R
Ph
20
N
O Rh
RhO
H
S O
O
t-Bu
4
Ph
Ph
CO2RPh
Ph NH2
CO2HPh
Ph
21 22
Ph
 
 
Scheme 7. Synthesis of 2-phenyl 1-amino cyclopropanecarboxylic acid 22 
 
1.2.2. Induction of turn ⁄ helical structures in short peptides. 
Unlike α- or β-methyl amino acids,26 2, 3-methano amino acids have rigidly defined χ1 
orientation. Consequently, 2, 3-methano amino acids should have marked effects on 
secondary structures. The solid state structures of some of the derivatives have been 
deduced via crystallography.27  
Burgess et al.28,29 reported methionine analogs of cyclopropane amino acids (methano-
methionine) which induce a γ-turn structure in solution when incorporated into a short 
peptide. Tetrapeptide H-Phe-(2S, 3S)-cyclo-Met-Arg-Phe-NH2 was prepared by using a 
solid phase approach. Different NMR studies confirmed that the tetrapeptide showed γ-
turn possessing i←i+2 (C=O…H-N) intramolecular hydrogen bond (Figure 3). 
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Figure 3. Truncated representation of the γ-turn region centered at cyclo-Met and the 
close proximity of the cyclopropane ring and the aromatic ring. The contact at 2.27 Å 
corresponds to an H-bond between the Arg NH and the Phe CO. 
 
Jiménez et al.30 have investigated the properties of Pro-cyclopropyl-2, 3-diphenyl α-
amino acid (c3diPhe) dipeptides. Coupling of N-terminally protected L-proline (23) with 
the racemic c3diPhe (24) yields two diastereomers 25 and 26 (Scheme 8). One of the 
diastereomers forms a β-turn (type II), which was confirmed by X-ray diffraction 
structure analysis (Figure 4). 
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N COOH
O
t-BuO Ph NH2
CONHi-Pr
Ph
+
N
O
t-Bu
O
N
O
NHi-Pr
Ph
Ph
H
N
O
t-Bu
O
N
O
NHi-Pr
H
Ph
Ph
23 24
25 26
N
NH
Ot-Bu
O
O
N
HH
Ph
Ph
CH3
H3C
25
 
 
Scheme 8. Coupling of 24 with N-substituted L-proline. 
 
 
 
Figure 4. X-ray diffraction structure of compound 25 (β-II-turn). Most of the hydrogen 
atoms are omitted for clarity. The intramolecular hydrogen bond is represented as 
dashed line. 
 
In 2005 Jiménez et al. reported31 that different substituents in cyclopropane α-amino 
acids give different turn structures if incorporated into a short peptide. Racemic N’-
methyl-2, 2-diphenyl-1-aminocyclopropane-carboxamide (H-c3Dip-NHMe) was 
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coupled to N-tert-butoxycarbonyl-L-proline by the mixed anhydride method. The two 
column separable diastereomers showed a β-turn type II structure and two consecutive 
γ-turns, respectively, in the solid state. The report described the first observation of two 
consecutive γ-turns (Figure 5). 
 
 
 
 
 
Figure 5. a) Top: X-ray diffraction structure of Piv-L-Pro-L-c3Dip-NHMe 
accommodating a β-II turn. The intramolecular i←i+3 hydrogen bond is indicated by a 
dashed line. Only the proline Cα and amide hydrogen atoms are shown, b) Bottom: X-
ray diffraction structure of Ac-L-Pro-D-c3Dip-NHMe exhibiting two consecutive γ turns, 
each stabilized by an intramolecular i←1+2 hydrogen bond (dashed lines). Only the 
proline Cα and amide hydrogen atoms are shown. 
 
Toniolo et al.32 used c3diPhe to investigate the relationship between the α-amino acid 
side- chain chirality and the screw sense of its turn or helical conformations in the 
absence of any potentially overlapping influence that arises from the asymmetric α-
carbon. Starting from Boc-(2R, 3R) c3diPhe-OH33 (27) they synthesized a series of 
terminally protected (2R, 3R) c3diPhe homochiral homopeptides up to the tetramer (28) 
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level in 61-80% yield by activating the amino acid carboxyl function with HOAt 
/HATU34 in dry DCM in the presence of DIPEA (Scheme 9). The compounds are long 
enough to fold into multiple β-turn conformations and even into short 310-helices.  
BuOt
H
N
N
HO
O
NHiPr
O
Ph
Ph
Ph
Ph
BuOt
H
N
O
O
Ph
Ph
OH
BuOt
H
N
O
O
Ph
Ph
NHiPr
n
n = 2-4
27 28
29
 
Scheme 9. Synthesis of helical peptides 28 and 29. 
 
The heterochiral dipeptide 29 was reported from the same groups,35 with excellent yield 
after 4 days of reaction between Boc-(2S, 3S) c3diPhe-OH and H-(2R, 3R) c3diPhe-
NHiPr using the same coupling reagents. The single crystal structure shows the 
molecule folded in a type-I’ β-turn conformation, stabilized by a weak intramolecular 
(Boc)C=O…H-N(NHiPr) hydrogen bond, which closes a 10-membered atom ring 
(Figure 6). But in the crystal state the self-assembly of compound 29 through 
intermolecular hydrogen bonds leads to the formation of a supramolecular helix of large 
diameter (18 Å), internally decorated with phenyl rings. As a result, a hollow helical 
channel large enough to accommodate guest molecules was observed. This implies that 
compound 29 incorporates a highly restricted cyclopropane phenyalanine analogue 
(c3diPhe) with remarkable conformational properties. 
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Figure 6. X-ray diffraction structure of Boc-[(2R, 3R) c3diPhe] 2-NHiPr (29). The 
intramolecular hydrogen bond is represented by a dashed line. 
 
Earlier work investigated the structures of homo-oligomers of Ac3c. For a detailed 
account we refer to ref. 14. The results indicated the propensity of tri- and tetrapeptides 
of this kind to fold into type I β-bends and distorted 310 helices, respectively.36,37,38 This 
is in contrast to homopeptides of 1-aminoisobutyric acid (Aib), 1-aminocyclopentane-
carboxylic acid (Ac5c) or 1-aminocyclohexanecarboxylic acid (Ac6c) of similar length, 
for which regular type III β-bends and 310 helices are found. 
 
1.3. 1-Aminocyclobutanecarboxylic acids 
1.3.1. Synthesis 
Although the chemistry of small ring systems is well studied,39 α-amino acids from the 
cyclobutane series have received only little attention. Recent use of 1-aminocyclobutane 
carboxylic acids in the field of medicinal chemistry is an exception (Figure 7).  
 
HO2C
NH2
HO2C
30
N
H
CO2H
31
HO2C
NH2
HOH2C
32
HO2C
NH2
(HO)2OP
33
 
 
Figure 7. Structures of typical 2, 4-methano α-amino acids (30-33). 
 
In 1980 Bell et al.40 reported the first isolation of 2, 4-methano amino acids (2, 4-
MAAs), namely cis -2, 4-methanoglutamic acid (2, 4-MGlu, 30) and 2, 4-
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methanoproline (2, 4-MPro, 31) from the seeds of Ateleia Herbert smithii. Later, cis-1-
amino-3-hydroxymethanocyclobutane carboxylic acid (32) was isolated by Austin et al. 
from the same source.41 In 1990 trans-2, 4-methanoglutamic acid was described as a 
highly potent NMDA agonist,42 whereas other 1, 3-disubstituted cyclobutane derived α-
amino acids, such as 33, act as NMDA antagonists and anticonvulsive drugs,43 
respectively. Furthermore, incorporation of various 2, 4-MAAs into bioactive peptides 
increases their stability towards enzyme degradation and altered their biological 
properties remarkably.44 The first synthetic approach was reported by Gaoni et al.,45 
providing a wide range of achiral or racemic 1-aminocyclobutane carboxylic acids and 
their corresponding 1, 3-dicarboxylic acids. 
In 2003, Frahm et al.46 and Fadel et al.47 reported the synthesis of β-alkylated 
cyclobutane amino acids using 2-substituted cyclobutanones as starting material (34). 
The racemic 2-substituted cyclobutanones 34 were prepared from cyclopropyl aldehyde 
by a modified enlargement method48 or from 1, 3-dibromobutane and 
tosylmethylisocyanide (TosMiC)49.  Under acidic conditions, the ketones 34 were 
condensed with the chiral auxiliary (S) - 1-phenylethylamine or derivatives 35 to give 
corresponding iminium mixtures, which by in situ addition of sodium cyanide to the 
C=N bond would predominantly afford one diastereomer of the four possible α-
aminonitrile isomers. In subsequent steps (hydrolysis and hydrogenolysis) the α-
aminonitrile isomers were converted into the desired amino acids (Scheme 10). 
 
 
Scheme 10. Synthesis of cyclobutane α-amino acids 37 and 39. 
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In 2006 Hazelard et al.50 reported the preparation of an enantiopure 1-amino-2-hydroxy-
cyclobutane carboxylic acid (serine analogue, c4Ser)-in four steps, starting from racemic 
cyclobutanones and a chiral benzylic amine as chiral auxiliary. 
An easy and efficient one-pot reaction from readily available 2-benzyloxycyclobutanone 
(41) gave a kinetic or thermodynamic nitrile with good selectivity by means of an 
asymmetric Strecker synthesis. After separation, the major trans-amino nitrile 
underwent basic hydrolysis and hydrogenolysis, followed by acidic hydrolysis, to give 
optically active (1R, 2R)-1-amino-2-hydroxycyclobutanecarboxylic acid (48), serine 
derivatives (Scheme 11). 
 
OH
O
O
OBn
O
(S)-40 (S)-41
OBn
O
rac. -41
H2N Ph
2 eq. AcOH
OBn
N
R*
H
OBn
N
R*
H
+
OBn
44
CN
N
H Ph
OBn
HN
CN Ph
45
+
OBn
HN
CN Ph
46
OBn
47
CN
N
H Ph
+
42 43
OH
48
NH2
COOH
 
 
Scheme 11. Stereoselective synthesis of 1-amino-2-hydroxycyclobutane carboxylic 
acid, an analogue of serine (48). 
 
The absolute configuration was established by X-ray diffraction structure analysis of the 
corresponding cis-amino nitrile, 44 (Figure 8) 
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Figure 8. X-ray diffraction structure of compound 44. 
 
Wanner and co workers 51 reported the synthesis of all four stereoisomers of [(1S, 2S)-, 
(1R, 2R)-, (1S, 2R)-, (1R, 2S)-] of 1-amino-2 hydroxymethyl-cyclobutanecarboxylic 
acid. The synthesis was based on the chiral glycine equivalent 49, which is available in 
both enantiomeric forms (Scheme 12). 
 
X
N
O
O
MeO
N
O
O
MeO
HsBuLi, -80oC
OTf
69%, >95% de
49 50
OsO4(Cat.),
O-NMe3, rt, 20h, 76%
N
O
O
MeO
H
51
N
O
O
MeO
H
52
X
Y Y
a X = OH, Y = OH 1 : 1
b X = OH, Y = OSiMe2tBu 1 : 1
c X = I, Y = OSiMe2tBu 1 : 1
N
O
O
MeO
53
N
O
O
MeO
54
OSiMe2tBu OSiMe2tBu
tBu-P4, -80oC
2h, 72%
H2N
HO
O
55
H2N
HO
O
56
OH OH
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Scheme 12. Synthesis of 1-amino-2-(hydroxymethyl)-cyclobutanecarboxylic acids 55 
and 56.  
The key step involves the cyclization of silyl-protected iodohydrines 51c and 52c to the 
corresponding spiro derivatives 53 and 54 with the aid of the phosphazenic base tBu-P4. 
The final compounds (55 and 56) were prepared in subsequent steps and displayed a 
moderate potency as ligands for the glycine binding site of the NMDA receptor. 
In 2003 Avenoza et al.52 described a thermal [2+2] cycloaddition involving 2-
acylaminoacrylates and ketene diethylacetal (Scheme 13). The reaction gave a new 
substituted cyclobutane skeleton that can be transformed into protected β-
hydroxycyclobutane-α-amino acids. An asymmetric version of this cycloaddition was 
reported using sterically hindered aluminium aryloxides or methylaluminoxane as Lewis 
acids. 
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OEt
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MeO2C
CO2Me
NHAc
OEt O
OMe
NHAc
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OEt
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NHAc
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57
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Scheme 13. Synthesis of protected β-hydroxycyclobutane-α-amino acids. 
 
The 3D-structure of compound 59 was unambiguously determined by X-ray diffraction 
(Figure 9). 
 
Figure 9. X-ray diffraction structure of compound 59.  
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1.3.2. Induction of turn ⁄helical structures in short peptides 
Toniolo et al.14,53 reported a series of homo peptides Z-(Ac4c)n-OtBu, with n = 3 and 4. 
Spectroscopic and X-ray diffraction analyses revealed that Ac4c, similar as Ac7c, Ac9c 
and Ac12c residues pass a remarkable conformational restriction to the peptide 
backbone. Figure 10 shows the structure of a tetramer Z-(Ac4c)4-OtBu in the solid state 
adopting a helical conformation. Interestingly, the largely preferred conformations of 
regular type III/III´ β-bends and 310/α-helices for 1-amino-1-cycloalkanecarboxylic 
acids (Acnc; n = 4 – 12) with cycles larger than cyclopropyl, closely resemble those of 
1-amino-isobutyric acid (Aib). For a more detailed discussion we refer to ref. 14. 
 
 
 
Figure 10 X-ray diffraction structure of Z-(Ac4c)4-OtBu. The two intramolecular H 
bonds are represented by dashed lines. 
 
1.4. 1-Aminocyclopentanecarboxylic acids 
1.4.1. Synthesis 
The unnatural α-amino acid 1-amino-cyclopentane carboxylic acid (ACPC) has been 
reported to inhibit the growth of Novikoff rat hepatoma,54 Walker rat carcinoma 256,55 
sarcoma 180 and carcinoma 755.56 Berlinguet et al.57 reported that this amino acid does 
not undergo any metabolic change and Sarkar and co workers58 established the 
mechanism of its action. 
Strecker or Bucherer-Bergs synthesis is the most frequently used method to prepare 1-
aminocyclopentane carboxylic acids starting from the cyclopropane ring. The four 
stereoisomers of 1-aminocyclopentane-1,3-dicarboxylic acid (ACPD), which are 
conformationally constrained analogues of glutamate, have been found to act as 
excitatory amino acids and were obtained from 3-oxocyclopentane carboxylic acid.59 A 
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mixture of the (1S, 2S) and (1R, 2R) stereoisomers of ACPD was obtained from the (R)-
enantiomer after Strecker-type formation of a hydantoin followed by hydrolysis. 
Fractional crystallization of the mixture allows the isolation of both compounds in 
diastereomerically pure form. (Scheme 14). 
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Scheme 14. Synthesis of two stereoisomers of 1-aminocyclopentane-1, 3-dicarboxylic 
acid (ACPD) (63 and 64). 
 
Asymmetric synthesis of 4-amino-4-carboxy-2-phosphonomethylpyrrolidines 71 and 
72, which can be viewed as novel conformationally restricted analogues of 2-amino-5-
phosphonopentanoic acid (AP 5) incorporated into the pyrrolidine ring, was achieved 
from trans-4-hydroxy-L-proline as a homochiral starting material. The hydroxy group 
was converted to the corresponding ketone by Swern oxidation60 to afford compound 
68. The Bucherer-Bergs reaction of 68 with ammonium carbonate and potassium 
cyanide in 60% aqueous ethanol gave the spirohydantoin (2S, 4R)-69 and (2S, 4S)-70 as 
pure diastereomers in the ratio of 84:16, respectively, in 75% yield. Finally, hydrolysis 
of 69 and 70 with 6 N HCl followed by hydrogenolysis gave the desired products 71 and 
72 after purification on ion exchange column (Scheme 15).  
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Scheme 15. Synthesis of 4-amino-4-carboxy-2-phosphonomethylpyrrolidines 71 & 72. 
 
1-Aminoindan-1, 5-dicarboxylic acid (AIDA)61 and 1-amino -5-phosphenoindan-1-
carboxylic acid (APICA)62are two subtype-selective antagonists for metabolic glutamate 
receptors (mGluRs)63. Recently, both racemic AIDA and APICA have become useful 
pharmaceutical tools in seeking the roles of mGluRs in physiological processes.  Ma et 
al.64 reported a new strategy to synthesize these compounds (Scheme 16). (R)- 
Phenylglycine (73) was protected by methyl chloroformate to afford the carbamate, 
which was reacted with benzaldehyde dimethyl acetal in methylene chloride in the 
presence of boron trifluoride etherate to produce cis-oxazolidinone (74)65. Alkylation of 
74 with tert-butyl bromoacetate provides compound 75 in 80% yields with more than 
97% diastereoselectivity. The oxazolidinone ring of 75 was opened by treatment with 
LiOH in methanol to give diester 76 in 95% yields. Selective deprotection of the tert-
butyl group with HCl in DCM yielded 77. Compound 77 was then cyclized by using 
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Friedel-Craft acylation in 92%. The subsequent reduction of the ketone 78 gave 
compound 79, which was further transformed to amino acid 80. 
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Scheme 16. Synthesis of 1-aminoindan-1-carboxylic acid 80. 
 
In situ generated isobenzofuran has been frequently used as reactive intermediate for the 
synthesis of 9-oxabenzonorbornenes.66 To synthesize the reactive intermediates, Tamaki 
and co workers67 examined the reaction of 1-methoxyphthalane (81) with methyl N-
acetyl-α, β-dehydroalaninate (82), which occurred smoothly in refluxing benzene in the 
presence of a catalytic amount of AcOH to afford the adducts 83 and 84 in good yield 
and in ratio of 7:1 (Scheme 17). 
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Scheme 17. Synthesis of compounds 83 and 84. 
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1.4.2. Induction of turn ⁄ helical structures in short peptides  
We have recently synthesized tetrahydrofuran Cα-tetrasubstituted α-amino acids 
(TAA),68 starting from L-methionine (85) (Scheme 18). Compound 87 reacted with 
aromatic aldehydes in the presence of KOH to afford compound 88. The reaction is 
highly diastereoselective (>97:3; trans : cis), but yields racemic products. Compounds 
89 were obtained upon hydrolysis of compounds 88 by 6M HCl. The racemic amino 
acid 90 was coupled with compound 91 under standard peptide coupling conditions to 
afford dipeptide 92 and its other diastereomer. The X-ray diffraction analysis of the 
compound 92 showed a type I β-turn structure with a strong intramolecular hydrogen 
bond (Figure 11)  
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Scheme 18. Synthesis of tetrahydrofuran Cα-tetrasubstituted amino acids (TAA). 
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Figure 11. X-ray diffraction structure of 92 shows a type I β-turn form with a 10-atom 
intramolecular hydrogen bond (showed by dashed line). 
  
Among proteinogenic L-α-amino acids, only isoleucine and threonine possess an 
additional chiral center in their side chain. However, it was not clear how the chirality of 
the side chain influences the secondary structure of peptides.69 Addressing this issue, 
Tanaka et al.70 reported in 2004 how the asymmetric center of the α-amino acid side 
chain alone controls the screw sense of oligopeptide helices consisting only of amino 
acids without a chiral center at the α-carbon. They synthesized a chiral, cyclic, Cα-
tetrasubstituted [(S, S)-Ac5c dOM] α-amino acid (96), in which the α-carbon has no 
asymmetric center, but the side chain β-carbons do. (S, S) - Ac5c dOM homopeptides 
therefore do not possess asymmetric centers along the backbone of the peptide, but they 
have asymmetric centers in the side-chain cyclopentane rings. Thus, the screw sence of 
the secondary structure is affected only by the side-chain chiral centers.71 The synthesis 
starts from optically active compound 93 (Scheme 19). The preferred secondary 
structure of the homopeptides in CDCl3 solution was first studied by FT-IR absorption 
and 1H NMR spectroscopy. The 3D-structures of the terminally protected octapeptide 
99c (Figure 12) and hexapeptide 99b were determined by X-ray diffraction. In the 
asymmetric unit of 99b one left-handed helical structure (mean value φ = 60.9º, ψ = 
46.8º), (which is not a 310-helix, but an α-helix) exists along with three water molecules. 
Five intramolecular hydrogen bonds stabilize the α-helical structure. 
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Scheme 19. Synthesis of (S,S)-Ac5cdOM and its homopeptides. Reagents and conditions: 
a) dimethyl malonate, KOtBu; b) 1. NaOH, 2. DPPA, 3. BnOH; c) NaOH; d) 1. Pd/C, 
H2, 2. EDC, HOBt, 96, MeCN, rt; e) 1. Pd/C, H2, 2. EDC, HOBt, 98, MeCN, rt. 
 
 
 
 
 
Figure 12. X-ray diffraction structure of compound 99b viewed perpendicular to the 
helical axis (top); ORTEP drawing viewed along the α-helical axis (α-helical wheel) 
(bottom). 
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Extending the work, the same group reported72 Cα-tetrasubstituted [(S, S)-Ac5c dOM] α-
amino acids having chirality only in the cyclic side chain. The synthesis started from (S, 
S)-cyclohex-4-ene-1,2-dicarboxylic acid (100) and is summarized in Scheme 20.73 
In the crystal state the asymmetric unit of 109b contains four independent molecules 
along with two ethanol molecules (Figure 13). Two molecules form a right-handed 310-
helix and the other two a left-handed 310-helix. 
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Scheme 20. Synthesis of Cα-tetrasubstituted α-amino acids having chirality only in the 
cyclic side chain. Reagents: (a) 1. LiAlH4; 2. I2, PPh3; (b) 1. NaH, CNCH2CO2Et; 2. 
HCl; 3. Boc2O; (c) H+; (d) NaOH; (e) O3; (f) NaBH4; (g) Oxone; (h) BnNH2, 
NaBH3CN; (i) H2, Pd-C; (j) H2, Pd(OH)2-C 
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Figure 13. Four crystallographically independent molecules (A-D) of 109b, determined 
by X-ray diffraction analysis. 
 
1.5. 1-Aminocyclohexanecarboxylic acid 
1.5.1. Synthesis 
The 1-aminocyclohexane carboxylic acid framework has been used in the design of 
potent cathepsin K inhibitors74 and V2 agonists of arginine vasopressin.75 The detailed 
synthetic strategy has been described by Cativiela13. 
In 2006 Fustero et al.76 reported β, β-difluorinated derivatives of these amino acids, 
because the presence of fluorine atoms often induces significant changes in the physical 
properties, biological activities and metabolic profiles of the resulting peptides.77 2, 2-
Difluoro-4-pentenoic acid (111) was transformed into the corresponding imidoyl 
chlorides (112), which were converted into imidoly iodides (113) with NaI in dry 
acetone. These intermediates were treated with CO and several alcohols in the presence 
of a catalytic amount of Pd2(dba)3 to afford imino esters (114) in moderate yields, which 
were subsequently chemoselective allylated. Among several organometallic reagents, 
allyl zinc compounds delivered the desired racemic product almost in quantitative 
yields, which was then cyclized to 116 using the Grubb’s 2nd generation catalyst. 
Subsequent steps gave the target di-fluorinated 1- aminocyclohexanecarboxylic acid 
(117) (Scheme 21). 
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Scheme 21. Synthesis of β, β-difluorinated 1-aminocyclohexane carboxylic acid 117. 
 
 
 
 Figure 14. X-ray diffraction structure of compound 116, with R1 = Ac, R2 = 
(CH2)2TMS, R3 and R4 = H. 
 
The synthesis of orthogonally protected 1-aminocyclohexane carboxylic acids begins 
with a reductive amination on the commercially available 1, 4-dicyclohexanone 
monoethylene ketal 118 with the amine of choice, acetic acid and sodium 
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triacetoxyborohydride in dichloromethane to afford 119. In the next two steps the acetal 
was deprotected to 120 and the secondary amine was Boc-protected to 121. Ketone 120 
was converted to hydantoin 121 using the Bucherer-Bergs procedure.78 Selective 
hydrolysis of 121 gave 122. (Scheme 22)79 
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Scheme 22. Synthesis of orthogonally protected 1-aminocyclohexane carboxylic acid 
122. 
 
1.5.2. Induction of turn ⁄ helical structures in short peptides 
The cyclic amino acids, which are constructed from a 6-membered ring backbone, have 
high helix promoting effects. Yokum et al.80 showed that even very short peptides, 
enriched with amino acids having the general structure 122, retain a 310-/α-helix 
equilibrium in organic and aqueous phase solvent mixtures. 
Jiménez et al.81 synthesized peptides Piv-L-Pro-(S,S)c6Phe-NHiPr (126) and Piv-L-Pro-
(R,R)c6Phe-NHiPr (127) (Scheme 23). Their conformational properties were studied in 
the crystal state by X-ray diffraction and in solution by 1H-NMR and FT-IR absorption 
spectroscopy, and the results were compared to those of the analogous dipeptides 
containing L- and D-Phe. They also showed by theoretical calculations that 
discrimination between the type-I and type-II β-turns occurs due to the existence of an 
NH to π-phenyl ring interaction. 
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Scheme 23. Synthesis of the two Piv-Pro-c6Phe-NHiPr dipeptides 126 and 127 from 
racemic H-c6Phe-OMe (123). Conditions: (a) Boc-L-Pro-OH/iBuOCOCl/NMM/CH2Cl2, 
-15º C 24 h; yield: 85%. (b) Eluant AcOEt/hexanes 1/1; Rf 0.67 (S,S), 0.50 (R,R). (c) 
iPrNH2/AlMe3/toluene, 0º C 1 h, 50º C 36 h; yield 48-50%. (d) 1: TFA/CH2Cl2 2/3, rt, 2 
h. 2: Piv2O/Et3N/DMAP/CH2Cl2, 0 C 1 h, rt overnight; yield 83-85%. 
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Scheme 24. Synthesis of compound 130a,b and their γ-turn conformation in CDCl3. 
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Amino acid derivatives 128a-b were prepared and coupled with (S)-H-Leu-OMe 
(Scheme 24)82. The di-peptides were unable to form a 1←4 H-bond, but adopted a γ-
turn structure in CDCl3 solution. The conformation was not retained in DMSO. 
 
1.6. Miscellaneous 
Hydrophobic amino acids play an essential role in the molecular architectures of 
proteins and peptides. Such amino acids are commonly found in the transmembrane 
regions of membrane proteins and ion channels, embedded in the lipid bilayers.83 
Farnesylation (transfer of 15 carbon atoms) and geranylgeranylation (transfer of 20 
carbon atoms) of cysteine side chains are known to have dramatic effects on the 
hydrophobicity of proteins and have been proposed to be important for signal 
transduction.84 Various unnatural amino acids with hydrophobic side chains have been 
explored as building blocks for peptides that provide novel hydrophobic cores.85 Amino 
acids with Cα-tetrasubstituted cycloaliphatic groups are intriguing, because α, α-
disubstitution constrains the conformation of a peptide chain and also causes changes in 
hydrophobicity.86 Ohwada et al.87 have described a general approach to synthesize the 
amino acids with large saturated hydrocarbon ring in the, α, α-position (Scheme 25). 
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Scheme 25. Synthesis of protected macrocyclic Cα-tetrasubstituted α-amino acids. a) 
CH2=CH(CH2)mBr, NaH, DMSO, rt; b) CH2=CH(CH2)nBr, NaH, DMSO, rt; c) 
[(PCy3)2Cl2Ru=CHPh], CH2Cl2, reflux.; d) H2, Pd/C, AcOEt; e) DPPA, Et3N, benzene, 
reflux; f) 9-fluorenylmethanol, toluene, reflux; rt.  
Section 1. Introduction                                                                                                  30 
 
 
 
Figure 15. X-ray diffraction structure of the N-benzoyl ethyl ester derivative of the 
macrocyclic α-amino acid containing an 18-membered ring. 
 
Cα-Tetrasubstituted α-amino acid derivatives bearing 21-membered (136a), 18-
membered (136b) and 15-membered (136c) rings, respectively, were synthesized 
efficiently through ring-closing metathesis reactions of the appropriate dialkenyl 
malonate precursors (133a-c), which were derived from malonates 131 (Scheme 25).88 
Stepwise alkylation of malonate derivative 131 in the presence of NaH/DMSO gave the 
monoalkylated products (132 a, b) in moderate to high yields, while the second 
alkylation step yield was generally high and insensitive to the chain length of the second 
alkyl bromide. The ring-closing metathesis reactions of the dialkenylated precursors 
(133a-c) leading to 134 a-c were carried out by treatment with Grubbs’ ruthenium 
catalyst in dichloromethane. 
The Cα-tetrasubstituted cycloaliphatic amino acids bearing large rings were incorporated 
into short peptide chains using the Fmoc solid-phase method. The design of these 
peptides was based on the sequence of helical peptides, composed of alanine, lysine and 
glutamic acid. In such helical peptide sequence two alanines at the 3 and 10 positions 
were replaced by C-18 rings on the same side of the helix. The energy minimized 
structure predicts stable conformers for the modified peptide. 
In 2000 Trancard et al.89 reported a new stereoselective approach to access so called 
‘proline chimeras’, in which the heterocyclic part of the amino acid is substituted in 
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such a way that the chimera combines the conformational constituent of proline with the 
side chain of another amino acid. Benzylation of the starting nicotinates (137 and 138) 
by benzyl halide gave the corresponding pyridinium salts (139 a, b) in excellent yield. 
The Wekert procedure90 was used for partial hydrogenation to 140 a, b. As bromide is a 
potential catalyst poison, it was exchanged with chloride using AgCl. Finally, the ring 
size reduction91 gave the desired products 141 a, b. The aldehyde group was converted 
to different functionalities (Scheme 26).  
 
N
CO2R
N
CO2R
Ph
X N
CO2R
Ph
N
Ph
CO2R
CHOPhCH2X
X = Cl, Br
AgCl, MeOH
Pd/C/H2
MeOH
Br2/Et2O
H2O/Et3N
R = Me
    = Menthol
N
Ph
CO2Me
CHO
N
Ph
CO2Me
NH2
N
Ph
CO2Me
137
138 139a, b 140a, b 141a, b
141a
142
143
 
 
Scheme 26. Synthesis of new proline chimeras. 
 
Cystine is an important four atom bridged bis-α-amino acid. The group of Undheim 
used C4-bridged analogues where the disulphide moiety was replaced by a C2-unit. In 
200192 they reported a methodology which leads to rigid bis-α-amino acid structures in 
the form of tricyclic bridges. The distance between the amino acid centers can be varied 
by the ring size in the tricyclic bridge.93 A C4-alkyne bridge was initially constructed by 
alkylation of lithiated (2R)-2, 5-dihydro-2-isopropyl-3, 6-dimethoxy-pyrroline (144) as 
chiral auxiliary with 1, 4-dibromo-2-butyne (Scheme 27). The reaction is stereoselective 
in that the electrophile becomes attached trans to the isopropyl group (145).94 The 
second alkylation with TMS protected propargyl chloride gave the dialkylated product 
146 in 60% yield. Removal of the TMS-protecting group in compound 146 proceeded 
Section 1. Introduction                                                                                                  32 
 
readily with tetrabutylammonium fluoride (TBAF) to give 147. The deprotected 
material was hydrolyzed with TFA in aqueous acetonitrile at room temperature to afford 
compound 148, which was acetylated using Ac2O and DMAP. This compound (150) 
undergoes RCM in the presence of a Ru (II) catalyst to yield compound 152 in 58%.  
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Scheme 27. Synthesis of indacene-bridged bis-(α-amino acid) derivatives. 
 
Toniolo and co workers53 investigated Cα-tetrasubstituted alicyclic α-amino acids 
containing larger rings (Acnc, n = 7, 8,95 9, and 12). In the peptides examined, all the 
Acnc residues are found in the helical region of the conformational space. Although their 
effective volume and hydrophobicity is quite different, a comparable conformational 
preference is observed. 
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1.7. Glossary 
Different types of bends are defined according to the number and spatial arrangement of 
the residues involved. β-Turns (or β-bend) (Figure 16) are the most abundant and best 
characterized group of secondary folding structures.2a,2b,96,97,98 They comprise four 
amino acid residues connected by three amide groups. About three-quarter of tight turns 
feature a 1←4 (C10) H-bond between the backbone CO (i) and NH (i+3) groups and the 
distance between the Cα (i) and the Cα (i+3) is < 7Å.  
A γ-turn is defined by the existence of a hydrogen bond between the CO group of one of 
the residue (i) and the NH of the (i+2) th residue.99,100  
A 310-helix101 is defined by the existence of a hydrogen bond between the CO group of 
one of the residue (i) and the NH of the (i+3) th residue (subtype III or helical β-
turn96,97,98). 
 
Figure 16. Schematic representation of the intramolecular hydrogen bond that stabilizes 
the β-turn (i←i+3), the γ-turn (i←i+2) and the α-turn (i←i+4) in a peptide chain. 
 
1.8. Conclusion  
Recent trends in the synthesis of cyclic Cα-tetrasubstituted amino acids with ring sizes 
varying from three to six and their incorporation in short peptide to give definite turn 
structure were summarized in this review. Most of those synthetic routes are based on 
stereoselective syntheses using chiral auxiliaries. The overall shape and intrinsic 
stereoelectronic properties of the amino acids important for molecular recognition, 
signal transduction, enzymatic specificity, immunomodulation, and other biological 
effects depends on the arrangement of the side chain groups in three-dimensional chi 
space (χ1, χ2 etc. torsional angles). Cyclic Cα-tetrasubstituted amino acids are valuable 
tools for the preparation of structurally defined peptides. In particular, their rigid and 
predictable structures and their good accessibility make them attractive as building 
blocks in the synthesis of artificial peptides. 
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Tetrahydrofuran Cα-Tetrasubstituted Amino Acids: Two Consecutive 
β-Turns in a Crystalline Linear Tripeptide* 
 
2.1. Introduction 
The conformation of a peptide is crucial for its biological activity.1 Most small natural 
peptides are conformational flexible, show structural dependence on the environment 
and are therefore not suitable to study or control secondary peptide structures. One of 
the successful approaches to restrict peptide conformation is the introduction of side 
chain restricted amino acids.2,3 Disubstitution by alkyl or aryl groups in the α position of 
an α amino acid leads to conformational constraint (Thorpe-Ingold effect) and a stereo- 
chemically stable quaternary carbon center.4 Different methods to incorporate 
functionality in the α position of an amino acid or using α, β-unsaturated amino acids as 
precursors have been reported5. Toniolo6 recently reviewed the effect of Cα 
tetrasubstitution on the structure of homo oligoamides mostly resulting in stable 310 or 
α-helices.7 In short peptides Cα-alkylated α-amino acids stabilize turn structures,8 which 
in general have received particular attention, because they play an important role in 
globular proteins from both structural and functional points of view.9  
A polypeptide chain cannot fold into a compact structure without turns, which usually 
occur on the solvent exposed surface of proteins and hence probably represent antigenic 
sites involved in molecular recognition.10 Many naturally occurring oligopeptides have 
been proposed to adopt turns in their bioactive conformation.11 Different types of bends 
are defined according to the number and spatial arrangement of the residues involved, 
and β-turns (β-bends reverse turn) are the most abundant and best characterized group of 
folded secondary structures.12 Subclasses of β-turns are further distinguished on the 
basis of the backbone dihedral angles (φ, ψ) associated with central i+1 and i+2 
positions. In the last years several artificial turn inducing structures were reported by 
Nowick,13 Schmuck,14 Frigel,15 Kelly,16 Gellman,17 Balaram18 and others. We report 
here the preparation and structural characterization of Cα-tetrasubstituted tetra-
hydrofuran amino acids (TAAs) from methionine, which induce two consecutive β-turns 
as part of a tripeptide of aliphatic alpha amino acids. 
                                                 
*
 The investigations described in this chapter have already published (Maity, P.; Zabel, M.; König, B. J. 
Org. Chem. 2007, 72, 8046-8053). All the X-ray crystallography was determined by Zabel, M. 
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2.2. Results and discussion 
The key step of the TAA (Tetrahydrofuran Amino Acid) synthesis is the aldol-type 
reaction of a methionine derived sulfonium salt19 with an aldehyde followed by a 
cyclization. Scheme 1 shows the preparation of the sulfonium salt rac-3 starting from 
the racemic amino acid methionine (rac-1). The methionine sulfonium iodide rac-3 was 
treated with KOH. Acidic protons are found at the sulfonium moiety and at the α-carbon 
of the amino acids. Under the reaction conditions the α-proton of the amino acid is 
removed and its stereoinformation is lost. The ester enolate reacts with the carbonyl 
group of the aromatic aldehyde and the intermediate alkoxide substitutes 
intramolecularly dimethylsulfide giving tetrahydrofuran amino acids rac-4 with high 
diastereoselectivity of the α- and β-stereocenters. A proposed mechanism of the reaction 
is outlined in Figure 1. 
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Scheme 1. Synthesis of the protected methionine sulfonium salt rac-3 and its 
conversion to TAA rac-4a: a) (Boc)2O, 1.25 (M) NaOH, 1,4-dioxan, 3.5h, rt, 90%; b) 
DCC, DMAP, tBuOH, DCM, 14h, rt, 82%; c) MeI, (CH3)2CO, 3d, rt in the dark, 78%. 
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Figure 1 Proposed reaction mechanism of tetrahydrofuran Cα tetrasubstituted amino 
acid formation. 
A series of optimizations revealed that aromatic aldehydes with an electron withdrawing 
substituent and a sterically demanding protecting group for the carboxyl function, such 
as tBu, give the best reaction conversions and stereoselectivities. Decrease of the 
reaction temperature from room temperature to -5oC increases product yields and 
selectivity. Several solvents and bases were tested. The reaction occurred smoothly in 
polar solvents. As KOH is not soluble in less polar solvents, such as dichloromethane 
and toluene, tetrabutlyammonium bromide was added as phase transfer catalyst. 
However, yields are moderate in these solvents. Among all solvents CH3CN gave the 
best yield of the desired product in 2 to 3 h (Table 1). Additionally, the scope of the 
reaction and its dependence on steric and electronic properties of the aryl aldehyde was 
investigated (Table 2). Electronic effects on the reaction yield are small, while 
diastereoselectivity depends on the aldehyde. The relative stereochemistry of the major 
diastereoisomer was confirmed by X-ray diffraction analysis of compound rac-4e 
(Figure 2) and compound rac-4n (benzyl ester of rac-4a, see appendix for X-ray 
structure). With benzene, naphthalene and cinnamic aldehydes high selectivity (trans/cis 
≥ 97/3) with moderate to good yields (45-78%; 50 – 95% according to aldehyde 
conversion) were obtained, whereas the diastereoselectivity was poor with furfural and 
p-cyanobenzaldehyde.  
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Table 1. Optimization of the reaction conditions converting compound rac-3 to TAA 
rac-4a 
Solvent Base 
Reaction 
temp. 
[0C] 
Reaction 
time [h] Yield [%] 
Anti/Synb 
ratio 
aDCM 
KOH 
KOtBu 
20 
5 
4.5 
40 
47 
97/3 
tBuOH KOH -5 3.5 40 97/3 
DMF 
KOH 
CsOH 
-5 
2 
1.5 
55 
54 
96/4 
aToluene 
KOH 
KOtBu 
20 
4 
3 
52 
60 
96/4 
CH3CN 
KOH 
KOtBu 
CsOH 
-5 
3 
2 
2 
78 
60 
65 
>97/3 
a 
 Tetrabutyl ammonium bromide (10 mol%) was added as phase transfer catalyst, b    
The trans/cis ratio was determined by HPLC.  
 
 
 
 
Figure 2. X-Ray diffraction analysis of the major diastereomere of compound rac-4e 
confirming the trans-configuration. For clarity only the amide hydrogen atoms are 
shown. 
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Table 2: Scope of the reaction of sulfonium salt rac-3 with aromatic aldehydes 
Entry 
 
Base Temp. 
(ºC) 
Time 
(h) 
Product Yielda 
(%) 
Trans/Cis 
ratio 
CHOBr
 
KOH -5 to rt 3 rac-4a 78 [95] 97/3b 
CHOO2N
 
KOH -5 0.5 rac-4b 35 [50] 96/4b 
CHO
 
KOH -5 to rt 2 rac-4c 70 [85] 97/3b 
CHOMeO
 
KOH -5 2 rac-4d 50 [80] 96/4b 
CHO
 
KOH -5 to rt 2 rac-4e 55 [90] 96/4b 
CHO
Br
 
KOH -5 3 rac-4f 47 [70] 20/1c 
CHOF
 
KOH -5 to rt 2 rac-4g 63 [74] 20/1c 
CHONC
 
CsOH -5 to rt 2.5 rac-4h 55 [87] 9/1c 
CHO
 
CsOH -5 3 rac-4i 55 [60] 20/1c 
CHOCl
 
CsOH -5 to rt 2.5 rac-4j 55 [70] 20/1c 
CHO
 
KOH -5 to rt 3 rac-4k 55 [67] 20/1c 
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CHO
 
KOH -5 to rt 2.5 rac-4l 58 [80] 20/1c 
O CHO
 
KO-tBu -5 4 rac-4m 56 [75] 3/1d 
 
 
 
a The isolated yield was determined with respect to the aryl aldehyde used. The 
isolated yield with respect to the converted aryl aldehyde is given in brackets. b 
Selectivity was determined by HPLC on achiral column. c Selectivity was determined by 
column chromatographic separation. d Determined by NMR. 
 
 
Compound rac-4a was converted into the carboxylic acid rac-5 (Scheme 2) by 
treatment with 6M HCl in methanol affording the hydrochloride salt of the free amino 
acid quantitatively. N-Reprotection with Boc-anhydrid gave compound rac-6.20 Using 
standard peptide coupling conditions, the racemic carboxylic acid rac-6 was coupled 
with L-alanine methyl ester hydrochloride and L-phenylalanine methyl ester 
hydrochloride giving dipeptides 7-10 in moderate yields. The diastereomers were 
separated by column chromatography and X-ray diffraction structure were obtained for 
the R,S,S-isomer 7 and S,R,S-isomer 9.  
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Scheme 2. Deprotection of TAA and coupling with chiral amino acids: a) 6M HCl, 
MeOH, reflux, 6h, quantitative; b) (Boc)2O, 1.25 (M) NaOH, 4h, rt, 60%; c) DIPEA, 
EDC, HOBt, L-alanine methyl ester hydrochloride or L-phenylalanine methyl ester 
hydrochloride, DCM, 24h, rt, 60% and 55%, respectively. 
 
 
TAAs were incorporated into a short peptide chain to demonstrate their ability to 
induce a turn structure (Scheme 3).21 Compound rac-6 was coupled with the benzyl 
amide of L-alanine and the diastereomers 11 and 12 were separated by column 
chromatography. The crystalline structure of dipeptide 11 confirmed the R,S,S 
configuration. The molecule adopts a β-turn type I conformation with terminal Boc-CO 
and benzylamide NH groups intramolecularly hydrogen bonded [N….O: 2.92 Å; 
N−H…O: 163º]. The torsion angles (φ, ψ) of the TAA i+1 (-61.7, -25.2) and L-Ala i+2 
(-82.9, -2.0) residues correspond to a β-turn type I (Figure 3).22 The X-ray diffraction 
analysis of the S,R,S diastereomer 12 (see appendix for X-ray structure) shows no 
intramolecular hydrogen bonds or turn structure formation. 
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Scheme 3 .Incorporation of TAA rac-6 into a short peptide chain: a) Et2O-HCl DIPEA, 
EDC, HOBt, DCM, 24h, rt, 50%; b) (i) Et2O-HCl, (ii) DIPEA, EDC, HOBt, DMF, 3d, 
rt, 41%. 
 
Figure 3. X-Ray diffraction structure of the compound 11 accommodating a β I turn in 
the crystal state. The intramolecular i+3→i hydrogen bond is indicated by a dashed line. 
Only the amide hydrogen atoms are shown. 
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After Boc-deprotection isomer 11 was coupled with acetylated glycine yielding 
tripeptide 13a. Instead of a simple elongated β-turn structure, a conformation consisting 
of two consecutive β turns type III, slightly deviating from an ideal 310 helix structure, 
was observed in the solid state (Figure 4). The torsion angles (φ, ψ) for the left side turn 
Gly i+1 (-62.4o, -21.0o), TAA i+2 (-55.1o, -26.0o) and for the right side turn TAA i+2 (-
55.1o, -26.0o), L-Ala (-71.6o, -31.5o) resemble the typical values (-60º, -30º and -60º, -
30º). The structure is stabilized by two intramolecular hydrogen bonds (N…O: 2.92 Å, 
N−H…O: 163º) and (N…O: 3.26 Å, N−H…O: 149º). A 2D ROESY spectrum (Figure 
6) provides evidence for the existence of the proposed conformation in solution. 
Additional support comes from a variable-temperature NMR study in DMSO-d6: 
Temperature coefficients of the amide protons Hd (-0.58 ppb/K) and Hc (-3.17 ppb/K) 
possibly indicate strong intramolecular hydrogen bonds, and temperature coefficients of 
Ha and Hb are significantly higher (-5.35 ppb/K and -7.20 ppb/K, respectively; see 
Figure 5 for data). However, temperature coefficients are only assessed as an indication 
because a more detailed analysis is required to unambiguously correlate their values to 
hydrogen bonding as shown by Andersen et al.23 Compound 12 was also coupled in 
same condition with acylated glycine to afford compound 13b. The X-ray crystal 
structure shows an intramolecular H-bond with 10-member ring has formed to give β-
turn type-II structure (see appendix for x-ray structure).  
Figure 4. Structure (i) and X-ray diffraction analysis (ii) of compound 13a exhibiting 
two consecutive β turns, each stabilized by an intramolecular i+3→i hydrogen bond 
(dashed lines). Only amide hydrogen atoms are shown. (iii) back bone structure of the 
tripeptide. 
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The bromine substituent in compound rac-4a allows a subsequent functionalization of 
the TAA, which may be of use for specific labelling or modification of properties of the 
turn motif. Conventional Suzuki,24 Heck,25 and Buchwald26 coupling (Scheme 4) gave 
derivatives rac-14 to rac-16a,b.  
 
O
BocHN O
Br
OtBu
O
BocHN O
OtBu
O
BocHN O
R
OtBu
O
BocHN O
OtBu
CO2Me
R = i) NHBn
ii) ON
rac-4a
rac-14
r ac-15
r ac-16a
rac-16b
b) c)
a)
 
 
Scheme 4. Cross coupling reactions: a) Methylacrylate, Et3N, Pd(OAc)2, P(o-tolyl)3, in 
DMF, 14h, 80°C, 71%; b) phenylboronic acid, Na2CO3, Pd(OAc)2, TBAB, in water : 
DMF (1:1), 100°C, 71%; c) benzylamine or morpholine, K3PO4, 2-isobutyryl-
cyclohexanone in DMF, 100°C, 75% or 35%. 
 
2.3. Temperature dependence of NMR chemical shifts 
Temperature dependence of chemical shifts was measured to identify possible strong 
intramolecular hydrogen bonds in solution. The 1H-NMR spectra were recorded at 
various temperatures on a 600 MHz spectrometer. Table 3 shows the determined 
chemical shift values (ppm) for each NH group of the examined compounds in the range 
of 293-373 K. 
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Table 3. Determined 1H resonance chemical shift in ppm for NH protons at various 
temperature in [d6]-DMSO  
 
A) Compound 13a 
 
T[K]/ 
NH[ppm] 
NHa NHb NHc NHd 
293K 8.245 9.027 7.356 7.558 
313K 8.137 8.886 7.288 7.550 
333K 8.026 8.738 7.225 7.537 
353K 7.924 8.593 7.160 7.520 
373K 7.819 8.446 7.097 7.497 
 
B) Compound 11 
 
T[K]/ NH[ppm] NHa NHb 
293K 7.975 7.873 
313K 7.972 7.858 
333K 7.970 7.841 
353K 7.964 7.823 
 
 
The resonance values from Table 3 were used to calculate the temperature dependence 
of the chemical shift. The measured values were plotted and fitted to a linear correlation 
function. From the plotted graph we calculated the corresponding temperature 
coefficient in ppb/K. These values were used to estimate the possibility of hydrogen 
bonds, using the following boundaries: Hydrogen bonds very likely for values smaller 
than -2 ppb/K; intermediate range from -2 to -3 ppb/K and no hydrogen bonding for 
values larger than -4 ppb/K. 
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Figure 5. Temperature dependence of amide proton resonances in tripeptide 13a   and 
dipeptide 11 
 
 
 
 
2.4. ROESY experiments 
 
1D-ROESY measurements in [d6]-DMSO was performed at 300K on a Bruker DRX-
600 spectrometer with a working frequency of 600.13 MHz. The difference ROESY 
experiment with selective excitation using the modified DPFGSE pulse sequence (q3 
Gaussian cascade Double Pulse Field Gradient Spin Echo) was used. For every 
irradiated proton a series of 5 experiments with different mixing times (from 10 ms to 1 
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s) and with a relaxation delay of 2 s were acquired. An exponential window function 
with 4 Hz line broadening was applied before the Fourier transformation (FT) and a 
baseline correction was conducted after the FT. 
2D-ROESY experiments with a mixing time of 500 ms were performed for structural 
calculations. Signal overlap restricts the number of observable intrastrand contacts. At 
least four ROESY interactions were detected for NH (13) and two for NH (16), as 
illustrated in Figure 6. 
 
 
 
Figure 6. ROESY spectrum for compound 13a and illustration of observed contacts in 
solution. 
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2.5. Fluorescent amino acid and it’s incorporation into peptide chain† 
 
Fluorescence spectroscopy has become one of the most useful tools in conformational 
studies of biopolymers27 and for visualizing intracellular processes or molecular 
interactions.28 Introduction of fluorescence moiety into the peptide chain can be 
achieved either by reaction with fluorescence prove with functional groups present in 
peptide chains (carboxylate, amino group, hydroxyl, sulphahydryl) or by direct use of an 
amino acid bearing fluorescent function at their side chain. Among the proteinogenic 
amino acids only two possess fluorescent properties (Trp, and Tyr), but sometimes 
native peptides do not contain these amino acids or their photophysical behavior in 
complex29. Incorporation of amino acid with photophysical behavior different from the 
native fluorescent amino acids into peptide chain seems to be beneficial. In this 
consequence synthetic fluorescent amino acids may exhibit significant advantages over 
the related protein (Trp, Tyr) residue in terms of potentially different and improved 
properties.30 So we prepared the pyrene substituted tetrahydrofuran Cα-tetrasubstituted 
amino acid, and incorporated in short peptide chain which shows turn structure in solid 
sate. Toniolo et al. 31 took advantage of the fluorescence, the rigidity and the axial 
chirality of 2’, 1’ : 1, 2; 1”, 2” : 3:4-dinaphthcyclo-hepta-1, 3-diene-6-amino-6-
carboxylic acid (Bin)32, a Cα-tetrasubstituted glycine derivative from 1, 1’-binapthyl, to 
carry out photophysical studies involving intramolecular energy transfer (fluorescence 
quenching) and intramolecular spin polarization (CIDEP) effects in conformationally 
constrained peptide based system. Cα-tetrasubstituted amino acids are effective for β-
turn and helix inducer in peptides.33 The compound rac-3 and pyrene aldehyde were 
reacted in presence of KOH as a base in CH3CN to give compound rac-4o 
diastereoselectily (trans/cis is 20:1) with moderate yield of 56% (Scheme 1). Then 
compound rac-4o was coupled with N-acetyl-L-proline in presence of HOAt34 and 
HUAT as coupling reagents in DCM. Column chromatography allowed the separation 
of the resulting diastereomeric dipeptides (17a, 17b), which were isolated in optically 
pure form (Scheme 4). 
 
                                                 
†
 Manuscript in preparation. 
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Scheme 5. Synthesis of fluorescent amino acid and it’s incorporation in peptide chain. 
 
 
 
Figure 7.  X-ray diffraction structure of compound 17a 
 
 
The absorption spectrum of compound 17b in MeOH shows two peaks at 377 nm and 
396 nm (Figure 8). 
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Figure 8. Absorption spectrum of compound 17b in MeOH 
 
 
2.6. Conclusion 
 
In summary, we have reported the racemic diastereoselective synthesis of Cα 
tetrasubstituted tetrahydrofuran amino acids (TAA) from readily available methionine. 
Dipeptides of TAA and chiral amino acids yield diastereomers, which are readily 
separated by column chromatography. Short peptide sequences containing the R,S-
isomer of TAA show a stable turn structure in the crystal state and in solution. Two 
consecutive β-turn type III turns, resembling a distorted 310 helix structure, are found for 
a tripeptide amide consisting of Gly-TAA-Ala. Good accessibility and variable 
modification by transition metal-catalyzed coupling reactions make TAAs a useful 
addition to the family of Cα-tetrasubstituted α-amino acids and artificial turn structures 
in peptide research. 
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2.7. Experimental Section: 
 
General: Melting points were determined on a melting point apparatus and are 
uncorrected. Specific rotations were measured on a polarimeter using a 10 cm cell. 
NMR spectra were recorded in CDCl3 at 300 MHz (1H) or 75 MHz (13C) unless stated 
otherwise. Structural assignments are based on DEPT and COSY experiments where 
applicable. The multiplicity of the carbon atoms is given as (+) = CH3 or CH, (-) = CH2 
and (Cquat) for quaternary carbon atoms. Analytical TLC plates (silica gel 60 F254) and 
silica gel 60 (70-230 or 230-400 mesh) for column chromatography (CC) were 
purchased from Merck. Visualization of spots by UV light and/or staining with 
phosphomolybdate or ninhydrin, both in ethanol. CH3CN, CH2Cl2, and Et2O were dried 
by standard procedures and stored over molecular sieves or Na. PE means petrol ether 
with a boiling range of 70-90 oC. All other solvents and chemicals were of reagent grade 
and used with out further purification. 
 
tert-Butyl methionine : Racemic methionine (10 g, 67 mmol), 1,4-dioxane (40 mL) and 
1.25 M aqueous NaOH (53 mL) were stirred and cooled to 6°C. Then a solution of di-
tert-butyl-dicarbonate (15.4 g, 70.4 mmol) in 1,4-dioxane (12 mL) was added over 15 
min. The cooling bath was removed and the reaction stirred for 3.5 h. The dioxane was 
removed in vacuo, the remaining mixture was diluted with 1M aqueous KHSO4 (68 mL) 
and extracted with EtOAc (1x40, 1x25 mL). The combined organic layers were washed 
with water (24 mL), brine (4 mL) and dried over MgSO4.The solvent was removed to 
give pure tert-butyl methionine as colourless liquid (15 g, 90%). 
 
tert-Butyl)-4-(2-(tert-butoxycarbonylamino methylthio)butanoate (rac-2a) 
 
 
 
To a cooled (0°C) solution of tert-butyl methionine (2 g, 8 mmol), DMAP (0.08 g, 0.67 
mmol) and tert-butanol (0.71 g, 9.6 mmol) in dry CH2Cl2 (20 mL) N,N´-
dicyclohexylcarbodiimide (2.15 g, 10.4 mmol) was added with stirring and the reaction 
mixture was stirred at 0°C for 2 h. After stirring for 12h at room temperature, the 
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precipitated dicyclohexylurea was filtered off and washed with DCM (2x10 mL). The 
organic layer was washed with 1M HCl (2x5 mL), a saturated aqueous solution of 
NaHCO3 (2x10mL) and water (2x5mL) and dried over MgSO4. Then the solvent was 
evaporated in vacuo, and the crude product was purified by column chromatography 
(SiO2, PE : diethyl ether 4:1) to give 2 g of compound 2 (82% yield). Rf = 0.20 (diethyl 
ether : PE = 1:4) 
1H NMR (300 MHz, CDCl3) δ =1.45 (s, 18H), 1.99 (m, 1H, -CHH-), 2.11 (s, 3H), 2.15 
(m, 1H, -CHH-), 2.58 (m, 2H), 4.45 (bs, 1H), 5.25 (bs, 1H). - 13C NMR (75.5 MHz, 
CDCl3), δ = 27.64 (+, 3C), 27.99 (+, 3C), 28.30 (-), 30.40 (-), 53.38 (+), 65.83 (+), 
72.08 (Cquat), 77.28 (Cquat), 155.33 (Cquat), 171.36 (Cquat). MS [ESI H2O/AcN]: m/z (%) 
= 305.5 [MH+] (100). 
 
(4-tert-Butoxy 3-(tert-butoxycarbonylamino)-4-oxobutyl)dimethylsulfonium iodide 
(rac-3a) 
 
 
 
Compound 2 (10 g, 32.7 mmol), methyl iodide (46.86 g, 0.33 mol) and acetone (10 mL) 
were stirred at room temperature for 3 d in the dark. During this time a white precipitate 
was formed. After cooling in an ice bath for 4 h, the precipitate was filtered off and 
washed with chilled solvent (0°C temp. diethyl ether : acetone 9:1, 2x10 mL). This solid 
was dried in vacuo yielding compound 3 (11.4 g, 78%) in analytical pure form. 
1H NMR (300 MHz, CDCl3) δ = 1.45 (s, 9H), 1.47 (s, 9H), 2.29 (m, 1H,-CHH-), 2.32 
(m, 1H, -CHH), 3.30 (d, 6H), 3.70 (m, 1H, -SCHH-), 3.75 (m, 1H, -SCHH-), 4.15 (bs, 
1H), 5.70 (bs, 1H). - 13C NMR (75.5MHz, CDCl3) δ = 15.48 (+), 28.00 (+), 28.05 (+), 
29.92 (-), 32.56 (-), 53.39 (+), 80.63 (Cquat), 82.12 (Cquat), 169.65 (Cquat), 171.00 (Cquat). 
MS [ESI, H2O/AcN]: m/z (%) = 320.1 [M+-I] (100). 
 
Sulfonium salt cyclization, typical procedure: An oven or flame dried flask was 
cooled under a stream of nitrogen and charged with sulfonium iodide 3 (1 mmol) in 
acetonitrile (4 mL/mmol). The colourless solution was cooled to 0°C and powdered 
KOH or KOtBu or CsOH (1 mmol ) was added and the reaction mixture was stirred for 
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15 min. Then the aryl aldehyde (0.9 mmol) was added and the mixture was stirred for 
another 2-4 h. After consumption of all of the starting material, the reaction mixture was 
quenched by adding water (3 mL/mmol). The reaction mixture was dilute with diethyl 
ether (4 mL/mmol) and transferred to a separatory funnel. The layers were separated and 
the aqueous layer was extracted with diethyl ether (2x5 mL/mmol). Then combined 
ether layers were washed with brine, dried over MgSO4 and the solvent was removed in 
vacuo. The crude product was purified by flash column chromatography on silica gel 
using 10-15% diethyl ether / PE as the eluant. 
 
2-(4-Bromo-phenyl)-3-tert-butoxycarbonylamino-tetrahydro-furan-3-carboxylic 
acid tert butylester (rac-4a)  
 
 
Yield = 60%, using KOtBu as a base, 82%, using KOH as a base and 65%, using CsOH 
as a base; Rf = 0.23 (diethyl ether : PE = 1:4), m.p = 131-133°C. 
1H NMR (300 MHz, CDCl3) δ = 1.09 (s, 9H), 1.45 (s, 9H), 2.61-2.68 (m, 2H), 4.16-
4.33(m, 2H), 5.00 (bs, 1H), 5.71 (bs, 1H), 7.20 (d, J = 8.23 Hz, 2H), 7.42 (d, J = 8.23 
Hz, 2H). - 13C NMR (75.5 MHz, CDCl3) δ = 27.42 (+), 28.40 (+), 35.80 (-), 67.91 (-), 
69.63 (+), 80.13 (Cquat), 82.62 (Cquat), 84.42 (Cquat), 121.75 (Cquat), 127.91 (+), 131.02 
(+), 136.7 (Cquat), 154.3 ( Cquat), 170.03 (Cquat), MS [ESI; CH2Cl2/MeOH+10mmol 
NH4OAc] = 442.2, 444.2 [MH+] (80), 459.3, 461.3 [M-NH4 +] (75) .- IR (KBr): ν~ cm-1 
= 3362, 2975, 2932, 2873, 2199, 1509, 1454, 1392. Anal. calcd. For C20H28BrNO5 
(442.34): C 54.30, H 6.38, N 3.17, found C 54.27, H 6.67, N 3.16. 
 
tert-Butly 3-(tert-butoxycarbonylamino)-2-(4-nitrophenyl)tetrahydrofuran-3-
carboxylate (rac-4b) 
O
BocHN
O
OtBu
NO2
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Yield = 35%, using KOH as base; Rf = 0.18 (diethyl ether : PE = 3:17), m.p.= 146-
148°C. 
1H NMR (300MHz, CDCl3) δ = 1.30 (s, 9H), 1.50 (s, 9H), 2.55 (m, 1H, -CHH-), 2.80 
(m, 1H, -CHH-), 4.05 (m, 1H, -OCHH-), 4.25 (m, 1H, -OCHH-), 4.45 (bs, 1H), 5.25 
(bs, 1H), 7.55 (d, J = 9.26 Hz, 2H), 8.23 (d, J = 9.26 Hz, 2H). - 13C NMR (75.5 MHz, 
CDCl3) δ = 27.92 (+), 28.12 (+), 35.80 (-), 67.04 (-), 68.09 (+), 82.65 (Cquat), 84.87 
(Cquat), 123.44 (+), 128.08 (Cquat), 147.88 (+), 154.45 (Cquat), 170.47 (Cquat), 171.5 
(Cquat). - MS [ESI; CH2Cl2/MeOH+10mmol/1 NH4OAc] = 409.2 [MH+] (100), 426.2 
[M-NH4+] (55) - IR (KBr): ν~  cm-1 = 3375, 2981, 2934, 2877, 1730, 1603, 1504, 1452. 
Anal. calcd. For C20H28N2O7 (408.45): C 58.81, H 6.91, N 6.86, found C 58.45, H 7.07, 
N 6.85.  
 
3-tert-Butoxycarbonylamino-2-phenyl-tetrahydro-furan-3-carboxylic acid tert 
butyl ester (rac-4c) 
 
Yield = 70%, using KOH as a base; Rf = 0.21 (diethyl ether / PE = 3:17), m.p.= 61-
63°C. 
1H NMR (300 MHz, CDCl3) δ = 1.09 (s, 9H), 1.45 (s, 9H), 2.50-2.80 (m, 2H), 4.23 (m, 
1H, -OCHH-), 4.33 (m, 1H, -OCHH-), 5.02 (bs,1H), 5.60 (bs, 1H), 7.25-7.30(m, 5H). - 
13C NMR (75.5 MHz, CDCl3) δ = 27.92 (+), 28.12 (+), 35.83 (-), 67.04 (-), 82.65 (Cquat), 
84.87 (Cquat), 123.44 (+), 128.08 (Cquat), 133.53 (+), 137.52 (+), 150.61 (+), 154.54 (+), 
155.36 (Cquat), 170.09 (Cquat). - MS [ESI; CH2Cl2/MeOH+10mmol/1 NH4OAc] = 364.3 
[MH+] (100), 381 [M-NH4+] (50). - IR (KBr): ν~  cm-1 = 3358, 2978, 2932, 2872, 1720, 
1494, 1454, 1365. Anal. calcd. For C20H29NO5 (363.45): C 66.09, H 8.04, N 3.85, found 
C 65.89, H 8.32, N 3.32.  
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3-tert-Butoxycarbonylamino-2-(4-methoxy-phenyl)-tetrahydro-furan-3-carboxylic 
acid tert butyl ester (rac-4d) 
 
 
Yield = 50%, using KOH as a base, 45%, using KOtBu as a base; Rf = 0.25 (diethyl 
ether / PE .= 1:4 ) m.p.= 97-99°C. 
1H NMR (300 MHz, CDCl3) δ = 1.13 (s, 9H), 1.49 (s, 9H), 2.52-2.65 (m, 1H, -CHH-), 
2.68-2.82 (m, 1H, -CHH-), 3.78 (s, 3H), 4.11-4.23 (m, 1H, -OCHH-), 4.27-4.35 (m, 1H, 
-OCHH-), 4.93 (bs, 1H), 5.48 (bs, 1H), 6.80 (d, J = 7.96 Hz, 2H), 7.25 (d, J = 7.96 Hz, 
2H). - 13C NMR (75.5 MHz, CDCl3) δ = 27.49 (+), 28.41 (+), 55.00, 67.74 (-), 69.14, 
82.08 (Cquat), 113.00 (+), 127.57 (Cquat), 129.50 (+), 154.54 (Cquat), 159.46 (Cquat), 
170.08 (Cquat). - MS [ESI; CH2Cl2/MeOH+10mmol/1 NH4OAc]. 394.2 [MH+] (60), 
411.2 [M-NH4+] (20). - IR (KBr): ν~  cm-1 = 3359, 2975, 2931, 2881, 1707, 1613, 1583, 
1510. Anal. calcd. For C21H31NO6 (393.47): C 64.10, H 7.94, N 3.56, found C 64.33, H 
7.64, N 3.37.  
 
3-tert-Butoxycarbonylamino-2-(4-methyl-phenyl)-tetrahydro-furan-3-carboxylic 
acid tert butyl ester (rac-4e) 
 
 
Yield = 55%, using KOH as a base; Rf = 0.22 (diethyl ether : PE = 3:17), m.p.= 135-
138°C. 
1H NMR (300 MHz, CDCl3) δ = 1.09 (s, 9H), 1.47 (s, 9H), 2.30 (s, 3H), 2.65 (m,1H,-
CHH-), 2.72 (m,1H,-CHH-), 4.11 (m, 1H, -OCHH-),4.32 (m, 1H, -OCHH) 5.02 
(bs,1H,CH-), 5.65 (bs,1H), 6.92 (d, J = 7.95 Hz, 2H), 7.45 (m, J = 7.95 Hz, 2H). - 13C 
NMR (75.5 MHz, CDCl3) δ = 21.12 (+), 27.41 (+), 29.94 (+), 35.73 (-), 67.78 (-), 69.74 
(+), 82.05 (Cquat), 82.07 (Cquat), 85.74 (Cquat), 126.21 (+), 128.61 (+), 134.38 (Cquat), 
137.63 (Cquat), 154.57 (Cquat), 170.07 (Cquat). - MS [ESI; CH2Cl2/MeOH+10mmol/1 
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NH4OAc] = 378.2 [MH+] (100), 395.2 [M-NH4+] (20), IR (KBr): ν~  cm-1 = 3357, 2978, 
2930, 2870, 2783, 2199, 1703, 1610, 1514, 1450. Anal. calcd. for C21H31NO5 (377.47): 
C 66.82, H 8.28, N 3.71, found C 66.91, H 8.62, N 3.58.  
 
tert-Butyl 2-(3-bromophenyl)-3-(tert-butoxycarbonylamino)tetrahydrofuran-3-
carboxylate (rac-4f) 
O
BocHN
O
OtBu
Br
 
 
Yield = 50%, using KOH as a base; Rf = 0.14 (diethyl ether: PE = 3:17). 
1H NMR (300 MHz, CDCl3) δ = 1.15 (s, 9H), 1.48 (s, 9H), 2.59-2.71 (m, 2H), 4.18-4.36 
(m, 2H), 5.07 (bs, 1H), 5.65 (bs, 1H), 7.13-7.23 (m, 2H), 7.36-7.41 (m, 1H), 7.53-7.55 
(m, 1H). - 13C NMR (75.5 MHz, CDCl3) δ = 27.43 (+), 28.41 (+), 35.76 (-), 67.97 (-), 
69.59 (+), 80.14 (Cquat), 82.70 (Cquat), 84.02 (Cquat), 122.27 (+), 124.67 (+), 129.35 
(Cquat), 129.54 (+), 130.88 (Cquat), 140.05 (+), 154.34 (Cquat), 170.03(Cquat). - MS[ESI; 
CH2Cl2/MeOH+10 mmol/1 NH4OAc]. 442.2 [MH+] (30), 459.0. [MNH4+] (30), 403.0 
[M-NH4+-C4H8] (100) - IR (KBr): ν~  cm-1 = 3361, 3070. 2978, 2621, 2534, 2199, 1698, 
1570, 1479, 1393.  
 
tert-Butyl 3-(tert-butoxycarbonylamino)-2-(4-fluro-phenyl)tetrahydrofuran-3-
carboxylate (rac-4g) 
O
BocHN
O
OtBu
F
 
 
Yield = 63%, using KOH as a base. Rf = 0.12 (diethyl ether : PE= 1: 4), m.p = 89-92°C. 
1H NMR (300 MHz, CDCl3) δ = 1.09 (s, 9H), 1.49 (s, 9H), 2.67-2.78 (m, 2H), 4.16-
4.33(m, 2H), 5.00 (bs, 1H), 5.71 (bs, 1H), 7.00 (m, 2H), 7.42 (m, 2H). - 13C NMR (75.5 
MHz, CDCl3) δ = 27.44(+), 28.40 (+), 35.80 (-), 67.91 (-), 69.63 (+), 80.13 (Cquat), 
82.62 (Cquat), 84.42 (Cquat), 114.99 (+), 127.98 (+), 131.01 (Cquat), 154.38(Cquat), 160 
(Cquat), 170.03 (Cquat). - MS [ESI; CH2Cl2/MeOH+10mmol NH4OAc]. =.382.1[MH+] 
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(40); 343.1[MNH4+-C4H8], (100); 326.1[MH+-C4H8],(60). - IR (KBr): ν~  cm-1 = 3377, 
2980, 2863, 2199, 1710, 1606, 1495, 1447. 
 
tert-Butyl 3-(tert-butoxycarbonylamino)-2-(4-cyano-phenyl)tetrahydrofuran-3-
carboxylate (rac-4h) 
 
O
BocHN
O
OtBu
CN
 
Syn/anti = 9:1. Yield = 55%, using KOH as a base; Rf = 0.14 (diethyl ether : PE. = 
3:17), m.p.= 128-130°C. 
Resonance signals of the anti isomer: 1H NMR (300 MHz, CDCl3) δ = 1.06 (s, 9H), 
1.46 (s, 9H), 2.71-2.49 (m, 2H), 4.31-4.20 (m, 2H), 5.02 (bs, 1H), 5.65 (bs, 1H), 7.45 (d, 
J = 8.78 Hz, 2H), 7.58 (d, J = 8.78 Hz, 2H). Resonance signals of the syn isomer: 1H 
NMR (300 MHz, CDCl3) δ = 1.28 (s, 9H), 1.47 (s, 9H), 2.56 (m, 1H, -CHH-), 2.77 (m, 
1H, -CHH-), 4.03 (m, 1H,-OCHH-), 4.23 (m, 1H, -OCHH-), 4.38 (bs, 1H), 5.15 (bs, 
1H), 7.45 (d, J = 8.78 Hz, 2H), 7.64 (d, J = 8.78 Hz, 2H).- 13C NMR (75.5 MHz, CDCl3) 
δ = 27.40 (+), 28.40 (+), 36.08 (-), 68.07 (-), 69.51, 80.31 (Cquat), 82.95 (Cquat), 83.52 
(+), 111.47 (Cquat), 118.78 (Cquat), 126.13 (+), 131.71(+), 143.47 (Cquat), 154.20 (Cquat), 
170.00 (Cquat). - MS [ESI; CH2Cl2/MeOH+10mmol/1 NH4OAc] = 389.3 [MH+] (30), 
406.3 [M-NH4+] (45), 350.3 [M-NH4+-C4H8] (56). - IR (KBr): ν~  cm-1 = 3357, 2982, 
2910, 2877, 1698, 1613, 1524, 1425. Anal. calcd. For C21H28N2O5 (388.14): .C 64.93, H 
7.27, N 7.21, found C 64.87, H 7.54, N 7.07. 
 
tert-Butyl 3-(tert-butoxyxycarbonylamino)-2-m-tolyltetrahydro-furan-3-
carboxylate (rac-4i) 
O
BocHN
O
OtBu
 
 
Yield = 55%, using KOH as a base; Rf = 0.14 (diethyl ether : PE = 3:17). 
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1H NMR (300 MHz, CDCl3) δ = 1.00 (s, 9H), 1.40 (s, 9H), 2.22 (s, 3H), 2.64-2.78 (m, 
1H, -CHH-), 2.72 (m, 1H, -CHH-), 4.13 (m, 1H, -OCHH-),4.24 (m, 1H, -OCHH) 4.89 
(bs, 1H, CH-), 5.60 (bs, 1H, NH-), 6.90-7,14 (m, 5H). - 13C NMR (75.5 MHz, CDCl3) δ 
= 21.12 (+), 27.41 (+), 29.94 (+), 35.73 (-), 67.78 (-), 69.74 (+), 82.05 (Cquat), 82.07 
(Cquat), 85.74 (Cquat), 126.21 (+), 128.61 (+), 134.38 (Cquat), 137.63 (Cquat), 154.57 
(Cquat), 170.07 (Cquat). - MS [ESI; CH2Cl2/MeOH+10mmol/1 NH4OAc]. 378.2 [MH+] 
(100), 395.2 [M-NH4+] (20) - IR (KBr): ν~  cm-1 = 3357, 2978, 2930, 2870, 2783, 2199, 
1703, 1610, 1514, 1450.  
 
tert-Butyl 3-(tert-butoxycarbonylamino)-2-(4-chloro-phenyl)tetrahydrofuran-3-
carboxylate (rac-4j) 
 
O
BocHN
O
OtBu
Cl
 
 
Yield = 55%, using KOH as a base; Rf = 0.13 (diethyl ether : PE= 3:17) m.p = 107-
110°C. 
1H NMR (300 MHz, CDCl3) δ = 1.12 (s, 9H), 1.47 (s, 9H), 2.60-2.65 (m, 2H), 4.15-4.38 
(m, 2H), 5.00 (bs, 1H), 5.60 (bs, 1H), 7.27 (m, 4H). - 13C NMR (75.5 MHz, CDCl3) δ = 
27.41 (+), 29.94 (+), 35.62 (-), 67.90 (-), 69.63 (Cquat), 82.52 (Cquat), 127.58 (+), 128.08 
(+), 133.65 (Cquat), 137.63 (Cquat), 154.57 (Cquat), 170.07 (Cquat). - MS [ESI; 
CH2Cl2/MeOH + 10mmol/1 NH4OAc] = 378.2 [MH+] (100), 395.2 [M-NH4+] (20) 
- IR (KBr): ν~  cm-1 = 3375 , 2981, 2934, 2877, 1730, 1603, 1504, 1452. Anal. calcd. For 
C20H28ClNO5 (397): C 60.37, H 7.09, N 3.51, found C 60.45, H 7.07, N 3.53. 
 
tert-Butyl 3-(tert-butoxycarbonylamino)-2-(naphthalene-2-ly)tetrahydrofuran-3-
carboxylate (rac-4k)  
O
BocHN
O
OtBu
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Yield = 55%, using KOH as a base; Rf = 0.22 (diethyl ether : PE = 1:4), m.p = 140-
143°C. 
1H NMR (300 MHz, CDCl3) δ = 1.00 (s, 9H), 1.45 (s, 9H), 2.50-2.80 (m, 2H), 4.23 (m, 
1H, -OCHH-), 4.33 (m, 1H, -OCHH-), 5.02 (bs, 1H), 5.60 (bs, 1H), 7.45 (m, 3H), 
7.80(m, 4H). - 13C NMR (75.5 MHz, CDCl3) δ = 27.92 (+), 28.12 (+), 35.83 (-), 67.04 (-
), 82.65 (Cquat), 84.87 (Cquat), 123.44 (+), 128.08 (Cquat), 133.53 (+), 137.52 (+), 150.61 
(+), 154.54 (+), 155.36 (Cquat), 170.09 (Cquat) - IR (KBr): ν~  cm-1 = 3360 , 2978, 2931, 
2878, 2199, 1703, 1504, 1454. - HRMS cald. for C24H31NO5 (413.2206) found 413.2205 
± .2. Anal. calcd. For C24H31NO5 (413): C 69.71, H 7.56, N 3.39, found C 69.51, H 7.74, 
N 3.30. 
 
(E)-tert-Butyl 3-(tert-butoxycarbonylamino)-2-styryltetrahydrofuran-3-carboxylate 
(rac-4l) 
 
O
BocHN
O
OtBu
 
 
Yield = 53%, using KOH as a base; Rf = 0.14 (diethyl ether : PE = 3:17), m.p = 134-
136°C. 
1H NMR (300 MHz, CDCl3) δ = 1.39 (s, 9H), 1.46 (s, 9H), 2.46 (m, 1H, -CHH-), 2.73-
2.82 (m, 1H, -CHH-), 4.07 (m, 1H, -OCHH-), 4.21 (m, 1H, -OCHH-), 4.44 (d, J = 6.31 
Hz, 1H), 5.30 (bs, 1H), 6.02-6.12 (dd, J = 15.92 Hz, 7.14 Hz, 1H), 6.60-6.65 (d, J = 
15.92 Hz, 1H), 7.22-7.35 (m, 5H). - 13C NMR (75.5 MHz, CDCl3) δ = 27.93 (+), 28.35 
(+), 35.17 (-), 67.61 (-), 69.5 (Cquat), 80.02 (Cquat), 82.17 (Cquat), 85.50 (+), 124.27 (+), 
126.66 (+), 128.00 (+), 133.36 (+), 136.13 (+), 154.78 (Cquat), 169.92 (Cquat). - MS [ESI; 
CH2Cl2/MeOH+10mmol/1 NH4OAc]. = 390.2 [MH+] (100), 278 [M-2xC4H8] (35), 
407.2 [M-NH4+] (15) - IR (KBr): ν~  cm-1 = 3375, 2981, 2934, 2877, 1730, 1603, 1504, 
1452. Anal. calcd. For C22H31NO5 (389.49): C 67.84, H 8.02, N 3.60, found C 67.73, H 
8.21, N 3.55. 
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tert-Butyl 3-(tert-butoxycabonylamino)octahydro-2, 2’-bifuran-3-carboxylate (rac-
4m)  
 
 
trans/cis. = 3:1. Yield = 56%, using KOtBu as a base; Rf= 0.26 (diethyl ether : PE = 
1:4), m.p.= 77-80°C. Resonance signals of trans isomer: 1H NMR (300 MHz, CDCl3) δ 
= 1.29 (s, 9H), 1.45 (s, 9H), 2.50 (m, 1H, -CHH), 2.87-2.99 (m, 1H, -CHH-), 4.13 (m, 
1H, -OCHH-), 4.30 (m, 1H, -OCHH-), 4.89 (bs, 1H), 5.35 (bs, 1H), 6.32 (m, 2H), 7.36 
(m, 1H). - 1H NMR (300 MHz, C6D6) δ = 1.25 (s, 9H), 1.43 (s, 9H), 2.39-2.52 (m, 1H, -
CHH), 2.96-3.08 (m, 1H, -CHH-), 3.81-3.91 (m, 1H, -OCHH-), 4.09-4.17 (m, 1H, -
OCHH-), 4.76 (bs, 1H), 5.34 (bs, 1H), 5.94-5.98 (m, 1H), 6.23-6.26 (m, 1H), 6.92-6.95 
(m, 1H). - Resonance signals of the cis isomer: 1H NMR (300 MHz, CDCl3) δ = 1.39 (s, 
9H), 1.49 (s, 9H), 2.56 (m, 1H, -CHH), 2.78-2.85 (m,1H,-CHH-), 4.13 (m, 1H, -OCHH-
), 4.30 (m, 1H, -OCHH-), 4.87 (bs, 1H), 5.30 (bs, 1H), 5.97 (m, 2H), 6,98 (m, 1H) - 13C 
NMR (75.5 MHz, CDCl3) δ = 27.58 (+), 28.33 (+), 35.17 (-), 68.12 (-), 69.05 (Cquat), 
80.15 (Cquat), 81.05 (+), 81.93 (Cquat), 108.19 (+), 110.32 (+), 142.38 (+), 150.63 (Cquat), 
154.93 (Cquat), 169.19 (Cquat). - MS[ESI;CH2Cl2/MeOH+10mmol/1 NH4OAc] = 354.1 
[MH+] (100), 371.2 [M-NH4+] (30). - IR (KBr): ν~  cm-1 = 3357, 3119, 2978, 2933, 
2868, 2199, 1737, 1703, 1514, 1448. Anal. calcd. For C18H27NO6 (353.42): C 61.17, H 
7.70, N 3.96, found C 60.94, H 7.69, N 3.90. 
 
Benzyl 2-(4-bromophenyl)-3-(tert-butoxycarbonylamino)tetrahydrofuran-3-
carboxylate (rac-4n) 
 
O
NHBocO
O
Br
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Yield = 20%, using KOH as a base; 25%, using CsOH as a base; Rf = 0.14 (diethyl ether 
: PE = 3 : 17), m.p. = 137-138°C. 
1H NMR (300 MHz, CDCl3) δ = 1.43 (s, 9H), 2.62 (m, 1H, -CHH-), 2.82 (m, 1H, -
CHH-), 4.20 (m, 1H, -OCHH-), 4.37(m, 1H, -OCHH-), 4.72 (s, 2H), 4.96 (bs, 1H), 5.54 
(bs, 1H,), 7.13 (m, 4H), 7.33 (m, 5H). - 13C NMR (75.5 MHz, CDCl3) δ = 28.32 (+), 
35.20 (-), 67.58(-), 67.97 (-), 70.04 (+), 80.50 (Cquat), 85.17 (Cquat), 122.29 (Cquat), 
127.69 (+), 128.46 (+), 128.50 (+), 128.54 (+), 131.23 (+), 134.72 (Cquat), 135.99 (Cquat), 
154.51 (Cquat), 170.79 (Cquat). - MS [ESI;CH2Cl2/MeOH+10mmol NH4OAc].=.476.1, 
478.1 [MH+] (50), 493.2, 495.2 (M+NH4+) - IR (KBr): ν~  cm-1 = 3348, 3303, 3061, 
3029, 2978, 2941, 2887, 2867, 2800, 2199, 1668, 1591, 1517, 1452. Anal. calcd. For 
C23H26BrNO5 (476.19): C 57.99, H 5.50, N 2.94, found C 57.95, H 5.72, N 2.93.  
 
tert-Butyl-3-(tert-butoxycarbonylamino)-2-(pyrene-1-yl)tetrahydrofuran-3-
carboxylate (rac-4o) 
O
BocHN
O
OtBu
 
 
Yield = 65%, using KOH as base; Rf = 0.18 (diethyl ether: PE = 3:17), m.p.= 159-
161°C. 
1H NMR (300MHz, CDCl3) δ = 0.80 (s, 9H), 1.58 (s, 9H), 2.80-2.99 (m, 2H), 4.39-
4.59(m, 2H), 5.72 (bs, 1H), 6.23 (bs, 1H), 7.97-8.31 (m, 9H). - 13C NMR (75.5 MHz, 
CDCl3) δ = 27.92 (+), 28.12 (+), 35.80 (-), 67.04 (-), 68.09 (+), 82.65 (Cquat), 84.87 
(Cquat), 123.44 (+), 128.08 (Cquat), 147.88 (+), 154.45 (Cquat), 170.47 (Cquat), 171.5 
(Cquat). - MS [ESI; CH2Cl2/MeOH+10mmol/1 NH4OAc] = 488.3 [MH+] (90), 505 [M-
NH4+] (100), 992.7 [2M-NH4+] (100), - IR (KBr): ν~  cm-1 = 3359, 2974, 2830, 2867, 
1750, 1703, 1506, 1454. Anal. calcd. For C30H33NO5 (487.36): C 73.90, H 6.82, N 2.87, 
found C 73.80, H 7.17, N 2.58.  
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3-Amino-2-(4-bromo-phenyl)-tetrahydro-furan-3-carboxylic acid hydrochloride 
(rac-5) 
 
 
To a solution of compound rac-4a (2 g, 4.5 mmol), in 20 mL of methanol 10 mL of 6 
(M) HCl was added. The reaction mixture was heated to reflux temperature for 6 h, then 
cooled to room temperature and stirred for another 2 h. The reaction mixture was 
concentrated by removal of methanol; remaining parts of the reaction mixture were 
lyophilized yielding quantitatively a white solid of the corresponding hydrochloride salt 
(1.4 g). The compound was used in the next step without further purification.  
1H NMR (300 MHz, MeOD) δ = 2.32 (m, 1H, -CHH-), 2.92 (m, 1H, -CHH-), 4.17 (m, 
1H, -OCHH-), 4.56(m, 1H, -OCHH-), 5.00 (bs, 1H), 7.34 (d, J = 8.23 Hz, 2H), 7.53 (d, 
J = 8.23 Hz, 2H). - 13C NMR (75.5 MHz, MeOD) δ = 36.23 (-), 68.59 (-), 69.91 (+), 
87.77 (Cquat), 123.89 (+), 129.76 (Cquat), 132.45 (Cquat), 136.24 (+), 170.39 (+). - MS 
[ESI;CH2Cl2/MeOH+10mmol NH4OAc].=.286.1, 288.1 [MH+-Cl] (30), 303.2, 305.2 
[M+NH4+] (100). 
 
2-(4-Bromo-phenyl)-3-tert-butoxycarbonylamino-tetrahydro-furan-3-carboxylic 
acid (rac-6) 
 
 
Procedure A (Starting from Compound rac-5) : Compound rac-5 (1 g, 3.13 mmol), 
1,4-dioxan (5 mL) and 1.25 M aqueous NaOH (7 mL) were stirred and cooled to 6°C for 
10 min. Then a solution of di-tert-butyl-dicarbonate (0.75 g, 3.45 mmol) in 1,4-dioxan 
(2 mL) was added over 5 min. The cooling bath was removed and the reaction stirred for 
3.5 h. The dioxane was removed in vacuo, the residue diluted with 1M aqueous KHSO4 
(2 mL) and extracted with EtOAc (1x4, 1x3mL). The combined organic layers were 
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washed with water (2 mL), brine (2 mL) and dried over MgSO4. The solvent was 
removed to give pure rac-6 as a white solid (0.72 g, 60%). 
 
Procedure B (Starting from compound rac-4n): Compound rac-4n (500 mg, 1.05 
mmol) was dissolved in ethanol (5 mL), then 150 mg of KOH was added to the solution 
and the mixture was refluxed for 24 h. The reaction mixture was cooled and ethanol was 
evaporated. The obtained yellow solid was dissolved in water (3 mL) and extracted with 
diethyl ether (2x2 mL) to remove all organic impurities. The aqueous solution was 
acidified with citric acid (10%, 2mL) and extracted with ethyl acetate (2 x 3 mL). The 
combined organic layers were washed with brine (1 mL) and dried over MgSO4. The 
solvent was removed to give pure compound rac-6 (97 mg) as a white solid in 24% 
yield. This compound was used for next step with out further purification. 
1H NMR (300 MHz, CDCl3) δ = 1.44 (s, 9H), 2.68-2.78 (m, 1H, CHH), 3.30 (m, 1H, 
CHH), 4.15-4.25(m, 1H, -OCHH), 4.32 (m, 1H, OCHH-), 5.10 (bs, 1H), 5.61 (bs, 1H), 
7.10-7.22 (m, 2H), 7.40-7.50 (m, 2H). - 13C NMR (75.5 MHz, CDCl3) δ = 28.40 (+), 
35.80 (-), 67.91 (-), 69.63 (+), 82.62 (Cquat), 84.42 (Cquat), 121.75 (Cquat), 127.91 (+), 
131.02 (+), 136.72 (Cquat), 154.3 (Cquat), 170.03 (Cquat). - MS 
[ESI;CH2Cl2/MeOH+10mmol NH4OAc].=.442.2 [M+H] (80), 459.3 [M-NH4+] 
- IR (KBr): ν~  cm-1 = 3362, 2975, 2932, 2873, 2199, 1509, 1454, 1392.  
 
Dipeptide esters 7 and 9  
 
 
Compound rac-6 (100 mg, .26 mmol) was dissolved in CH2Cl2 (1.5 mL) and the 
hydrochloride salt of alanine methylester (36 mg, 0.26 mmol), EDC (40 mg, 0.26 
mmol), HOBT (35 mg, 0.26 mmol) and DIPEA (84 mg, 0.65 mmol) were added. The 
reaction mixture was stirred at room temperature for 24 h, quenched with water (2 mL) 
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and 1M KHSO4 (3 mL), diluted by adding 3 mL of diethyl ether and transferred to a 
separating funnel. The aqueous layer was extracted with diethyl ether (2x3 mL). Then 
combined ether layers were washed with brine solution (2 mL), dried over MgSO4 and 
the solvent was removed in vacuo. The crude product was purified by flash column 
chromatography on silica gel using 30-40% diethyl ether / petrol ether as the eluant to 
give 73.2 mg (60%) of compounds 7 and 9 as white solids. Compound 7: mp = 117-
118°C, [α]D25° = +34.3 (c = 1.0, CHCl3). 1H NMR (600 MHz, CDCl3) δ = 0.90 (bs, 3H), 
1.49 (s, 9H), 2.50 (m, 1H, -CHH-), 2.85 (m, 1H, -CHH-), 3.65 (s, 3H), 4.10 (qn, J = 6.79 
Hz, 1H), 4.27-4.38 (m, 2H), 5.43(bs, 1H), 6.25 (bs, 1H), 6.45 (bs, 1H), 7.20 (d, J = 8.25 
Hz, 2H), 7.40 (d, J = 8.25 Hz, 2H). - 13C NMR (75.5 MHz, CDCl3) δ = 17.55 (+), 28.43 
(+), 36.08 (-), 48.01(+), 52.47 (+), 66.62 (-), 67.11 (+), 80.07 (Cquat), 121.44 (Cquat), 
126.82 (+), 131.13 (+), 136.12 (Cquat), 154.51 (Cquat), 170.79 (Cquat), 172.98 (Cquat). - MS 
[PI-LSIMS; MeOH/Glycerine].=.471.3, 473.3 [MH+] (60), 415.3, 417.3 [M+-C4H8] (50) 
- IR (KBr): ν~  cm-1 = 3356, 3348, 3303, 3061, 3029, 2978, 2941, 2887, 2867, 2800, 
2199, 1668. Anal. calcd. For C20H27BrN2O6 (476.19): C 50.96, H 5.77, N 5.94, found C 
50.92, H 6.05, N 5.87. Compound 9: mp = 127-130°C, [α]D25° = -34.3 (c = 1.0, CHCl3). 
1H NMR (600 MHz, CDCl3) δ = 0.92 (d, J = 6.24 Hz, 3H), 1.49 (s, 9H), 2.53 (m, 1H, -
CHH-), 2.88 (m, 1H, -CHH-), 3.72 (s, 3H), 4.24 (qn, J = 7.34 Hz, 1H), 4.34 (m, 2H), 
5.44 (bs, 1H), 6.28 (bs, 1H), 6.47 (d, J = 5.87 Hz, 1H), 7.22 (d, J = 8.44 Hz, 2H), 7.41 
(d, J = 8.44 Hz, 2H). - 13C NMR (75.5 MHz, CDCl3) δ = 18.26 (+), 28.38 (+), 35.91 (-), 
48.18 (+), 52.46 (+), 66.69 (-), 67.78 (+), 80.27 (Cquat), 121.65 (Cquat), 127.30 (+), 
131.01 (+), 135.71 (Cquat), 154.32 (Cquat), 170.61 (Cquat), 172.66 (Cquat). - MS [PI-
LSIMS; MeOH/Glycerine].=.471.3, 473.3 [M+H] (60), 415.3, 417.3 [M+-C4H8] (50) 
- IR (KBr): ν~  cm-1 = 3348, 3303, 3061, 3029, 2978, 2941, 2887, 2867, 2800, 2199, 
1668, 1591, 1517, 1452. Anal. calcd. For C20H27BrN2O6 (476.19): C 50.96, H 5.77, N 
5.94, found C 51.02, H 6.12, N 5.86.  
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Dipeptide esters 8 and 10:  
 
 
 
The compounds were prepared following the same procedure as given for the 
preparation of 7 and 9, using phenylalanine hydrochloride salt instead of alanine 
hydrochloride salt. The reaction gave 55% isolated product yield. Compound 8: 1H 
NMR (300 MHz, CDCl3) δ = 1.47 (s, 9H), 2.79 (m, 1H, -CHH-), 2.97-3.10 (m, 1H, -
CHH-), 3.60 (s, 3H), 4.02 (m, 1H), 4.15-4.31 (m, 3H), 4.41 (m, 1H), 5.38 (bs, 1H), 6.19 
(bs, 1H), 6.57 (bs, 1H), 7.02-7.14 (m, 4H), 7.26-7.37 (m, 5H). - 13C NMR (75.5 MHz, 
CDCl3) δ = 28.43 (+), 35.45 (-), 37.61 (-), 52.38 (+), 53.19 (+), 53.82 (+), 66.21 (-), 
80.08 (Cquat), 121.46 (Cquat), 126.82 (+), 127.28 (+), 127.40 (+), 128.62 (+), 128.94 
(Cquat), 129.13 (+), 131.19 (+), 135.77 (Cquat), 154.06 (Cquat), 171.05 (Cquat), 171.67 
(Cquat). - MS [PI-LSIMS; MeOH/Glycerine] = 546.14, 547.4 [MH+] (60),- IR (KBr): ν~  
cm-1 = 3356, 3348, 3303, 3061, 3029, 2978, 2941, 2887, 2867, 2800, 2199, 1668.  
Compound 10: 1H NMR (300 MHz, CDCl3) δ = 1.49 (s, 9H), 2.81 (m, 1H, -CHH-), 2.95 
(m, 1H, -CHH-), 3.65 (s, 3H), 4.04 (m, 1H), 4.20-4.34 (m, 3H), 4.43 (m, 1H), 5.40 (bs, 
1H), 6.23 (bs, 1H), 6.60 (bs, 1H), 7.00-7.12 (m, 4H), 7.22-7.35 (m, 5H). - 13C NMR 
(75.5 MHz, CDCl3) δ = 29.43 (+), 36.45 (-), 37.61 (-), 52.38 (+), 53.19 (+), 53.82 (+), 
66.21 (-), 80.08 (Cquat), 121.46 (Cquat), 123.82 (+), 127.38 (+), 127.45 (+), 128.69 (+), 
128.94 (Cquat), 129.13 (+), 131.19 (+), 135.77 (Cquat), 155.06 (Cquat), 171.06 (Cquat), 
171.77 (Cquat). 
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Dipeptide amides 11 and 12.  
 
 
 
The compounds were prepared as described above. The reaction gave an isolated yield 
of 50% of the two diastereomers. Compound 11: 1H NMR (300 MHz, CDCl3): δ = 1.15 
(d, J = 7.12 Hz, 3H), 1.43 (s, 9H), 2.55-2.64 (m, 1H, -CHH-), 2.69-2.81 (m, 1H, -CHH-
), 4.00 (m, 1H), 4.20-4.28 (m, 2H), 4.34-4.44 (m, 3H), 5.12(bs, 1H), 5.88 (bs, 1H), 6.24 
(bd, 1H), 6.34 (t, 1H), 7.17-7.39 (m, 9H). - 13C NMR (75.5 MHz, CDCl3) δ = 17.98 (+), 
28.29 (+), 36.08 (-), 43.34 (-), 49.20 (+), 67.16 (-), 68.42 (+), 80.91 (Cquat), 83.01 (Cquat), 
122.05 (Cquat), 127.35 (+), 127.50 (+), 128.58 (+), 131.32 (+), 135.74 (Cquat), 137.99 
(Cquat), 154.78 (Cquat), 170.54 (Cquat), 171.22 (Cquat). - MS [ESI; CH2Cl2/MeOH + 10 
mmol NH4OAc].=.546.2, 548.2 [MH+] (100), 490.1, 492.1 [M+-C4H8] (26). 
Compound 12: 1H NMR (300 MHz, CDCl3): δ = 0.93 (d, J = 6.82 Hz, 3H), 1.48 (s, 
9H), 2.38-2.53 (m, 1H, -CHH-), 2.69-2.81 (m, 1H, -CHH-), 4.00-4.10 (m, 1H), 4.25-
4.48 (m, 4H), 5.32 (bs, 1H), 6.12 (bs, 1H), 6.25 (bt, 1H), 6.60 (d, J = 6.60 Hz, 1H), 
7.16-7.40 (m, 9H). - 13C NMR (75.5 MHz, CDCl3) δ = 17.76 (+), 28.42 (+), 35.82 (-), 
43.53 (-), 49.02(+), 66.75 (-), 67.70 (+), 80.35 (Cquat), 81.24 (Cquat), 121.60 (Cquat), 
127.08 (+), 127.59 (+), 128.77 (+), 131.14 (+), 136.16 (Cquat), 137.81 (+), 154.20 (Cquat), 
170.92 (Cquat), 171.38 (Cquat). 
  
Tripeptide amide 13a and 13b. 
 
Compound 11 (100 mg, .26 mmol) was dissolved in 5 mL of DCM. To this solution 2 
mL of HCl saturated diethyl ether solution was added and the mixture was stirred for 20 
min at room temperature. The solvent was evaporated and the resulting white solid was 
dissolve in DMF
 
(1.5 mL). DIPEA (89 mg, 0.67 mmol), Ac-Gly-OH (36 mg, 0.32 
mmol), EDC (65 mg, 0.41 mmol), and HOBT (66 mg, 0.41 mmol) were added. The 
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reaction mixture was stirred at room temperature for 3 days, quenched with water (2 
mL) and 1M KHSO4 (3 mL), diluted by adding 3 mL of diethyl ether and transferred 
into a separatory funnel. The aqueous layer was extracted with diethyl ether (2x3 mL), 
the combined ether layers were washed with brine solution (2 mL), dried over MgSO4 
and the solvent was removed in vacuo. The crude product was purified by HPLC to give 
41 mg of compound 13a (40% yield). 
 
Compound 13a: 
 
 
1H NMR (600 MHz, d6-DMSO): δ = 0.80 (d, J = 7.47 Hz, 3H, COSY, HSQC: H-24), 
1.74 (s, 3H, COSY, HSQC: H-11), 1.99 (m, 1H, COSY, HSQC: H-4a/b), 2.97 (m, 1H, 
COSY, HSQC: H-4b/a), 3.50-3.7 (m, 2H, COSY, HMBC: H-14 and H-8a/b), 3.82 (dd, 
1H, J = 15.94 Hz, 5.14 Hz, COSY, HMBC: H-8b/a), 3.87 (m, 1H, COSY, HMBC: H-
5a/b), 4.15 (m, 1H, COSY, HMBC: H-17a/b), 4.25(m, 2H, COSY, HMBC: H-17b/c and H-
5b/a), 4.98 (s, 1H, COSY, HMBC: H-2), 7.16 (m, 3H, aromatic ), 7.27 (m, 4H, aromatic), 
7.35 (d, J = 7.47 Hz, 1H, COSY, HMBC: H-13), 7.49 (m, 2H, aromatic), 7.58 (t, J = 
6.36 Hz, 1H, COSY, HMBC: H-16), 8.20 (t, J = 5.25 Hz, COSY, HMBC: H-9), 9.00 (s, 
1H, COSY, HMBC: H-6). - 13C NMR (151 MHz, d6-DMSO) δ = 16.40 (+, HSQC: C-
24), 22.10 (+, HSQC: C-11), 35.67 (-, HSQC: C-4), 41.82 (-, HSQC: C-8 or C-17), 
43.10 (-, HSQC, C-8 or C-17), 48.61(+, HSQC: C-14), 67.31 (-, HSQC: C-5), 69.65 (+, 
HSQC: C-2), 84.83 (Cquat, HSQC, C-3), 121.00 (Cquat), 126.51 (+), 126.77 (+), 127.04 
(+), 128.09 (+), 128.23 (+), 128.67 (+), 130.40 (+), 137.30 (Cquat), 139.19 (+), 168.50 
(Cquat, HMBC: C-12), 170.45 (Cquat, HMBC: C-10), 171.46 (Cquat, HMBC: C-7), 171.70 
(Cquat, HMBC: C-15). - MS [PI-LSIMS; MeOH/glycerine].=.545.3, 547.3 [MH+] (100). 
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Compound 13b: 
 
 
1H NMR (600 MHz, d6-DMSO): δ = 0.95 (d, J = 7.06 Hz, 3H), 1.84 (s, 3H), 2.21-2.26 
(m, 1H), 2.49 (s, 3H), 2.26-2.72 (m, 1H), 3.30 (s, 2H), 3.37-3.79 (m, 2H), 3.82-3.92 (m, 
2H), 4.21-4.26 (m, 3H), 5.02 (s, 1H), 7.17-7.23 (m, 5H), 7.30-7.35 (m, 4H), 7.41-7.43 
(d, J = 8.07 Hz, 1H), 8.00 (t, J = 6.36 Hz, 1H),  8.18 (t, J = 6.36 Hz, 1H). 
13C NMR (151 MHz, d6-DMSO): δ = 17.67 (+), 22.26 (+), 33.73 (-), 42.00 (-), 42.64 (-
), 48.32 (+), 66.99 (-), 69.69 (+), 84.36 (Cquat), 120.66 (Cquat), 126.66 (+), 127.01 (+), 
128.19 (+), 128.57 (+), 130.70 (+), 137.70 (Cquat), 139.14 (+), 167.92 (Cquat), 169.83 
(Cquat), 169.89 (Cquat), 171.37 (Cquat), 201.75 (Cquat). –MS [PI-LSIMS; MeOH/glycerine] 
= 545.2, 547.2 [MH+] (100). Anal. Calcd. For C25H29N4O5Br (544.34) C 55.05, H 5.36, 
N 10.27 found C 54.49, H 5.39, N 10.38. 
 
Peptide coupling reaction: Compound rac-4o (100 mg, .21 mmol) was dissolved in 3 
mL of CH2Cl2. To this solution 2 mL of HCl saturated ether solution was added and 
stirred for 20 min at room temperature. The solvent was evaporated by vacuo and the 
resulting light yellow solid was dissolve in dry 3 mL CH2Cl2 followed by N-acetylated 
L-proline (39 mg, .25 mmol) , HOAt (16.7 mg, .12 mmol), HBTU ( 95 mg, .25 mmol) 
and DIPEA (133 mg, 1.25 mmol). The reaction mixture was stirred at room temperature 
for 2 days, quenched with 1M KHSO4 (2 mL), diluted with 4 mL EtOAc and transferred 
to a separating funnel. The aqueous layer was extracted with EtOAc (2x3 mL). The 
combined EtOAc layers were washed with 3 mL of brine solution, dried over MgSO4 
and the solvent was removed in vacuo. The crude product was purified by flash column 
chromatography on silica gel using 40-45% EtOAc in CH2Cl2 as eluent to afford 40 mg 
(75% of yield, total 80 mg of product) of each compound 17a and 17b as light yellow 
solid.  
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(2S, 3R)-tert-Butyl 3-((S)-1-acetylpyrrolidine-2-carboxamido)-2-(pyren-1-
yl)tetrahydrofuran-3-carboxylate (17a) 
 
O
HN
O
Ot-Bu
O
N O
 
 
Rf = 0.28 (EtOAc : CH2Cl2 = 1:1), m.p.= 159-161°C, [α]D = +53.9º (c = 0.2, CHCl3). 
1H NMR (600MHz, CDCl3) δ = 0.45 (s, 9H), 1.87-1.93 (m, 1H), 2.00-2.05(m, 1H), 
2.07-2.14 (m, 1H), 2.29 (s, 3H), 2.53-2.61 (m, 2H), 3.07-3.13 (m, 1H), 3.46-3.55 (m, 
2H), 4.25-4.29 (m, 1H), 4.52-4.55(m, 1H), 4.71-4.80 (m, 1H), 6.11 (s, 1H), 7.98-8.36 
(m, 9H), 8.67 (s, 1H). - 13C NMR (150.9MHz, CDCl3) δ = 22.73 (+), 25.28 (-), 36.80 (-
), 38.65 (+), 48.47 (-), 59.57 (+), 68.34 (-), 71.48 (+), 81.09 (Cquat), 84.35 (Cquat), 123.72 
(+), 124.40 (+), 124.64 (+), 124.85 (+), 125.53 (Cquat), 125.53 (Cquat), 125.75 (Cquat), 
127.29 (Cquat), 127.34 (Cquat), 127.50 (Cquat), 128.77 (+), 130.52 (+), 130.99 (Cquat), 
131.32 (Cquat),  131.69 (+), 168.68 (Cquat), 170.26 (Cquat), 171.33 (Cquat). - MS [ESI; 
CH2Cl2/MeOH+10mmol/1 NH4OAc] = 544.4 [MH+] (60), 505 [M-NH4+] (100), 
- IR (KBr): ν~  cm-1 = 3258, 3223, 3049, 2976, 2889, 1923, 1730, 1685, 1618, 1550, 
1452, 1430. Anal. calcd. For C32H34N2O5 (526.25): C 72.98, H 6.51, N 5.32, found C 
72.70, H 6.77, N 5.30.  
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(2R, 3S)-tert-Butyl 3-((S)-1-acetylpyrrolidine-2-carboxamido)-2-(pyren-1-
yl)tetrahydrofuran-3-carboxylate (17b) 
 
O
HN
O
OtBu
O
N
O
 
 
Rf = 0.20 (EtOAc: CH2Cl2 = 1:1), m.p.= 159-161°C, [α]D = -53.9º (c = 0.2, CHCl3). 
1H NMR (600MHz, CDCl3) δ = 0.45 (s, 9H), 1.87-1.93 (m, 1H), 2.00-2.05(m, 1H), 
2.07-2.14 (m, 1H), 2.29 (s, 3H), 2.53-2.61 (m, 2H), 3.07-3.13 (m, 1H), 3.46-3.55 (m, 
2H), 4.25-4.29 (m, 1H), 4.52-4.55(m, 1H), 4.71-4.80 (m, 1H), 6.11 (s, 1H), 7.98-8.36 
(m, 9H), 8.67 (s, 1H). - 13C NMR (150.9MHz, CDCl3) δ = 22.73 (+), 25.28 (-), 36.80 (-
), 38.65 (+), 48.47 (-), 59.57 (+), 68.34 (-), 71.48 (+), 81.09 (Cquat), 84.35 (Cquat), 123.72 
(+), 124.40 (+), 124.64 (+), 124.85 (+), 125.53 (Cquat), 125.53 (Cquat), 125.75 (Cquat), 
127.29 (Cquat), 127.34 (Cquat), 127.50 (Cquat), 128.77 (+), 130.52 (+), 130.99 (Cquat), 
131.32 (Cquat),  131.69 (+), 168.68 (Cquat), 170.26 (Cquat), 171.33 (Cquat). - MS [ESI; 
CH2Cl2/MeOH+10mmol/1 NH4OAc] = 544.4 [MH+] (60), 505 [M-NH4+] (100), 
- IR (KBr): ν~  cm-1 = 3349, 3041, 2976, 2880, 2208, 1924, 1624, 1531, 1447. Anal. 
calcd. For C32H34N2O5 (526.25): C 72.98, H 6.51, N 5.32, found C 72.70, H 6.77, N 
5.30.  
 
Benzyl 2-(tert-butoxycarbonylamino)-4-(methylthio) butanoate (rac-2b) 
 
S
O
NHBoc
O
 
 
1H NMR (300MHz, CDCl3) δ =1.45 (s, 18H), 1.99 (m, 1H, CHH-), 2.11 (s, 3H), 2.15 
(m, 1H, CHH), 2.58 (m, 2H), 4.45 (bs, 1H), 5.25 (bs, 1H).13C NMR (75.5 MHz, CDCl3), 
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δ =27.64 (+), 27.99 (+), 28.30 (-), 30.40 (-), 53.38 (+), 65.83 (+), 72.08 (Cquat ), 77.28 
(Cquat), 155.33 (Cquat), 171.36 (Cquat). MS [ESI H2O/AcN]: m/z (%) = 305.5 [MH+] (100) 
 
(4-(Benzyloxy)-3-(tert-butoxycarbonylamino)-4-oxobutyl)dimethylsulfonium iodide 
(rac-3b) 
 
S
O
NHBoc
O
I-
 
 
1H NMR (300 MHz, CDCl3) δ = 1.45 (s, 9H), 1.47 (s, 9H), 2.29 (m, 1H,-CHH-), 2.32 
(m, 1H, -CHH), 3.30 (d, 6H), 3.70 (m, 1H, -SCHH-), 3.75 (m, -SCHH-), 4.15 (bs, 1H), 
5.70 (bs, 1H). 13C NMR (75.5MHz, CDCl3) δ = 15.48 (+), 28.00 (+,), 28.05 (+), 29.92 (-
), 32.56 (-), 53.39 (+), 80.63 (Cquat), 82.12 (Cquat), 169.65 (Cquat), 171.00 (Cquat). MS 
[ESI, H2O/AcN]: m/z (%) = 320.1 [M+] (100) 
 
tert-Butyl 3-(tert-butoxycarbonyl)-2-(4-((E)-2-(methoxycarbonyl)vinyl)phenyl)-
tetrahydrofuran-3-yl carbamate (rac-14) 
 
 
A mixture of 0.57 mmol of compound rac-4a (250 mg), 0.68 mmol methylacrylate (58 
mg), 0.68 mmol triethyl amine, 1 mol% palladium acetate and 0.03 mmol tris(o-
tolyl)phosphine in 2 mL of DMF was heated to 100°C under argon for 14h. After the 
consumption of all of the starting material the mixture was cooled to room temperature, 
2 mL of 1M KHSO4 were added and the mixture was extracted (3x1 mL) with diethyl 
ether. The combined organic fraction was dried over MgSO4 and the solvent was 
evaporated to give a solid crude product, which was purified by column chromatography 
(silica gel, 1:1 diethyl ether : petrol ether) affording 180 mg (71%) of the white solid 
product rac-14, m.p = 146-149°C. 
1H NMR (300 MHz, CDCl3) δ = 1.09 (s, 9H), 1.46 (s, 9H), 2.61-2.68 (m, 2H), 3.80 (s, 
3H) 4.16-4.33(m, 2H), 5.09 (bs, 1H), 5.65 (bs, 1H), 6.41 (d, J = 15.92 Hz,, 1H), 7.35 (d, 
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J = 8.23 Hz, 2H), 7.50 (d, J = 8.23 Hz, 2H), 7.65 (d, J = 15.92 Hz, 1H). - 13C NMR 
(75.5 MHz, CDCl3) δ = 27.38 (+), 28.41 (+), 35.94 (-), 51.72 (+), 67.97 (-), 69.71 (+), 
80.10 (Cquat), 82.50 (Cquat), 84.72 (Cquat), 117.73 (+), 126.72 (Cquat), 127.66 (+), 131.95 
(+), 140.16 (Cquat), 144.47 (+), 154.3 ( Cquat), 167.45 (Cquat), 170.05 (Cquat). - MS 
[ESI;CH2Cl2/MeOH+10mmol NH4OAc].=.448.2 [MH+] (40), 465.3 [M-NH4+] (35), 
409.2 [M-NH4+-C4H8] (100). - IR (KBr):  cm-1 = 3362, 2975, 2932, 2873, 2199, 1509, 
1454, 1392. Anal. calcd. For C24H33NO7 (447.34): C 64.41, H 7.43, N 3.13, found C 
64.27, H 7.67, N 3.16.  
 
Compound rac-15. 
 
 
In a 25 mL Schlenk flask were placed compound rac-4a (250 mg, 0.567 mmol), 
phenylboronic acid (83 mg, 0.68 mmol), Na2CO3 (240 mg, 2.27 mmol), Pd(OAc)2 (2 
mg, 6 µmol), tetrabutyl ammonium bromide (183 mg, 0.567 mmol) and 2 mL of a water 
/ DMF (1:1) mixture. The flask was sealed with a septum and placed into an oil bath 
preheated to 100ºC. The reaction mixture was held at this temperature for 20h, cooled to 
room temperature, water and diethyl ether (10 mL of each) were added and organic 
material was removed by extraction. After further extraction of the aqueous layer with 
diethyl ether the organic phases were combined, dried over MgSO4 and the diethyl ether 
was removed in vacuo, leaving the crude product, which was purified by column 
chromatography (silica gel, 1:4 diethyl ether: PE) affording 250 mg (71%) of the white 
solid product 15, m.p = 80-83°C. 
1H NMR (300 MHz, CDCl3) δ = 1.12 (s, 9H), 1.50 (s, 9H), 2.57-2.85 (m, 2H), 4.18-
4.41(m, 2H), 5.09 (bs, 1H), 5.56 (bs, 1H), 7.31-7.59 (m, 9H). - 13C NMR (75.5 MHz, 
CDCl3) δ = 27.40 (+), 28.44 (+), 35.95 (-), 67.49 (-), 69.89 (+), 80.07 (Cquat), 82.26 
(Cquat), 85.47 (Cquat), 126.73 (Cquat), 127.08 (+), 127.32 (+), 127.41 (+), 127.59 (+), 
127.97 (+), 128.89 (+), 131.04 (+), 136.65 (Cquat), 140.94 (Cquat), 154.3 ( Cquat), 170.10 
(Cquat). - MS [ESI;CH2Cl2/MeOH+10mmol NH4OAc].=440.3 [MH+] (65), 457.3 [M-
NH4+] (60), 401.2 [M-NH4+-C4H8] (100). - IR (KBr):  cm-1 = 3362, 2975, 2932, 2873, 
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2199, 1509, 1454, 1392. Anal. calcd. For C26H33NO5 (439.54): C 71.05, H 7.57, N 3.19, 
found C 70.82, H 7.66, N 3.15.  
 
tert-Butyl 3-(tert-butoxycarbonyl)-2-(4-(benzylamino)phenyl)-tetrahydrofuran-3-yl 
carbamate (rac-16a) 
 
 
An oven-dried Schlenk flask equipped with a Teflon septum was charged with a 
magnetic stir bar, 3 mL of DMF, compound rac-4a (250 mg, 0.567 mmol), CuI (5.5 mg, 
0.028 mmol, 5 mol%), and K3PO4 ( 240 mg, 1.134 mmol). The flask was evacuated and 
filled with argon (this procedure was repeated three times). Under a flow of argon, the 
appropriate amine (91 mg, 0.851 mmol) was added by syringe. Finally, 2-isobutyryl-
cyclo hexanone (20 mg, 0.113 mmol, 20 mol%) was added via syringe. The mixture was 
heated to 100ºC for 10h. Upon completion of the reaction, the mixture was allowed to 
cool to room temperature, diluted with 5 mL of water, the aqueous layer was extracted 
with diethyl ether (3x3 mL), the total organic fraction was dried over MgSO4 and the 
solvent was removed in vacuo. The crude product was purified by column 
chromatography (silica gel, diethyl ether: PE 2:3) affording 200 mg (yield, 75%) of pure 
compound rac-16a as white solid. m.p.122-125ºC. 
1H NMR (300 MHz, CDCl3): δ = 1.15 (s, 9H), 1.47 (s, 9H), 2.47-2.60 (m, 1H), 2.72-
2.84 (s, 1H), 4.10 (q, J = 8.05 Hz, 1H), 4.25-4.30 (m, 1H), 4.32 (s, 2H), 4.80 (bs, 1H), 
5.40 (bs, 1H), 6.55 (d, J = 8.50 Hz, 2H), 7.15 (d, J = 8.50 Hz, 2H), 7.27-7.35 (m, 5H). - 
13C NMR (75.5 MHz, CDCl3) δ = 27.53 (+), 28.40 (+), 35.59 (-), 48.09 (-), 67.62 (-), 
69.85 (+), 79.90 (Cquat), 81.81 (Cquat), 86,56 (Cquat), 112.40 (+), 126.00 (Cquat), 127.16 
(+), 127.31 (+), 127.56 (+), 128.59 (+), 139.36 (Cquat), 147.97 (Cquat), 154.74 (Cquat), 
170.05 (Cquat). - MS [ESI;CH2Cl2/MeOH+10mmol NH4OAc].=.469.3 [MH+] (100), 
486.3 [M-NH4+] (65). - IR (KBr):  cm-1 = 3362, 2975, 2932, 2873, 2199, 1509, 1454, 
1392. Anal. calcd. For C27H36N2O5 (468.58): .C 69.21, H 7.74, N 5.98, found C 69.17, 
H 7.67, N 6.00.  
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tert-Butyl 3-(tert-butoxycarbonylamino)-2-(4-morpholinophenyl)tetrahydrofuran-3 
carboxylate (rac-16b) 
O
BocHN
O
OtBu
N
O
 
 
The compound was prepared by using the same procedure as described for rac-16a. The 
isolated yield was 35%. 
1H NMR (300 MHz, CDCl3): δ = 1.14 (s, 9H), 1.50(s, 9H), 2.52--2.60 (m, -CHH-, 1H), 
2.70-2.80 (m, -CHH-, 1H), 3.10 (m, 4H) 3.80-3.90 (m, 4H), 4.09-4.18 (m, -OCHH-, 
1H), 4.27-4.38 (m, -OCHH-, 1H), 4.90 (bs, 1H), 5.50 (bs, 1H), 6.80 (d, J = 8.42 Hz, 
2H), 7.20 (d, J = 8.42 Hz, 2H). - 13C NMR (75.5 MHz, CDCl3): δ = 27.51 (+), 28.40 (+), 
35.94 (-), 49.59 (-), 66.79 (-), 67.74 (-), 67.79 (+), 69.80 (+), 81.95 (Cquat), 82.50 (Cquat), 
84.72 (Cquat), 117.73 (+), 126.72 (Cquat), 127.66 (+), 131.95 (+), 140.16 (Cquat), 144.47 
(+), 154.3 ( Cquat), 167.45 (Cquat), 170.05 (Cquat). - MS [ESI;CH2Cl2/MeOH+10mmol 
NH4OAc].=.449.2 [MH+] (100). 
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Synthesis of 3-Oxo-2,3-dihydro-pyrrole Amino Acids as Chiral 
Dipeptidomimics* 
3.1. Introduction 
A peptidomimic imitates peptide structures by controlled spatial disposition of 
functional groups and a general analogous structure. Previously reported peptidemimics 
based on oligo-3-oxo-2,3-dihydro-pyrroles have been used as protease inhibitor and 
ligand for hormone and protein receptors.1 Their chiral sequence can adopt the bioactive 
conformation of peptide ligands while exhibiting good pharmacokinetic properties.2 
Smith and Hirschmann3 first prepared 2,5-linked 3-oxo-2,3-dihydro-pyrroles 1 starting 
from chiral natural amino acids (Figure 1). Seebach et al.4 have prepared α-substituted 
proline derivatives with retaining the chirality, which was further developed into β-turn 
peptide mimics 2 by Gmeiner et al.5 Recently Chakarborty et al. introduced 5-
(aminomethyl)pyrrole-2-carboxylic acid as a constrained surrogate of Gly-∆-Ala6. Our 
group elaborated the pyrrole amino acid building block and reported the synthesis of 
methoxypyrrole amino acids (MOPAS), their facile introduction into peptide structures 
and intra- and intermolecular peptide binding properties7. We have also reported chiral 
dipeptide mimic H2N-Val-∆-Ala-OEt, which has been prepared using chiral auxiliary 
approach8.  
Extending this, we are reporting here the synthesis of 2-allyl-2,3-dihydro-3-oxo pyrrole 
amino acids by stereoselective chiral allylation using the Trost ligand9 as chiral control 
element. 
 
 
Figure 1 Structures of 2,5-linked 3-oxo-2,3-dihydro-pyrroles 1 and β-turn peptide 
mimics 2. 
                                                        
*
 The results of this chapter have been published:  Maity, P.; König, B. Synthesis, 2006, 2719-2724.   
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3.2. Results and discussion 
First, we prepared 3-hydroxy pyrrole amino acids (HOPAS) 7 as starting material for the 
asymmetric synthesis of a chiral 3-oxo-2,3-dihydro pyrrole amino acid, such as 8. 
Scheme 1 summarizes the synthetic steps. The hydroxyl group of pyrrol 3,10 was benzyl 
protected, formylated in 5-position, converted into Boc-protected amino ester 6 and 
debenzylated to give 7 
 
 
Scheme 1. Synthesis of HOPAS 7. a) BnCl, K2CO3, in DMF, 85o C, 16h. b) POCl3, 
DMF, in DCE, reflux, 2.5h c) NH2Boc, HCOOH, p-TsONa, in THF/H2O, rt, 72h, d) 
NaBH4, THF, rt., 2h e) Pd-C/H2, MeOH, rt, 24h. 
The basic hydrolysis of 2-ethyl-3-hydroxy-pyrrole carboxylates is known to be difficult. 
In basic media the compound exists in its two tautomeric forms (Figure 2).11 Using this 
property we intended to introduce an allyl group at carbon C-2 via Pd-catalyzed 
allylation in a stereoselective manner using the chiral Trost ligand.12,13 The allylated 3-
oxo-2,3-dihydro pyrrole amino acids 8 was obtained (Scheme 2), but the yield (35%) 
and the enantiomeric excess (28 % ee) of the reaction are unsatisfactory. 
 
 
Figure 2. Tautomers of 2-ethyl-3-hydroxy-pyrrolcarboxylate 
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During the alkylation reaction the thermodynamically unfavourable loss of aromaticity 
occurs, which may explain the difficulties. Introduction of an electron withdrawing 
group on the pyrrole nitrogen, which reduces the availability of the lone pair,14 may 
improve the situation. Therefore, N-Boc protected pyrrole 10 was prepared starting from 
5 (Scheme 3). The NMR spectrum of 3-hydroxyl pyrrole 11 in CDCl3 reveals the 
presence of the keto tautomer as the only isomer, which indicates the reduced 
heteroaromatic character of the pyrrole ring. 
 
 
 
Scheme 2. Synthesis of allylated 3-oxo-2,3-dihydro-pyrrole amino acid 8. 
The reaction of 3-oxo-2,3-dihydro pyrrole 11 with allylacetate in the presence 
allylpalladium(II)chloride as catalyst and the chiral Trost ligand gave the desired 
compound in good yield. Table 1 summarizes the results for different conditions. An ee 
of 68% was observed at 0oC with KOtBu as base in CH3CN. Decrease of the reaction 
temperature to -35oC increased the optical purity of the isolated product to 71% ee with 
a chemical yield of 87%. Compound 12 was fully characterized by spectroscopic 
methods. The transition state model for the formation of the quaternary centre predicts 
an “R” configuration if the [R,R] stereoisomer of the Trost ligand is used.12 This is 
supported by the optical rotation of 12 [α]D = +143.8º, which corresponds to [α]D = 
+22.0º reported for the structurally related compound R-2,4-dibenzyl-2-(3-methyl-but-2-
enly)-1,2-dihydro-pyrrole-3-one.1 
KOtBu, rt,
CH3CN, L* ,
Pd(II)
7
35 %
L* = NH
N
H
OO
PPh2 Ph2PNH
O
BocHN
O
OEt
8
OAc
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Scheme 3. Synthesis of Boc-protected pyrrol 10 and its asymmetric allylic alkylation to 
3-oxo-2,3-dihydro-pyrrole amino acid 12. a) Boc2O, DMAP in DCM, 2h, room temp. b) 
NH2Boc, HCOOH, p-TsONa, THF/H2O, room temp., 2d c) NaBH4, THF, room temp., 
2h d) Pd/C, H2, MeOH:CHCl3 (8:1). 
Base Solvent Reaction time [h] 
Temper
-ature 
[ºC] 
Yield 
[%] 
eea 
[%] 
KOtBu CH3CN 2.0 
0 
 
83 68 
KOtBu CH3CN 2.5 -22 
 
87 71 
NaH THF 0.2 rt 
 
90 17 
NaH THF 6.0 -15 to 0 
 
95 31 
nBuLi THF 1.5 -78 
 
80 9 
 
aOptical purity was determined by chiral HPLC analysis. 
 
Table 1. Yield and optical purity of compound 12 at different reaction conditions. 
 
 
To demonstrate the ability of compound 12 to be incorporated into peptide chains, the 
Boc protecting group of the primary amine was removed selectively using HCl in ether. 
The amine was coupled using standard peptide coupling conditions with Boc-Phe-OH 
giving tripeptide 13 in 52% yield. The allyl group of 12 allows the introduction of 
additional functional groups if desired. The conversion into aldehyde 14 succeeds using 
K2OsO4 and NaIO4 in THF and H2O.15 The aldehyde was converted into the 
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corresponding acid 15 by using NaClO2, NaH2PO4 and H2O2 (30 vol.% in water) in 
CH3CN and H2O.16 Compound 15 resembles the structure of a partially constrained 
dipeptide of glycine and a β-amino acid. Acid 15 was coupled using standard peptide 
coupling conditions with Boc-deprotected compound 12 to give the tetrapeptide 
structure 1617 in 30 % yield. 
 
 
 
Scheme 4. Synthesis of peptides 13 and 16. a) HCl, ether b) EDC, HOBT, DIPEA, 
CH2Cl2, rt.; c) K2OsO4, NaIO4, THF/H2O; d) NaClO2, NaH2PO4, H2O2 in CH3CN & H2O 
(4:1), rt. 
 
3.3. Conclusion 
We have used the enantioselective Pd-catalyzed allylic alkylation with the Trost ligand 
to convert N-Boc protected 3-hydroxy pyrrole 11 into 3-oxo-2,3-dihydro-pyrrole amino 
acid 12 breaking the heteroaromatic π-system. With KOtBu as a base at low reaction 
temperatures an ee of 71% with a chemical yield of 87% was obtained. 3-Oxo-2,3-
dihydro-pyrrole amino acid 12 resembles the structure of a partially constrained dipep-
tide, which may find use in the synthesis of more extended peptide mimics. 
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3.4. Experimental section 
Melting points were determined on a melting point apparatus and are uncorrected. 
Specific rotations were measured on a polarimeter using a 10 cm cell. NMR spectra 
were recorded in CDCl3 at 300 MHz (1H) or 75 MHz (13C) unless stated otherwise. 
Structural assignments are based on DEPT and COSY experiments where applicable. 
The multiplicity of the carbon atoms is given as (+) = CH3 or CH, (-) = CH2 and (Cquat) 
for quaternary carbon atoms. Analytical TLC plates (silica gel 60 F254) and silica gel 60 
(70-230 or 230-400 mesh) for column chromatography (CC) were purchased from 
Merck. Visualization of spots by UV light and/or staining with phosphomolybdate or 
ninhydrine, both in ethanol. DMF, CH3CN, THF, and Et2O were dried by standard 
procedures and stored over molecular sieves or Na. PE means petrol ether with a boiling 
range of 70-90 oC. All other solvents and chemicals were of reagent grade and used with 
out further purification. The Trost ligand was prepared as described in the literature.9,18 
 
Ethyl 3-benzyloxy-4-methyl-1H-pyrrole-2-carboxylate (4):  
 
To a stirred solution of hydroxypyrrole 3 (12 g, 70.9 mmol) in dry DMF, K2CO3 (9.8 g, 
71 mmol) was added followed by benzylchloride (8.98 g, 70.9 mmol). The suspension 
was stirred for 14 h at 70ºC and 4 h at 110ºC. Then 820 mg (6.47 mmol) of 
benzylchloride was added and the solution was heated for another 1 h at the same temp. 
The reaction mixture was allowed to cool down to rt, and poured into 1L of water. The 
aqueous layer was extracted with ethyl acetate (3 x 150 mL). Then the combined 
organic layers were washed with 10% of aqueous Na2CO3 (100 mL), water (2 x 100 
mL) and dried over MgSO4. The solvent was removed in vacuum to get the oily product 
which was solidified by addition of PE. The solid was recrystallized from MeOH to 
afford 9.93 g (54%) of compound 4. m.p. 78-83ºC.  
1H NMR : δ = 1.35 (t, J = 7.14  Hz, 3 H), 1.91 (s, 3 H), 4.35 (q, J = 7.14  Hz, 2 H), 5.07 
(s, 2 H), 6.57 (m, 1 H), 7.27-7.50 (m, 5 H), 8.45 (bs, 1 H). 13C NMR (75 MHz, CDCl3): 
δ = 8.3 (+), 14.3 (+), 59.0 (-), 75.4 (-), 110.5 (Cquat), 111.4 (Cquat), 120.3 (+), 127.7 (+), 
128.0 (+), 128.0 (+), 137.7 (Cquat), 149.1 (Cquat), 159.6 (Cquat). MS (70 eV): m/z (%)= 
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259 (48) [M+], 186 (14) [M+-C3H5O2], 91 (100) [C7H7+]. IR (KBr): ν~  (cm-1) = 3298, 
2974, 2862, 1660, 1466, 1411, 1288. Anal. calcd. For C15H17NO3 (259.31): C 69.48, H 
6.61, N 5.40, found C 69.26, H 6.27, N 5.34. 
 
3-Benzyloxy-5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (5):  
 
A solution of compound 4 (7.43 g, 28.7 mmol) in 75 mL of 1,2-dichloroethane was 
added drop wise to an ice cold solution of DMF (2.3 g, 31.5 mmol) in 75 mL of 1,2-
dichloroethane containing POCl3 (4.83 g, 31.5 mmol). After stirring at room temp. for 1 
h the mixture was heated to reflux for 2 h, then cooled to room temp., 50 mL of EtOAc 
and 100 mL of H2O were added and the organic layer was separated. The aqueous layer 
was washed with EtOAc (2 x 100 mL) and the combined organic layer were washed 
with 10% aqueous Na2CO3 (5 x 150 mL) and dried over MgSO4. Evaporation of the 
solvent gave 7.85 g crude product which was purified by CC on silica gel (PE : EtOAc, 
70 : 30; Rf = 0.43) Yield: 7.60 g (92%) of 3, m.p.= 81-83ºC.  
1H NMR: δ = 1.38 (t, J = 7.14 Hz, 3 H), 2.12 (s, 3 H), 4.38 (q, J = 7.14 Hz, 2 H), 5.06 
(s, 2 H), 7.30-7.47 (m, 5 H), 9.25 (bs, 1 H), 9.71 (bs, 1 H). 13C NMR: δ = 6.8 (+), 14.4 
(+), 61.2 (-), 77.1 (-), 117.8 (Cquat), 123.1 (Cquat), 127.7 (Cquat), 128.3 (+), 128.5 (+), 
128.5 (+), 137.0 (Cquat), 148.7 (Cquat), 159.6 (Cquat), 179.1 (+). MS (70 eV): m/z (%)= 
287 (22) [M+], 91 (100) [C7H7+]. IR (KBr):  ν~  (cm-1) = 3258, 2938, 2817, 169, 1672, 
1555, 1507, 1487, 1377, 1280. Anal. calcd. For C16H17NO4 (287.32): C 66.89, H 5.96, N 
4.88, found C 66.79, H 5.95, N 4.87. 
 
Ethyl 3-benzyloxy-5-(tert-butoxycarbonyl amino-methyl)-4-methyl-1H-pyrrole-2-
carboxylate (6):  
 
A mixture of tert-butylcarbamate (554 mg, 4.73 mmol), 1.9 mL of THF, 2 mL of H2O, 
sodium p-toluene sulfinate (843 mg, 4.73 mmol), aldehyde 5 (1 g, 4.73 mmol) and 1.18 
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mL of formic acid were stirred until it became homogeneous and stirred for 6 days at 
room temp. The solid product was filtered off with suction, washed successively with 
water, PE and dried over P2O5 to give 2.02 g of a tosylated intermediate, which was used 
for the next step without further purification. The compound (522 mg) was added 
portion wise to a suspension of NaBH4 (72 mg, 1.92 mmol) in 5 mL of THF while the 
mixture was ice cooled. Stirring was continued for 15 min with ice cooling and 2 h at 
room temp. The mixture was ice cooled again, quenched with 1 mL of sat. aqueous 
NH4Cl, stirring was continued for 30 min, the organic layer was separated and the 
aqueous layer was extracted with 15 mL of CH2Cl2. The combined layers was dried over 
MgSO4 and evaporated. The crude product was purified by CC on silica gel (CHCl3: 
acetone 95:5 to 90:10; Rf (90:10) = 0.68) to give 232 mg (59%) of compound 6 m.p. 
compound 6: 112.5-113ºC;  
1H NMR: δ = 1.34 (t, J = 7.14 Hz), 1.46 (s, 9 H), 1.86 (s, 3 H), 4.16 (m, 2 H), 4.32 (q, 
J = 7.14 Hz, 2H), 4.98 (bs, 1 H), 5.04 (s, 2 H), 7.27-7.49 (m, 5 H), 9.08 (bs, 1 H).  
13C NMR: δ = 7.2 (+), 14.5 (+), 28.4 (+), 35.9 (-), 60.1 (-), 76.7 (-), 80.1 (Cquat), 110.4 
(Cquat), 110.7 (Cquat), 127.9 (+), 128.2 (+), 128.3 (+), 129.5 (Cquat), 137.8 (Cquat), 149.7 
(Cquat), 156.6 (Cquat), 160.4 (Cquat).  IR (KBr): ν~  (cm-1) = 3357, 3282, 2980, 2934, 1687, 
1665, 1531, 1461, 1294, 1171, 1027. Anal. calcd. For C21H28N2O5 (388.47) : C 64.93, 
H7.27, N 7.21, found C 64.74, H 7.64, N 7.00. 
 
Ethyl 5-(tert-butoxycarbonylamino-methyl)-3-hydroxy-4-methyl-1H-pyrrole-2-
carboxylate (7):  
 
To a solution of compound 6 (100 mg, 257µmol) in EtOAc (3 mL), 10 mg of Pd-C 
(10% Pd) was added and the mixture was transferred to an autoclave. The mixture was 
stirred for 48 h under H2 (10 bar) at room temp. The solution was filtered through celite. 
The solvent was evaporated in vacuum to give compound 7 (76.7 mg, 257µmol, quant.), 
m.p. 102-103ºC.  
1H NMR: δ = 1.34 (t, 3J =7.14 Hz, 3 H), 1.46 (s, 9 H), 1.94 (s, 3 H), 4.15 (m, 2 H), 4.31 
(q, 3J = 7.14 Hz, 2 H), 4.89 (bs, 1 H), 7.69 (bs, 1 H), 8.47 (bs, 1 H). 13C NMR: δ = 6.5 
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(+), 14.6 (+), 28.3 (+), 59.9 (-), 77.2 (Cquat), 80.3 (Cquat), 104.2 (Cquat), 104.6 (Cquat), 
131.2 (Cquat), 152.7 (Cquat), 156.7 (Cquat). IR (KBr) : ν~  (cm-1) = 3354, 3281, 2972, 2929, 
1675, 1536, 1482, 1293, 1247.  MS (ESI, CH2Cl2/MeOH + 10 mmol/1 NH4OAc): m/z 
(%) = 299 (100) [M+H+], 243 (13) [M+H+-C4H8].  Anal. calcd. For C14H22N2O5 
(298.34): C 56.36, H 7.43, N 9.39, found C 56.17, H 7.78, N 9.06. 
 
Ethyl 2-allyl-5-(tert-butoxycarbonylamino-methyl)-4-methyl-3-oxo-2,3-dihydro-
1H-pyrrole-2-carboxylate (8): 
 
To a flask containing a solution of compound 7 (2 g, 6.5 mmol) in 25 ml of dry CH3CN, 
KOtBu (0.73 g, 6.5 mmol) was added under dinitrogen. The mixture was stirred for 15 
min at 0ºC. Meanwhile, the palladium complex (η3-C3H5PdCl)2 (36.5 mg, 100 µmol) 
and (R, R)-Trost ligand (69.2 mg, 100 µmol) were dissolved in dry CH3CN and stirred 
for 15 min at rt before ally acetate (2.10 mL, 19.54 mmol) was added and stirring was 
continued at room temp. for additional 5 min. The catalyst solution was cooled to 0ºC 
before syringed into the enolate solution at 0ºC. The mixture was stirred for 1 d. The 
reaction was quenched with sat. aqueous NH4Cl (10 mL) and the mixture was stirred 
vigorously for 10 min. Water (20 mL) was added to dissolve the precipitates. Extraction 
with ether (3 x 30 mL), drying of the organic phase (MgSO4) and removal of the solvent 
in vacuum gave the crude product which was purified by CC on silica gel (PE : EtOAc; 
1 : 1; Rf = 0.32) to give 768 mg of 8 as a colorless oil in 35% yield.  
1H NMR: δ = 1.27 (m, 3 H), 1.46 (s, 9 H), 1.66 (s, 3 H), 2.43 (m, 1 H), 2.93 (m, 1H), 
4.16 (m, 1 H), 4.19 (m, 2 H), 4.24 (m, 1 H), 4.98 (m, 1 H), 5.10 (m, 1 H), 5.15 (m, 1 H), 
5.67 (m, 1 H), 5.81 (m, 1 H). 13C NMR: δ = 6.0 (+), 14.2 (+), 28.3 (+), 38.0 (-), 39.9 (-), 
62.4 (-), 72.6 (Cquat), 105.5 (Cquat), 119.8 (-), 131.6 (+), 156.4 (Cquat), 167.4 (Cquat), 173.7 
(Cquat), 196.1 (Cquat). IR (NaCl): ν~  (cm-1) = 3327, 2983, 2933, 1772, 1729.  MS (ESI, 
CH2Cl2/MeOH + 10 mmol/1 NH4OAc): m/z (%) = 339.1 (100) [M+H+], 283.0 (15) 
[M+H+-C4H8]. 
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1-tert-Butyl-2-ethyl 3-benzyloxy-5-formyl-4-methyl-pyrrole-1,2-dicarboxylate (9) :  
 
To a solution of compound 5 (5 g, 17.42 mmol) in dry CH2Cl2 (100 mL) at room temp. 
DMAP (2.2 g, 18.0 mmol) was added and the mixture was stirred for 10 min under 
nitrogen. (Boc)2O (3.93 g, 18.0 mmol) was added and the mixture was stirred for 
another 30 min. The solution was washed with water (4 x 100 mL) and dried over 
MgSO4. The solvent was evaporated in vacuum and the crude product was purified by 
CC on silica gel (PE: EtOAc; 2:1; Rf = 0.60; 1:4, EtOAc : PE) to give 6.7 g of 9 
(quantitative yield) as a colorless oil.  
1H NMR: δ = 1.35 (3 H, t, J = 7.14 Hz), 1.69 (s, 9 H), 2.20 (s, 3 H,), 4.35 (q, J = 7.14 
Hz, 2 H), 5.00 (s, 2 H), 7.27-7.50 (m, 5 H), 10.05 (s, 1 H).  13C NMR: δ = 8.3 (+), 14.2 
(+),27.5 (+), 61.6 (-), 77.4 (-) , 86.4 (Cquat), 118.9 (Cquat), 125.1 (Cquat), 128.3 (+), 128.4 
(+), 128.6 (+), 136.60 (+), 148.23 (Cquat), 148.81 (Cquat), 160.05 (Cquat), 181.55 (Cquat). 
IR (NaCl): ν~  (cm-1) = 3444, 3145, 3005, 2977, 2933, 2875, 2200, 1729, 1754, 1603, 
1500, 1462, 1432, 1389, MS (ESI, CH2Cl2/MeOH + 10 mmol/1 NH4OAc) : m/z (%) = 
388.2 (95) [M+H+], 288.1 (100) [M+H+-C4H8].– Anal. calcd. For C21H25NO6 (387.44) : 
C 65.10, H 6.50, N 3.62, found C 64.92, H 6.57, N 3.52 
 
1-tert-Butyl-2-ethyl-3-benzyloxy-5-(tert-butoxycarbonylamino-methyl)-4-methyl-
pyrrole-1,2-dicarboxylate (10):  
 
A mixture of tert-butylcarbamate (302 mg, 2.58 mmol), 1.9 mL of THF, 2 mL of H2O, 
sodium p-toluene sulfinate (459.8 mg, 2.58 mmol), aldehyde 9 (1 g, 2.58 mmol) and 
1.18 mL of formic acid were stirred until a homogeneous mixture was obtained, which 
was stirred for 2 days at room temp. The solid product was filtered off with suction, 
washed successively with water, PE and dried over P2O5 to give 2.02 g of 1-tert-butyl-2-
ethyl-3-benzyloxy-5-[tert-butoxycarbonylamino-(toluene-4-sulfinyloxy)-methyl]-4-
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methyl pyrrole-1,2-dicarboxylate, which was used for the next step without further 
purification. 
To a suspension of NaBH4 (72 mg, 1.92 mmol) in 5 mL THF 1-tert-butyl-2-ethyl-3-
benzyloxy-5-[tert-butoxycarbonylamino-(toluene-4-sulfinyloxy)-methyl]-4-methyl-
pyrrole-1,2-dicarboxylate (522 mg) was added portion wise while the mixture was ice 
cooled. Stirring was continued for 15 min with ice cooling and 2 h at room temp. The 
mixture was ice cooled again, quenched with 1 mL of sat. aqueous NH4Cl, stirring was 
continued for 30 min, the organic layer was separated and the aqueous layer was 
extracted with 15 mL of CH2Cl2. The combined layers was dried over MgSO4 and 
evaporated. The crude product was purified by CC on silica gel (EtOAc: PE; 1:4, Rf = 
0.59) to give 232 mg (55%) of compound 10, which was recrystallyzed from ether, m.p. 
= 103-105ºC. 
1H NMR: δ = 1.34 (t, J = 7.14 Hz, 3H), 1.47 (s, 9 H), 1.63 (s, 9H), 2.06 (s, 3 H), 4.25 
(m, 4H), 5.05 (s, 2 H), 5.51 (bs, 1 H), 7.27-7.49 (m, 5 H). 13C NMR: δ = 7.6 (+), 14.6 
(+), 15.3 (+), 27.6 (+),28.4 (+), 35.1 (-), 60.8 (-), 60.8 (+), 77.1 (-), 85.3 (Cquat), 114.1 
(Cquat), 115.3 (Cquat), 128.1 (+), 128.1 (+), 128.4 (+), 132.1 (+), 137.6 (+), 149.6 (Cquat), 
151.6 (Cqart), 155.6 (Cquat), 160.7 (Cquat).  MS (ESI, CH2Cl2/MeOH + 10 mmol/1 
NH4OAc): m/z (%) = 489.3 (100) [M+H+], 433.1 (10) [M+H+-C4H8] , 389.2 (20) 
[M+H+-2C4H8].  IR (KBr): ν~  (cm-1) = 3448, 3245, 3035, 2977, 2933, 2875, 2200, 1739, 
1714, 1603, 1500, 1462, 1432, 1389, 1336, 1302, 1238. Anal. calcd. For C26H36N2O7 
(488.59) : C 63.92, H 7.43, N 5.73, found C 63.83, H 7.71, N 5.64. 
 
1-tert-Butyl-2-ethyl-5-(tert-butoxycarbonylaminomethy)-4-methyl-3-oxo-2,3-
dihydro-pyrrole-1,2-dicarboxylate (11):  
 
 
Compound 10 (2 g, 4.1 mmol) was dissolved in 2 mL of CHCl3 and 10 mL of MeOH. 
Pd/C (200 mg, 10 % Pd) was added and the mixture was transferred into an autoclave. 
The mixture was stirred for 2 h under H2 (8 bar) at room temp. The solution was filtered 
through celite and the solvent was evaporated in vacuum to give the crude product, 
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which was purified by CC on silica gel (PE : EtOAc, 4 : 1; Rf = 0.32 (1:4 , EtOAc: PE) 
to give 1.2 g (75 %) of compound 11 as a colorless oil. At room temperature the 
compound shows slow decomposition; refrigerate. 
1H NMR: δ = 1.34 (t, 3J =7.14 Hz, 3 H), 1.43 (s, 9 H), 1.53 (s, 9 H), 1.86 (s, 3 H), 4.31 
(q, 3J = 7.14 Hz, 2 H), 4.54 (m, 2 H), 4.79 (s, 1 H), 5.56(bs, 1 H).  13C NMR: δ = 6.6 
(+), 14.2 (+), 28.0 (+), 28.4 (+), 36.5 (-), 62.0 (-), 67.0 (+), 79.3 (Cquat), 83.7 (Cquat), 
117.7 (Cquat), 149.2 (Cquat), 155.5 (Cquat), 164.1 (Cquat), 165.5 (Cquat), 192.3 (Cquat).  IR 
(NaCl): ν~  (cm-1) = 3453, 3412, 3101, 2973, 2943, 1763, 1724, 1698, 1623, 1489, 1367. 
MS (ESI, CH2Cl2/MeOH + 10 mmol/1 NH4OAc): m/z (%) = 399 (100) [M+H+], 343.1 
(17) [M+H+-C4H8].  Anal. calcd. For C19H30N2O7 (398.46) : C 57.27, H 7.59, N 7.03, 
found C 55.28, H 7.31, N 6.65. 
 
1-tert-Butyl-2-ethyl-2-allyl-5-(tert-butoxycarbonylamino-methy)-4-methyl-3-oxo-
2,3-dihydro-pyrrole-1,2-dicarboxylate (12):  
 
To a flask containing a solution of compound 11 (0.3 g, 0.8 mmol) in 15 mL of dry 
CH3CN, KOtBu (0.09 g, 0.8 mmol) was added under nitrogen. The mixture was stirred 
for 15 min at -22ºC. Meanwhile the palladium catalyst (η3-C3H5PdCl)2 (27.6 mg, 75 
µmol) and (R,R)-Trost ligand (52.2 mg, 75 µmol) were dissolved in 5 mL dry CH3CN 
and stirred for 15 min at rt before allyl acetate (0.4 mL, 3.8 mmol) was added. Stirring 
was continued at rt for additional 5 min. The catalyst solution was cooled to -22ºC 
before syringed into the enolate solution at -22ºC. The resulting mixture was stirred for 
2.5 h at -22ºC. The reaction was quenched with sat. aq NH4Cl (5 mL) and the mixture 
was stirred vigorously for 10 min. Water (10 mL) was then added to dissolve the formed 
precipitates. Extraction with ether (3 x 15 mL), drying of the organic phase (MgSO4) 
and removal of the solvent in vacuum gave the crude product, which was purified by CC 
on silica gel (PE: EtOAc; 1:4; Rf = 0.37) to give 275 mg (87%) of 12 as colorless oil. 
[α]D = +143.8º (c = 0.2, CHCl3). 
1H NMR: δ  = 1.27 (m, 3J= 7.14 Hz, 3 H), 1.43 (s, 9 H), 1.49 (s, 9H), 1.66 (s, 3 H), 3.05 
(d, 2 H), 4.16 (q, 3J=7.14 Hz, 2 H), 4.36-4.54 (m, 2 H), 4.96-5.10 (m, 2 H), 5.23-5.37 
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(m, 1 H), 5.50-5.60 (bs, 1 H). 13C NMR: δ = 6.0 (+), 14.2 (+), 28.3 (+), 38.0 (-), 39.9  (-
), 62.4 (-), 72.6 (Cquat), 105.5 (Cquat), 119.8 (-), 131.6 (+), 156.4 (Cquat), 167.4 (Cquat), 
173.7 (Cquat), 196.1 (Cquat). IR (NaCl): ν~  (cm-1) = 3454, 3402, 3081, 2980, 2933, 1753, 
1716, 1698, 1622, 1489, 1367, 1285, 1246, 1166, 1115, 1068. MS (ESI, CH2Cl2/MeOH 
+ 10 mmol/1 NH4OAc) : m/z (%) = 339.1 (100) [M+H+], 283.0 (15) [M+H+-C4H8].  
Anal. calcd. For C22H34N2O7 (438.53) : C 60.26, H 7.82, N 6.39, found C 59.71, H 7.64, 
N 6.09. 
 
2-Allyl-5-[(2-tert-butoxycarbonylamino-3-phenyl-propinoylamino)-methyl]-4-
methyl-3-oxo-2,3-dihydro-pyrrole-1,2-dicarboxylicacid-1-tert-butyl ester-2-ethyl 
ester (13):  
 
Compound 12 (100 mg, 0.25 mmol) was dissolved in CH2Cl2 (4 mL) in which HCl-
saturated ether (4 mL) was added and the mixture was stirred at rt overnight. The 
resulting ammonium salt (90 mg, 0.24 mmol) was dissolved in a solution of N-Boc 
phenylalanine (82.7 mg, 0.312 mmol), EDC (60 µL, 0.312 mmol), HOBT (42.1 mg, 
0.312 mg), and DIPA (o.09 mL, 0.528 mmol) in 5 mL of CH2Cl2 and stirred for 4 h at 
room temp. Then the reaction mixture was washed with water (2 x 5 mL), 5% aqueous 
KHSO4 (5mL), and 2 mL of saturated aqueous NaHCO3. The resulting solution was 
dried over MgSO4, and the solvent was evaporated to give compound 13 as a white solid 
in 52% yield. [α]D = -110.3º (c = 0.007, CHCl3), m.p. = 58-60ºC. 
1H NMR: δ = 1.25 (t, 3J =7.14 Hz, 3 H), 1.43 (s, 9 H), 1.53 (s, 9 H), 1.86 (s, 3 H), 2.85-
3.14 (m, 4H), 4.19 (q, 3J = 7.14 Hz, 2 H), 4.29-4.51 (m, 2H), 4.61-4.72 (m, 1H), 4.75-
5.10 (m, 3H), 5.16-5.27 (m, 1H), 6.90 (bs, 1H), 7.13-7.37 (m, 5H).  13C NMR: δ = 6.6 
(+), 14.1 (+), 28.1 (+), 28.2 (+),35.3  (-), 38.3(-), 38.8 (-),55.5 (+), 62.4 (-), 73.7 (Cquat), 
84.0 (Cquat), 83.7 (Cquat), 117.7 (Cquat), 119.9 (-), 120.0 (+), 128.6 (+), 129.4 (+), 129.8 
(+), 136.4 (Cquat),.149.2 (Cquat), 164.7 (Cquat), 165.5 (Cquat), 170.7(Cquat), 195.6 (Cquat).  
IR (KBr): ν~  (cm-1) = 3424, 3365, 2978, 2933, 2872, 2362, 2199, 1944, 1753, 1702, 
1620, 1498, 1454, 1367, 1280. MS (ESI, CH2Cl2/MeOH + 10 mmol/1 NH4OAc): m/z 
(%) = 586.5 (100) [M+H+], 530.5 (21) [M+H+-C4H8], 630.6 (25) [M+NH4+]. Anal. 
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calcd. For C31H43N3O8 (585.70): C 63.57, H 7.40, N 7.17, found C 63.80, H 7.21, N 
7.54 
 
1-tert-butyl-2-ethyl-5-(tert-butoxycarbonylaminomethyl)-4-methyl-3-oxo-2-(-2-oxo-
ethyl)-2,3-dihydro-pyrrole-1,2-dicarboxylate (14):  
 
Compound 12 (200 mg, 0.46 mmol) was dissolved in THF: H2O (4: 1, 12 mL). This 
solution was stirred under N2 and potassium osmate (VI)-dihydrate (20 mg) was added. 
The reaction turned dark brown. After 5 min NaIO4 (312 mg) was added in three batches 
over a 10 min period. The reaction turned light green, and stirring was continued for 5 h. 
The reaction was diluted with Et2O (10 mL) and water (5 mL). The aqueous layer was 
extracted with Et2O (2 x 12 mL). The combined ether layers were washed with brine 
(5mL), and dried over MgSO4. Removal of solvent in vacuum gave a colourless oil, 
which was chromatographed on silica gel (EtOAc: PE 1 : 3; Rf = 0.4) to give 150 mg 
(75%) of compound 14, as a colourless oil. . [α]D = +17.7º (c = 0.007, CHCl3). 
1H NMR: δ = 1.27 (t, 3J = 7.14 Hz, 3 H), 1.43 (s, 9 H), 1.47 (s, 9 H), 1.90 (s, 3 H), 3.20-
3.42 (m, 2 H), 4.15-4.23 (q, 3J = 7.14 Hz, 2 H), 4.45-4.51(d, 2 H), 5.40-5.55 (bs, I H), 
9.55(s, 1 H).  13C NMR: δ = 6.0 (+), 14.2 (+), 28.3 (+), 38.0 (-), 39.9  (-), 62.4 (-), 72.6 
(Cquat), 105.5 (Cquat), 119.8 (-), 131.6 (+), 156.4 (Cquat), 167.4 (Cquat), 173.7 (Cquat), 196.1 
(Cquat).  IR (NaCl): ν~  (cm-1) = 3453, 2980, 2930, 2728, 2199, 2097, 1789, 1698, 1622, 
1492, 1365, 1284, 1247, 1167. MS (ESI, CH2Cl2/MeOH + 10 mmol/1 NH4OAc): m/z 
(%) = 441.2 (100) [M+H+], 385.1 (30) [M+H+-C4H8], 285.0 (30) [M+H+-2C4H8-CO2]. 
Anal. calcd. For C21H32N2O8 (440.50): C 57.26, H 7.32, N 6.36, found C 57.28, H 7.51, 
N 6.65 
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5-(tert-Butoxycarbonylaminomethyl)-2-carboxy methyl-4-methyl-3-oxo-2,3-
dihydro-pyrrole-1,2-di carboxylic acid-1-tert-butyl ester-2-ethyl ester (15): 
 
The aldehyde 14 (40 mg, 0.09 mmol) and sodium dihydrogenphosphate monohydrate 
(21 mg, 0.17 mmol) were dissolved in a 4:1 CH3CN - H2O solution (2.5 mL). H2O2 (1.5 
mL) and sodium chlorite (32 mg, 0.35 mmol) were added and the resulting mixture was 
stirred for another 30 mins. Water (1 mL) was added and the aqueous layer was 
extracted with EtOAc (3 x 1 mL). The combined organic layers were washed with brine 
(1 mL), dried over MgSO4 and concentrated to give compound 15 (35 mg, 85 % yield). 
Rf = 0.12 (1:1, EtOAc: P.E).  [α]D = +15.4º (c = 0.015, CHCl3). 
1H NMR: δ = 1.27 (t, 3J = 7.14 Hz, 3 H), 1.43 (s, 9 H), 1.47 (s, 9 H), 1.90 (s, 3 H), 3.20-
3.42 (m, 2 H), 4.15-4.23 (q, 3J = 7.14 Hz, 2 H), 4.45-4.51(d, 2 H), 5.40-5.55 (bs, I H), 
9.55(s, 1 H).  13C NMR: δ = 6.0 (+), 14.2 (+), 28.3 (+), 38.0 (-), 39.9 (-), 62.4 (-), 72.6 
(Cquat), 105.5 (Cquat), 119.8 (-), 131.6 (+), 156.4 (Cquat), 167.4 (Cquat), 173.7 (Cquat), 196.1 
(Cquat). IR (NaCl): ν~  (cm-1) = 3435, 2982, 2913, 2728, 2200, 2097, 1698, 1650, 1622, 
1492, 1365, 1284, 1247, 1167. MS (ESI, CH2Cl2/MeOH + 10 mmol/1 NH4Ac): m/z (%) 
= 457.3 (100) [M+H+], 474.3 (75) [M+NH4+]. HRMS (C21H32N2O9): calcd For 
C21H33N2O9 [MH+] 457.2186, found 457.2188 ± .42 
 
Compound 16:  
 
Compound 12 (28 mg, 0.06 mmol) was dissolved in CH2Cl2 (2 mL), HCl-saturated ether 
(2 mL) was added and the reaction mixture was stirred at rt overnight. The resulting 
ammonium salt (24 mg, 0.06 mmol) was dissolved in a solution of compound 15 (30 
mg, 0.065 mmol), EDC (0.01 mL, 0.065 mmol), HOBT (10.0 mg, 0.065 mmol), and 
DIPA (0.03 mL, 0.15 mmol) in 2 mL of CH2Cl2 and stirred for 4 h at room temp. The 
reaction mixture was washed with water (2x1 mL), 5% aqueous KHSO4 (1 mL), and 1 
mL of saturated aqueous NaHCO3. The resulting solution was dried over MgSO4 and the 
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solvent was evaporated to give a colourless oil which was chromatographed on silica gel 
(EtOAc: PE 1 : 3; Rf = 0.15) to give 12 mg (30%) of compound 16, as a colorless oil. 
1H NMR: δ  = 1.26 (m, 6 H), 1.45 (s, 9 H), 1.51 (s, 9H),1.54 (s, 9H), 1.80 (s, 3 H), 1.90 
(s, 3 H), 3.05 (m, 2 H), 3.20 (m, 2 H), 4.18 (m, 4 H), 4.30 (dd, 3J = 5.88 Hz, 2J = 14.75 
Hz., -CHH), 4.48 (m, 2H), 4.58 (dd, 3J = 5.88 Hz, 2J = 14.75 Hz., -CHH),  5.05-5.07 (m, 
2 H), 5.23-5.26 (m, 1 H), 5.58 (bs, 1 H), 6.60 (bs, 1 H). 13C NMR: δ = 6.5 (+), 6.7 (+), 
14.3 (+), 14.2 (+), 28.3 (+), 28.4 (+), 29.0 (+), 34.9 (-), 36.7 (-), 38.2 (-), 40.6 (-), 62.2 (-
), 62.6 (-), 71.8 (Cquat), 73.8 (Cquat), 79.5 (Cquat), 84.0 (Cquat), 117.5 (Cquat), 119.9 (-), 
120.2 (Cquat), 129.5 (+), 129.7 (+), 148.9 (Cquat), 149.3 (Cquat), 155.5 (Cquat), 164.7 
(Cquat), 165.3 (Cquat), 165.4 (Cquat), 166.0 (Cquat), 166.4 (Cquat),  195.0 (Cquat), 195.5 
(Cquat).  MS (ESI, CH2Cl2/MeOH + 10 mmol/1 NH4OAc): m/z (%) = 777.6 (100) 
[M+H+], 794 (20) [M+NH4]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 3. Chiral dipeptidomimics                                                                                 99                       
3.5. References and Notes 
 
 
1
  Smith, A. B. III.; Akaishi, R.; Jones, D. R.; Keenan, T. P.; Guzman, M. C.; Holcomb, R. C.; 
Hirschmann, R.; Wood, J. L.; Hirschmann, R.; Holloway, M. K. Biopolymers 1995, 37, 29-53. 
2
  Smith, A. B. III.; Hirschmann, R.; Pasternak, A.; Guzman, M. C.; Yokoyama, A.; Sprengeler, P. A.; 
Darke, P. L.; Emini, E. A.; Schleif, W. A. J. Am. Chem. Soc. 1995, 117, 11113-11123. 
3
  Smith, A. B. III.; Guzman, M. C.; Sprengeler, P. A.; Keenan, T. P.; Holocomb, R. C.; Wood, J. L.; 
Carroll, P. J.; Hirschmann, R. J. Am. Chem. Soc. 1994, 116, 9947-9962. 
4
  Seebach, D.; Boes, M.; Naef, R.; Schweizer, W. B. J. Am. Chem. Soc. 1983, 105, 5390-5398. 
5
  Bittermann, H.; Gmeiner, P. J. Org. Chem. 2006, 71, 97-102. 
6
  (a) Chakraborty, T. K.; Mohan, B. K.; Kumar, K. S.; Kunwar, A. C. Tetrahedron Lett. 2003, 44, 
471-473. (b) Chakraborty, T. K.; Mohan, B. K.; Kumar, S. K.; Kunwar, A. C. Tetrahedron Lett. 
2002, 43, 2589-2592. 
7
  (a) Bonauer, C.; Zabel, M. König, B. Org. Lett. 2004, 6, 1349-1352. (b) Kruppa, M.; Bonauer, C.; 
Michlová, V.; König, B. J. Org. Chem. 2005, 70, 5305-5308. 
8
  Bonauer, C.; König, B. Synthesis, 2005, 2367-2372 
9
  Trost, B. M.; Van Vranken, D. L.; Bingel, C. J. Am. Chem. Soc. 1992, 114, 9327-9343. 
10
  The compound was prepared according to Bonauer, C. Dissertation 2004, Universität Regensburg. 
11
  Momose, T.; Tanaka, T.; Yokota, T.; Nagamoto, N.; Yamada, K. Chem. Pharm. Bull. 1978, 26, 
3521-3529. 
12
  Trost, B. M.; Schroeder, G. M. Chem. Eur. J. 2005, 11, 174-184. 
13
  For examples of non-enantioselective, stoichiometric related reactions, see: (a) Beyer, M.; 
Ghaffari-Tabrizi, R.; Jung, M.; Margaretha, P. Helv. Chim. Acta 1984, 67, 1535 - 1539. (b) 
Plieninger, H.; Herzog, H. Monatsh. Chem. 1967, 98, 807 - 824. 
14
  (a) Drew, M. G. B.; George, A. V.; Isaaces, N. S.; Rzepa, H. S. J. Chem. Soc.; Perkin Trans 1 1985, 
7, 1277-1284. (b) Bennes, R.; Babiloni, M. S.; Hayes, W.; Philip, D. Tetrahedron Lett. 2001, 42, 
2377-2380. (c) Chen, Z.; Trudell, M. L. Chem. Rev. 1996, 96, 1179-1193. 
15
  Genin, M. L.; Johnson, R. L. J. Am. Chem. Soc. 1992, 114, 8778-8783. 
16
  Zhang, R.; Mamai, A.; Madalengoitia, J. S. J. Org. Chem. 1999, 64, 547-555. 
17
  The 1H-NMR coupling constant (3J) between NH of the peptide bond and the α-CH shows a value 
of 5.9 Hz, which indicates free rotation of the 3-oxo-2,3-dihydro pyrrole moieties around the 
connecting single bond. 
18
  a) Trost, B. M.; Schroeder, G. M.; Kristensen, J, Angew. Chem. Int Ed.2002, 41, 3492-3495. b) 
Trost, B. M.; Toste, F. D. J. Am. Chem. Soc. 1999, 121, 4545-4554 
 
 
Section 3. Chiral dipeptidomimics                                                                                 100                       
 
 
 
 
Section 4. α-Helix Mimetics                                                                                         101 
Synthesis of 1, 4-Dipiperazino-Benzene Scaffolds as α-Helix Mimetics* 
 
 
4.1. Introduction 
 
The α-helix is one of the most common structural motifs in protein secondary structures. 
Over 40% of all residues in proteins exist in an α-helical geometry.1 α-Helices are of 
particular importance for protein-protein, protein-DNA, and protein-RNA interactions.2 
However, to study such interactions with peptides is difficult, because they are flexible 
and proteolytically unstable. Therefore mimicking scaffolds3 have been developed that 
project side-chain functionality with similar distance and angular relationships to those 
found in α-helices. The critical interactions are found along a ‘face’ of the helix 
involving side chains from the i, i+3 or i+4, i+7, and i+11 residues. These side chains 
take defined distances and angular relationships in α-helices.4 Molecules that can 
predictably and selectively reproduce these projections are valuable tools in molecular 
biology and potential leads in drug discovery.5 Advantages, if compared to peptides, are 
an improved stability, lower molecular weight, and in some case a better bioavailability. 
Kahne et al.6 reported a pentasaccharide scaffold as an α-helix mimic presenting 
multiple charged groups that selectively bind the minor grove of DNA and not RNA. β-
Peptides have been used by Gellman et al.7 and Schepartz et al.8 to mimic an α-helix. 
Recently, Hamilton and co-workers9 have developed mimetics of the hydrophobic face 
of an α-helix using a terphenyl scaffold. The tris-ortho-substituted terphenyl can mimic 
the i, i+4, and i+7 residues of the α-helix by adopting a staggered conformation that 
closely reproduces the angular orientation of the peripheral functionalities on the helical 
surface. Synthetic foldamers mimicking extended α-helices are accessible using 
benzoylurea oligomers.10 Rebek et al. reported the synthesis of small libraries of low 
molecular weight α-helix mimetics having a pyridazine ring in the central position.11  
We now describe the synthesis of a new class of inherently chiral α-helix mimetics 
consisting of a 1,4-disubstituted central benzene ring and two substituted piperazines12 
bearing hydrophobic side chains, with defined configuration. Inspired by Hamilton’s 
terphenyl scaffolds, we sought for an improved synthetic accessibility, good water 
solubility and inherent chirality, while keeping dynamic and relative orientation of the 
key side chain functionalities. Figure 1 shows the structure of the calculated13 most 
stable conformer of a 1,4-di-piperazino benzene and its relation to the α-helix structure.  
                                                 
*
 Manuscript  in preparation 
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Figure 1. Residues in an α-helix and 1,4-di-piperazino benzene 
 
4.2. Results and discussion 
 
We follow a previously reported route14 to synthesize enantiomerically pure mono 
substituted piperazines (Scheme 1) starting from chiral amino acids. The amino esters 1 
were treated with ClCH2COCl and NaHCO3 in a mixture of water and benzene, which 
gave the products 2 in high purity and good yields. The crude products were reacted 
with benzylamine in methanol giving the key intermediate diketopiperazines 3 in good 
yield through a 1,5-cyclo condensation reaction.15 The diketopiperazines 3 were reduced 
by LiAlH4 to give mono-substituted piperazines 4 bearing a Bn protecting group on 
nitrogen atom 4. A series of deprotection and reprotection steps leads to piperazines 7, 
which are Bn protected at nitrogen atom 1.  
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Scheme 1 Synthesis of protected chiral piperazines 4a-c and 7a-b 
 
The synthesis of 1,4-dipiperazino benzene starts from 2-bromo-5-iodotoluene (8) and 
(S)-1-benzyl-3-alkylpiperazine (4a-c). The preferred substitution of the iodo-substituent 
is expected in transition metal catalyzed N-arylation reactions. Several ligands have 
been introduced to promote copper-catalyzed N-arylation of aliphatic secondary amines, 
most notably N,N-diethylsalicylamide,16 amino acids,17 and amino alcohols.18 Wan and 
co-workers reported copper powder/rac-BINOL or (copper+CuI)/rac-BINOL as a 
catalytic system; but the N-arylation requires elevated temperatures of 90-125ºC.19 
Recently Buchwald and co-workers developed a highly selective room temperature 
copper-catalyzed N-aryl coupling reaction using CuI and a cyclic β-diketone as the 
catalytic system and Cs2CO3 as base.20 Jiang and co-workers reported room temperature 
copper catalyzed Caryl-N coupling using CuBr/ rac-BINOL as catalyst.21 The number of 
reported examples of room temperature coupling reactions of aryl-iodides and ortho-
substituted cyclic secondary amines is small. 22  
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Ligand Base Solvent R Yield (%) 
A K3PO4 DMF CH3 10 
A K3PO4 DMSO CH3 7 
A Cs2CO3 DMF CH3 16 
B Cs2CO3 DMSO CH3 0 
C (20%) K3PO4 DMF CH3 30 
C (20%) Cs2CO3 DMF CH3 40 
C (30%) Cs2CO3 DMF CH3 60 
C (30%) Cs2CO3 DMF iBu 48 
C (30%) Cs2CO3 DMF Bn 54 
 
Table 1. Optimization of the catalytic condition for the copper-catalyzed Caryl-N bond 
formation of 2-bromo-5-iodotoluene (8) and (S)-1-benzyl-3-alkylpiperazine (4a-c) to 
give 1,4-dipiperazino benzenes 9 
 
We used the inexpensive and readily available catalytic system consisting of CuBr, 
racemic BINOL (1,1´-binapthyl-2,2`-diol) and Cs2CO3 to achieve the formation of C 
aryl-N (ortho-substituted piperazine) bonds at room temperature. The reaction conditions 
were optimized (Table 1) with (S)-1-benzyl-3-methylpiperazine (4a) and 2-bromo-5-
iodotoluene (8). 2-Isobutyrylcyclohexanone, L-proline, and racemic BINOL as ligands 
were reacted in DMF or DMSO with 20 mol% CuBr and Cs2CO3 as the base. Racemic 
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BINOL (30 mol%) gave the highest yields and 90% of the racemic BINOL was 
recovered after the reaction; yields decease with increasing steric bulk of the alkyl side 
chain in the piperazine ring. The X-ray diffraction analysis of compound 9b (Figure 2) 
reveals a chair conformation of the piperazine ring in the solid state which the i-Bu 
substituent in an axial position.  
 
 
Figure 2. Structure of compound 9b in the solid state determined by Röntgen analysis 
 
The second Caryl-N bond formation was accomplished by a palladium-catalyzed reaction 
(Table 2). Palladium-catalyzed amination of aryl halides has been shown to be a general 
method for the formation of aromatic carbon-nitrogen bonds.23 More recently, 
Buchwald and co-workers24 reported substituted and unsubstituted biaryl mono-
phosphine ligands (D), which are very effective in Caryl-N bond formation processes. 
We have tested the three ligands D, E and F for the formation of the second Caryl-N 
bond in compounds 9. In all cases, Pd2(dba)3.CHCl3 / L* (D/E/F) was used as the 
catalyst, NaOtBu as the base, and toluene as the solvent. Again, racemic-BINAP (F) 
gave the highest yield (up to 75%) at 125-128ºC for this reaction in our hands (Table 2). 
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Ligand R1 R2 Yield (%) 
D CH3 CH3 0 
E CH3 CH3 5 
F CH3 CH3 75 
F iBu iBu 70 
F iBu Bn 72 
 
Table 2. Optimization of the catalytic conditions for the palladium-catalyzed Caryl-N 
bond formation of compounds 9a-c and (S)-1-benzyl-2-alkylpiperazine (7a-b) giving 
compounds 10 
 
The dibenzyl protected compounds 10a-c were deprotected by Pd-C/H2 (Scheme 2) to 
afford compounds 11a-c which show good water solubility. 
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Scheme 2. 1,4-Dipiperazino-benzenes 11 
 
 
Figure 3. a) Schematic representation of an idealized ala α-helix with i, i + 3, and i + 7 
substituents; b) structure of compound 11a as HBr-salt in the solid state, determined by 
X-ray analysis; for clarity all H-atoms and Br-atoms were omitted; c) Superposition of 
the structure of compound 11a with the structure of Hamilton´s methyl substituted 
terphenyl compound;9a both structures were determined by Röntgen structure analysis 
 
The distance between the substituents [i to i+3 = 5.55 Å, i+3 to i+7 = 6.22 Å, i to i+7= 
8.89 Å] in key position were calculated from the X-ray diffraction structure (Figure 3b). 
The values are comparable with these found in an idealized alanine α-helix [i to i+3 = 
5.6 Å, i+3 to i+7 = 6.3 Å, i to i+7= 10.6 Å]. A comparison of the structure of 
compound 11a with the reported structure of Hamilton´s methyl-substitued terphenyl 
compound,9a shows a striking similarity of arrangement of the methyl substituents. 
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4.3. Concentration dependence of the circular dichroism signal and NMR 
resonances 
A circular dichroism (CD) spectra of compound 11b was measured at 21° C between 
200 and 300 nm in water (see supporting info for experimental details). The CD 
spectrum (Figure 4) shows a signal in the range of 245-255 nm arising from the 
aromatic chromophore in its chiral environment. The intensity of the CD signal depends 
on the concentration of 11b: With increasing concentration the signal intensity 
decreases, which is interpreted as an increasing aggregation of the hydrophobic helix 
parts in the polar solvent. 
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Figure 4. Concentration dependent CD spectrum of compound 11b 
 
Resonances of the 1H-NMR spectrum of compound 11b show also a dependence on the 
sample concentration. Figure 5 gives the resonance signals of the methyl protons of the 
isobutyl groups. The splitting pattern clearly changes with concentration of 11b. This 
observation confirms the suggested aggregation of 1,4-dipiperazino benzene in aqueous 
solution at concentrations higher than approx. 10 µmol/L. 
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Figure 5. Concentration dependence of the NMR-resonance signals of the isobutyl 
methyl groups of compound 10b. 
 
4.4. Conclusion 
1,4-Dipiperazino benzenes have been prepared as a new class of inherently chiral α-
helix structural mimetics. Protected piperazines as the key synthetic intermediates were 
synthezised from chiral amino acids. Subsequent copper- and  palladium-catalyzed Carly-
N coupling reactions lead to the target products in good yields. Racemic BINAP proved 
to be the best ligand for both reactions. The X-ray structure analysis of the 1,4-dipipera-
zino benzenes reveals a suitable spatial arrangement of the key substituents to act as a 
structural mimetic for α-helical structures. The compounds start to aggregate in aqueous 
solution at concentrations exceeding approx. 10 µmol/L, as indicated by CD and NMR 
measurements. If compared to previously reported α-helix mimetics, 1,4-dipiperazino 
benzenes possess chiral centers, which determine the overall chirality of the compound. 
The CD signal of the central benzene chromophor shows this induction. 1,4-
Dipiperazino benzenes allow now the investigation of the effect of the helix mimetic 
chirality on its protein binding ability. Studies in this direction are in progress. 
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4.5. Experimental section 
 
General: Melting points were determined on a melting point apparatus and are 
uncorrected. Specific rotations were measured on a polarimeter using a 10 cm cell. 
NMR spectra were recorded in CDCl3 at 300 MHz (1H) or 75 MHz (13C) unless stated 
otherwise. Structural assignments are based on DEPT and COSY experiments where 
applicable. The multiplicity of the carbon atoms are given as (+) = CH, CH3 or (-) = 
CH2 and (Cquat) for quaternary carbon atoms. Analytical TLC plates (silica gel 60 F254) 
and silica gel 60 (70-230 or 230-400 mesh) for column chromatography (CC) were 
purchased from ACROS. Spots were visualized by UV light and/or staining with 
phosphomolybdate or ninhydrin, both in ethanol. DMF, toluene, and MeOH were dried 
by standard procedures and stored over molecular sieves or Na. PE means petrol ether 
with a boiling range of 70-90ºC. All other solvents and chemicals were of reagent grade 
and used without further purification. 
 
(S)-Methyl 2-(2-chloroacetamido)propanoate (2a): 
 
 
 
To a suspension of L-alanine (26.7 g, 0.30 mol) in CH3OH (200 mL) cooled in an ice-
salt bath, SOCl2 (87.5 mL, 1.2 mol) was added drop-wise while stirring. After the 
addition the resulting mixture was stirred for an additional 6h at rt. The clear solution 
was concentrated to dryness, and without any further purification, the solid was 
dissolved in water (120 mL) and cooled in ice-salt bath. To the solution, NaHCO3 (60 g, 
0.71 mol) was added in one portion, and then the solution of chloroacetyl chloride (23.8 
mL, 0.3 mol) in benzene (100 mL) was added dropwise. After the addition, the reaction 
mixture was stirred for an additional 3h at rt. The aqueous layer was extracted twice 
with benzene (100 mL), and the combined organic phases were dried over anhydrous 
MgSO4. Subsequent filtration and removal of organic solvent in vacuo gave a crude 
product (47.95 g, 89%), which was purified by column chromatography on silica gel 
(3:1, PE: EtOAc) to give 43.0g (81%) of product as a colorless oil.  
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1HNMR (CDCl3): δ = 1.45 (d, J = 7.13 Hz, 3H), 3.77 (s, 3H), 4.06 (s, 2H), 4.60 (m, 1H), 
7.12 (b s, 1H). 
 
(S)-Methyl 2-(2-chloroacetamido)-4-methylpentanoate (2b):  
 
 
The compound was prepared by the same procedure described above. Yield: 78%, 
colorless oil.  
1HNMR (CDCl3): δ = 0.95 (d, J = 7.13 Hz, 6H), 1.57-1.78 (m, 3H), 3.77 (s, 3H), 4.06 (s, 
2H), 4.60 (m, 1H), 7.01 (bs, 1H). 
 
(S)-Methyl 2-(2-chloroacetamido)-3-phenylpropanoate (2c):  
 
Cl
N
H
O
O OMe
 
The compound was prepared by the same procedure described above. Yield: 80%, 
colorless oil. 
1HNMR (CDCl3): δ = 3.13-3.18 (dd, J = 3.89 Hz, J = 3.89Hz, 2H), 3.77 (s, 3H), 4.01 (s, 
2H), 4.83-4.91 (m, 1H), 6.94-7.02 (bs, 1H), 7.09-7.34 (m, 5H). 
13CNMR (CDCl3): δ = 37.8 (-), 42.4 (-), 52.5 (+), 53.4 (+), 127.4 (+), 128.7 (+), 129.24 
(+), 135.0 (+), 135.4 (+), 165.6 (Cquat), 171.3 (Cquat). 
 
(S)-1-Benzyl-3-methylpiperazine-2, 5-dione (3a):  
 
 
A solution of benzylamine (24.1 mL, 0.22 mol) in CH3OH (180 mL) was added 
dropwise over 1.5 h to a solution of compound 2a (32.8 g, 0.183 mol) and TEA (73.2 
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mL, 0.55 mol) in CH3OH (180 mL) and refluxed for 20h, the pale yellow solution was 
cooled to rt and concentrated, and the residue was dissolved in 150 mL CH2Cl2. The 
organic phase was washed with 100 mL of 5% aqueous citric acid, 100 mL of saturated 
aqueous NaHCO3, and 100 mL of brine, and dried over MgSO4. Subsequent filtration 
and removal of organic solvent in vacuo gave a pale yellow solid, which was 
recrystallized from toluene to give 31.1 g (78%) of compound 3a as a white solid. Mp 
138-140ºC; [α]D = -8.85º (c = 2, CHCl3); 
1HNMR (CDCl3): δ = 1.53 (d, J = 7.04 Hz, 3H), 3.83 (s, 2H), 4.16 (m, 1H), 4.60 (s, 2H), 
7.23-7.39 (m, 5H).  
 
(S)-1-Benzyl-3-isobutylpiperazine-2, 5-dione (3b):  
 
N
H
O
Bn
N O
 
The compound was prepared by the same procedure described above. Yield: 70%, white 
crystalline solid.  
1HNMR (CDCl3): δ = 0.96 (d, J = 6.31 Hz, 3H), 0.98 (d, J = 6.31 Hz, 3H), 1.57-1.86 (m, 
3H), 3.83 (m, 2H), 4.16 (m, 1H), 4.63 (d, J = 14.82 Hz, 1H), 4.64 (d, J = 14.82Hz, 1H), 
7.20-7.39 (m, 5H).  
 
(S)-1, 3-Dibenzylpiperazine-2, 5-dione (3c):  
 
N
H
O
Bn
N O
 
The compound was prepared by the same procedure described above. Yield: 65%, white 
crystalline solid.  
1HNMR (CDCl3): δ = 2.89 (d, J = 17.59 Hz, 1H), 3.12 (d, J = 4.52 Hz, 1H), 3.15 (d, J = 
4.52 Hz, 1H), 3.23 (d, J = 6.18 Hz, 1H), 3.25 (d, J = 6.18 Hz, 1H), 3.48 (d, J = 17.59 Hz, 
1H), 4.40 (m, 1H), 4.60 (s, 2H), 7.13-7.39 (m, 10H). 
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13CNMR (CDCl3): δ = 40.9 (-), 48.4 (-), 49.7 (-), 56.5 (+), 127.5 (+), 128.1 (+), 128.7 
(+), 128.9 (+), 130.1 (+), 134.8 (Cquat), 134.9 (Cquat), 165.3 (Cquat), 166.3 (Cquat). 
MS [CI-MS; NH3] = 312.2 [M-NH4+] (100), 295.1 [M-H+] (20). 
 
(S)-1-Benzyl-3-methylpiperazine (4a):  
 
N
H
Bn
N
 
A solution of diketopiperazine, 3a (11.5 mmol) in THF (25 mL) was added dropwise to 
the refluxing mixture of LiAlH4 (52 mmol) in THF (50 mL). The mixture was refluxed 
for 3h, and then stirred overnight at rt. The mixture was quenched with saturated MgSO4 
solution, and the aluminate salts were filtered. The salts were extracted several times 
with ether. The combined organic layers were concentrated to afford the crude 
piperazine as oil. Yield: 86%. 
1HNMR (CDCl3): δ = 1.00 (d, J = 6.20 Hz, 3H), 1.66 (m, 1H), 1.95-2.05 (m, 1H), 2.74-
2.94 (m, 5H), 3.48 (s, 2H), 7.24-7.33 (m, 5H). 
 
(S)-1-Benzyl-3-isobutylpiperazine (4b):  
 
 
The compound was prepared by the same procedure described above. Yield: 72%, 
colorless oil, becomes solid on standing. 
1HNMR (CDCl3): δ = 0.86 (d, J = 4.94 Hz, 3H), 0.88 (d, J = 4.94 Hz, 3H), 1.05-1.28 (m, 
2H), 1.57-1.73 (m, 2H), 1.95-1.97 (dt, J = 4.12 Hz, J = 10.70 Hz, 1H), 2.70-2.98 (m, 
5H), 3.50 (q, J = 7.96 Hz, 2H), 7.21-7.33 (m, 5H). 
 13CNMR (CDCl3): δ = 22.4 (+), 23.3 (+), 24.3 (+), 43.8 (-), 45.9 (-), 52.8 (+), 54.0 (-), 
60.6 (-), 63.4 (-), 127.0 (+), 128.2 (+), 129.0 (+), 129.3 (+), 138.1 (Cquat). MS [CI-MS; 
NH3] = 233.2 [M-H+] (100). 
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(S)-1, 3-Dibenzylpiperazine (4c):  
 
 
The compound was prepared by the same procedure described above. Yield: 70%, 
colorless oil, become solid upon standing. 
1HNMR (CDCl3): δ = 2.89 (d, J = 17.59 Hz, 1H), 3.12 (d, J = 4.52 Hz, 1H), 3.15 (d, J = 
4.52 Hz, 1H), 3.23 (d, J = 6.18 Hz, 1H), 3.25 (d, J = 6.18 Hz, 1H), 3.48 (d, J = 17.59 Hz, 
1H), 4.40 (m, 1H), 4.60 (s, 2H), 7.13-7.39 (m, 10H). 
13CNMR (CDCl3): δ = 40.9 (-), 48.4 (-), 49.7 (-), 56.5 (+), 127.5 (+), 128.1 (+), 128.7 
(+), 128.9 (+), 130.1 (+), 134.8 (Cquat), 134.9 (Cquat), 165.3 (Cquat), 166.3 (Cquat). 
MS [CI-MS; NH3] = 312.2 [M-NH4+] (100), 295.1 [M-H+] (20). 
 
(S)-tert-Butyl 4-benzyl-3-methylpiperazine-1-caboxylate (6a):  
 
N
Bn
Boc
N
 
A mixture of compound 4a (9.51 g, 0.05 mol), 10% palladium on carbon (1.2 g) and 
CH3COOH (0.5 mL) in CH3OH (100 mL) was stirred under 5 atm of H2 at rt for 24h. 
The catalyst was removed by filtration and washed with CH3OH. The combined filtrate 
was concentrated to afford 5a as colorless solid, with 99% of yield.  
Without any further purification the solid 5a (49.9 mmol) was dissolved in 44 g 1-
butanol (0.05 wt. % H2O content), cooled to 0ºC. To this solution (Boc)2O (50 mmol) in 
10 mL of 1-butanol was added dropwise. The reaction mixture was stirred for 2h at 0-
5ºC and 12h at rt. 1-Butanol was removed by vacuo to afford crude oil which was dried 
in high vacuum overnight. The crude product was dissolved in 15 mL dry CH3CN. 
Benzyl bromide (45 mmol) and K2CO3 (10g) were added, and the reaction mixture was 
stirred at room temperature for 4h. After consumption of all starting material, the 
reaction mixture was quenched by 50 mL of water, and the product was extracted with 
ethyl acetate (3x 30 mL). The organic phase was dried over NaSO4 and the solvent was 
removed in vacuo. The product was purified by column chromatography, eluting with 
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petrol ether and ethyl acetate (4:1) to afford 6a as colorless oil. Overall two steps yield 
was 89%. 
1HNMR (CDCl3): δ = 1.13 (d, J = 6.31 Hz, 3H), 1.45 (s, 9H), 2.07 (m, 1H), 2.44(m, 
1H), 2.61-2.67 (m, 1H), 2.78-2.95 (m, 1H), 3.02-3.21 (m, 2H), 3.16-3.80 (m, 2H), 7.23-
7.36 (m, 5H). 
 
(S)-1-Benzyl-2methylpiperazine (7a) 
N
Bn
H
N
 
 
The compound 6a (1g) was dissolved in 20 mL of CH2Cl2 and HCl saturated ether (10 
mL) and reaction mixture was stirred until all the starting material consumed (checked 
by TLC). After completion of the reaction, solvent was removed in vacuo to afford the 
product as HCl-salt. Then the product was passed through strongly basic ion-exchange 
column to give pure product as light yellow oil quantitatively. 
 
General Procedure for Cu (I) mediated C-N Coupling: 
 
  An oven dried schlenk flask was charged with CuBr.Me2S (41 mg, 0.2 mmol) and then 
it was preheated at 50-60ºC under high vacuum for the removal of complexed Me2S. It 
was backfilled with nitrogen, then 1,1’-binaphthyl-2,2’-diol (57 mg, 0.2 mmol), Cs2CO3 
(424 mg, 2 mmol), and amine (1.5 mmol) were added to the flask. Aryl halide (1 mmol) 
liquid and DMF (1 mL) were added to the flask under nitrogen atmosphere. The mixture 
was allowed to stir under nitrogen atmosphere at the rt for 24h. After completion of the 
reaction, the mixture was diluted with diethyl ether and the solution filtered to remove 
insoluable inorganic salts. Removal of the solvent at rotary evaporator, followed by 
column chromatography on silica gel, using petroleum ether/diethylether (60:1 to 4:1) as 
eluent was afforded the desired product. 
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(S)-4-Benzyl-1-(4-bromo-3-methylphenyl)-2-methylpiperazine (9a):  
 
 
 
1HNMR (CDCl3) δ: 1.08 (d, J = 6.60 Hz, 3H), 2.33 (s, 3H), 2.31-2.37 (dd, J = 3.81, J = 
3.96 Hz, 1H), 2.45-2.48 (dd, J = 3.81, J = 3.96 Hz, 1H), 2.60-2.63 (dd, J = 1.75, J = 1.75 
Hz, 1H), 2.81-2.83 (m, 1H), 3.10-3.21 (m, 2H), 3.48 (d, J = 13.20 Hz, 1H), 3.59 (d, J = 
13.20 Hz, 1H), 3.75-3.86 (m, 1H), 6.60-6.62 (dd, J = 3.23, J = 3.23 Hz, 1H), 6.77 (d, J = 
3.23 Hz, 1H), 7.24-7.42 (m, 6H). 
13CNMR (CDCl3) δ: 13.2 (+), 23.3 (+), 44.6 (-), 51.2 (+), 53.4 (-), 58.6 (-), 62.8 (-), 
114.1 (+), 116.0 (+), 119.3 (+), 127.0 (+), 128.2 (+), 128.8 (+), 132.5 (+), 138.1 (+), 
138.5 (+), 149.6 (Cquat). - MS [CI-MS; (NH3)] = 359.1, 361.1 [M-H+] (100), 281.3 [M-
Br+] (15). 
 
(S)-4-Benzyl-1-(4-bromo-3-methylphenyl)-2-isobutylpiperazine (9b): 
 
N
N
Bn
Br
 
 
1HNMR (CDCl3) δ: 0.81 (d, J = 6.58 Hz, 3H), 0.83 (d, J = 6.58 Hz, 3H), 1.04-1.08 (m, 
1H), 1.31-1.37 (m, 1H), 1.90-1.94 (m, 1H), 2.24-2.32 (m, 2H), 2.33 (s, 3H), 2.75-2.78 
(dt, J = 11.18, J = 2.19 Hz, 1H), 2.87-2.88 (dq, J = 11.18, J = 2.19 Hz, 1H), 3.12-3.14 
(dt, J = 11.61, J = 3.28 Hz, 1H), 3.22-3.24 (td, J = 3.28, J = 11.61 Hz, 1H), 3.41 (d, J = 
13.37 Hz, 1H), 3.63 (d, J = 13.37 Hz, 1H), 3.70-3.74 (m, 1H), 6.56 (dd, J = 2.85, J = 
2.63 Hz, 1H), 6.70 (d, J = 2.65 Hz, 1H), 7.24-7.37 (m, 6H). 
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13CNMR (CDCl3) δ: 21.5 (+), 23.6 (+), 23.8 (+), 25.1 (+), 35.2 (-), 43.4 (-), 53.3 (+), 
53.8 (-), 54.8 (-), 62.8 (-), 112.9 (+), 114.8 (+), 117.9 (+), 127.0 (+), 128.2 (+), 128.8 
(+), 132.5 (+), 138.0 (+), 138.6 (+), 149.2 (Cquat). - MS [CI-MS; (NH3)] = 401.1, 403.1 
[M-H+] (100), 323.2 [M-Br+] (15). 
 
(S)-2, 4-Dibenzyl-1-(4-bromo-3-methylphenyl) piperazine (9c): 
 
N
N
Bn
Br
 
 
1HNMR (CDCl3) δ: 2.13 (dd, J = 11.26, J = 3.07 Hz, 1H), 2.30 (dt, J = 11.26, J = 3.58 
Hz, 1H), 2.39 (s, 3H), 2.50 (dd, J = 12.80, J = 2.30 Hz, 1H), 2.87-2.88 (dq, J = 11.18, J 
= 2.19 Hz, 1H), 3.12-3.14 (dt, J = 11.61, J = 3.28 Hz, 1H), 3.22-3.24 (td, J = 3.28, J = 
11.61 Hz, 1H), 3.41 (d, J = 13.37 Hz, 1H), 3.63 (d, J = 13.37 Hz, 1H), 3.70-3.74 (m, 
1H), 6.56 (dd, J = 2.85, J = 2.63 Hz, 1H), 6.70 (d, J = 2.65 Hz, 1H), 7.24-7.37 (m, 6H). 
13CNMR (CDCl3) δ: 21.5 (+), 23.6 (+), 23.8 (+), 25.1 (+), 35.2 (-), 43.4 (-), 53.3 (+), 
53.8 (-), 54.8 (-), 62.8 (-), 112.9 (+), 114.8 (+), 117.9 (+), 127.0 (+), 128.2 (+), 128.8 
(+), 132.5 (+), 138.0 (+), 138.6 (+), 149.2 (Cquat). - MS [CI-MS; (NH3)] = 401.1, 403.1 
[M-H+] (100), 323.2 [M-Br+] (15). 
 
General Procedure for Pd (0) mediated C-N Coupling: 
 
An ovendried Schlenk flask was charged with the aryl iodide (0.5 mmol), amine (0.6 
mmol), NaO-tBu (67 mg, 0.7 mmol), Pd2(dba)3.CHCl3 (2.3 mg, 0.0025 mmol, 1 mol % 
of Pd), BINAP (4.7 mg, 0.0075 mmol) and purged with argon. Toluene (1 mL) was 
added, and the reaction mixture was heated at 120-125ºC under argon for 8h until the 
reaction had proceeded to completion as judged by GC or TLC analysis. The reaction 
mixture was taken up in ethyl acetate (20 mL), filtered, and concentrated in vacuo. The 
crude product was then purified by flash chromatography on silica gel. 
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(S)-1-Benzyl-4-(4-((S)-4-benzyl-2-methylpiperazine-1-yl)-2-methylphenyl)-2-
methylpiperazine (10a) 
 
 
1HNMR (CDCl3) δ: 1.05 (d, J = 6.46 Hz, 3H), 1.24 (d, J = 5.72 Hz, 3H), 2.30 (s, 3H), 
2.34-2.40 (m, 1H), 2.45-2.51 (m, 2H), 2.57-2.61 (m, 1H), 2.63-2.76 (m, 3H), 2.78-2.84 
(m, 2H), 2.87-2.91 (m, 1H), 2.95-2.98 (m, 1H), 3.11-3.14 (m, 2H), 3.29 (d, J = 13.05 
Hz, 1H), 3.51 (d, J = 13.05 Hz, 1H), 3.61 (d, J = 13.05 Hz, 1H), 3.63-3.67 (m, 1H), 4.11 
(d, J = 13.05 Hz, 1H),  6.77-6.79 (dd, J = 8.51 Hz, J = 2.64 Hz, 1H), 6.83 (d, J = 2.64 
Hz, 1H), 6.97 (d, J = 8.51 Hz, 1H), 7.26-7.41 (m, 10H). 
13CNMR (CDCl3) δ: 14.1 (+), 18.0 (+), 47.2 (-), 51.5 (-), 52.0 (+), 52.4 (-), 53.7 (-), 55.7 
(+), 58.2 (-), 59.3 (-), 59.6 (-), 62.9 (-), 116.6 (+), 119.6 (+), 121.5 (+), 126.8 (+), 126.9 
(+), 128.2 (+), 128.9 (+), 129.1 (+), 133.4 (+), 138.5 (Cquat), 139.0 (Cquat), 145.0 (Cquat), 
146.2 (Cquat). - MS [CI-MS; (NH3)] =   469.2 [M-H+] (100). 
 
(S)-1-Benzyl-4-(4-((S)-4-benzyl-2-isobutylpiperazine-1-yl)-2-methylphenyl)-2-
isobutylpiperazine (10b) 
 
N
N
Bn
N
Bn
N
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1HNMR (CDCl3) δ: 0.80-0.84 (dd, J = 6.74, J = 13.59 Hz, 6H), 0.89-0.96 (dd, J = 6.724, 
J = 21.04 Hz, 6H), 1.07-1.13 (m, 1H), 1.33-1.40 (m, 1H), 1.57-1.67 (m, 2H), 1.81-1.87 
(m, 1H), 2.26 (s, 3H), 2.32-2.41 (m, 3H), 2.58-2.65 (m, 2H), 2.67-2.74 (m, 1H), 2.75-
2.86 (m, 4H), 3.03 (d, J = 9.10 Hz, 1H), 3.10-3.17 (m, 1H), 3.18-3.22 (m, 1H), 3.28 (d, J 
= 12.55 Hz, 1H), 3.42 (d, J = 12.55 Hz, 1H), 3.61-3.67 (m, 3H),  4.07 (d, J = 13.01 Hz, 
1H), 6.65-6.69 (dd, J = 8.60 Hz, J = 2.68 Hz, 1H), 6.72 (d, J = 2.68 Hz, 1H), 6.94 (d, J = 
8.60 Hz, 1H), 7.23-7.40 (m, 10H). 
13CNMR (CDCl3) δ: 18.1 (+), 21.5 (+), 22.2 (+), 23.8 (+), 23.9 (+), 25.1 (+), 25.9 (+), 
35.3 (-), 38.3 (-), 44.8 (-), 51.0 (-), 51.9 (-), 53.6 (+), 54.1 (-), 55.4 (-), 57.2 (+), 58.0 (-), 
58.9 (-), 114.4 (+), 119.2 (+), 119.8 (+), 126.7 (+), 126.9 (+), 128.1 (+), 128.2 (+), 128.8 
(+), 129.0 (+), 133.4 (+), 133.5 (Cquat), 138.6 (+), 139.4 (Cquat), 143.9 (Cquat), 145.9 
(Cquat). – HRMS (EI-MS) calculated for C37H52N4 [M.+]: 552.4192; found 552.4182. 
 
(S)-1, 2-Dibenzyl-4-(4-((S)-4-benzyl-2-isobutylpiperazine-1-yl)-2-methylphenyl) 
piperazine (10c) 
N
N
Bn
N
Bn
N
 
 
1HNMR (CDCl3) δ: 0.92-0.96 (dd, J = 22.14, J = 6.14 Hz, 6H), 1.12-1.19 (m, 1H), 1.52-
1.73 (m, 3H), 2.17-2.19 (dd, J = 11.18, J = 2.85 Hz, 1H), 2.31 (m, 4H), 2.38-2.43 (m, 
1H), 2.63-2.67 (m, 2H), 2.71-2.73 (dt, J = 11.18, J = 1.32 Hz, 1H), 2.81-2.89 (d, J = 
11.18 Hz, 1H), 2.96 (d, J = 8.55 Hz, 1H), 3.19 (t, J = 11.83 Hz, 1H), 3.19-3.32 (m, 3H), 
3.40 (d, J = 14.03 Hz, 1H), 3.59 (d, J = 14.03 Hz, 1H), 3.78-3.81 (dd, J = 10.74, J = 2.41 
Hz, 1H), 4.09 (d, J = 11.83 Hz, 1H), 6.77-6.80 (dd, J = 2.63, J = 8.55 Hz, 1H), 6.82 (d, J 
= 2.41 Hz, 1H), 6.95-6.97 (m, 2H), 7.03 (d, J = 8.55 Hz, 1H), 7.10-7.25 (m, 3H), 7.25-
7.42 (m, 10H). 
13CNMR (CDCl3) δ: 18.2 (+), 22.2 (+), 23.9 (+), 25.8 (+), 32.3 (-), 38.5 (-), 43.9 (-), 
51.2 (-), 51.9 (+), 53.5 (-), 53.8 (-), 57.26 (+), 58.0 (-), 58.8 (-), 63.0 (-), 113.3 (+), 114.1 
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(+), 117.1 (+), 118.8 (+), 120.1 (+), 125.7 (+), 126.8 (+), 127.1 (+), 128.2 (+), 129.0 (+), 
129.3 (+), 129.4 (+), 133.8 (+), 138.5 (Cquat), 139.5 (Cquat), 140.3 (Cquat), 144.0 (Cquat), 
145.6 (Cquat). - MS [CI-MS; (NH3)] =   587.2 [M-H+] (100). 
 
General procedure for benzyl deprotection reaction: 
A mixture of dibenzyl protected compound (0.05 mmol), 10% palladium on carbon (20 
mol% ) and CH3COOH (2 drops) in CH3OH (3 mL) was stirred under 15 atm of H2 at rt 
for 24 h. After completion of the reaction the solution was passed over celite to remove 
the catalyst and washed several times with CH3OH. The combined filtrate was 
concentrated to give a hygroscopic solid in quantitative yield 
 
(S)-2-isobutyl-1-(4-((S)-3-isobutylpiperazine-1-yl)-3-methylphenyl) piperazine 
(11b) 
N
N
H
N
H
N
 
 
1HNMR (D2O) δ: 0.66-0.68 (dd, J = 2.74, J = 6.31 Hz, 6H), 0.81-0.84 (dd, J = 2.19, J = 
6.31 Hz, 6H), 1.02-1.14 (m, 1H), 1.27-1.62 (m, 5H), 2.19 (s, 3H), 2.23-2.71 (m, 1H), 
2.28-2.94 (m, 1H), 3.10-3.49 (m, 10H), 3.68 (m, 1H), 6.85-7.00 (m, 3H). 
 
Circular dichroism measurements. 
Measurements were performed on a Jasco J-710 spectrometer. The length of the 
cylindrical cuvettes was 1 cm. The resolution was 0.2 nm, the band width 1.0 nm, the 
sensitivity 20 mdeg, the response 0.25 s, and the speed 20 nm/min. The background was 
subtracted to each spectrum. The absorption values were measured as molar ellipticity 
per residue (deg cm2 dmol-1). 
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5.1. X-ray diffraction structure 
 
 
 
 
  
Crystal Data: 
    
   
Empirical formula;  C23H26BrNO5  
Formula weight;  476.35  
Crystal size; 0.48 x 0.19 x 0.11 mm  
Crystal description;  prism  
Crystal colour;   colourless  
Crystal system;    Monoclinic  
Space group; C c  
Unit cell dimensions              a = 15.5362(9) Å    α = 90º  
                                        b = 13.2881(12) Å                   β = 102.158 (7)º 
                                         c = 22.1144(13) Å                    γ = 90º.  
Volume  4463.0(6) Å3  
Z, Calculated density  8, 1.418 Mg/m3  
Absorption coefficient  1.875 mm-1  
F(000) 1968 
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Crystal Data  
   
Empirical formula C20H27BrN2O6  
Formula weight 471.34  
Crystal size 0.270 x 0.140 x 0.140 mm  
Crystal description needle  
Crystal colour colourless  
Crystal system Monoclinic  
Space group P 21  
Unit cell dimensions               a = 10.7776(14) Å     α = 90º 
                                         b = 6.1129(13) Å      β = 91.201(13)º 
                                         c = 16.069(3) Å     γ = 90º 
Volume 1058.4(3) Å3  
Z, Calculated density 2, 1.456 Mg/m3  
Absorption coefficient 2.937 mm-1  
F (000) 488  
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  Crystal Data  
   
Empirical formula C20H27BrN2O6  
Formula weight 471.34  
Crystal size 0.340 x 0.085 x 0.024 mm  
Crystal description thin plate  
Crystal colour colourless  
Crystal system Monoclinic  
Space group P 21  
Unit cell dimensions              a = 10.7567(4) Å     α = 90º 
                                         b = 6.1367(3) Å      β = 102.512(3)º 
                                         c = 16.4151(6) Å     γ = 90º 
Volume 1057.84(8) Å3  
Z, Calculated density 2, 1.477 Mg/m3  
Absorption coefficient 1.981 mm-1  
F(000) 486  
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Crystal Data  
   
Empirical formula C26H32BrN3O5  
Formula weight 546.45  
Crystal size 0.420 x 0.250 x 0.010 mm  
Crystal description flat needle  
Crystal colour colourless  
Crystal system Orthorhombic  
Space group P 21 21 21  
Unit cell dimensions               a = 5.97218(14) Å    α = 90º 
                                         b = 10.8774(3) Å      β = 90º 
                                         c = 38.7354(11) Å     γ = 90º 
Volume 2516.32(12) Å3  
Z, Calculated density 4, 1.442 Mg/m3  
Absorption coefficient 2.575 mm-1  
F(000) 1136   
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Crystal Data  
   
Empirical formula  C25H29BrN4O5  
Formula weight  545.42  
Crystal size  0.480 x 0.040 x 0.010 mm  
Crystal description  needle  
Crystal colour  colourless  
Crystal system Orthorhombic  
Space group  P 21 21 21  
Unit cell dimensions               a = 5.71880(10) Å     α = 90º 
                                         b = 15.9547(2) Å     β = 90º 
                                         c = 27.6460(4) Å     γ = 90º 
Volume  2522.47(7)Å3  
Z, Calculated density  4, 1.436 Mg/m3  
Absorption coefficient  2.581 mm-1  
F(000)  1128 
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Crystal Data  
   
Empirical formula C30H33NO5  
Formula weight 487.57  
Crystal size 0.410 x 0.060 x 0.020 mm  
Crystal description flat needle  
Crystal colour colourless  
Crystal system Monoclinic  
Space group P 21/c  
Unit cell dimensions               a = 5.88530(10) Å     α = 90º 
                                         b = 20.9715(3) Å      β = 91.4300(10)º 
                                         c = 20.6745(3) Å     γ = 90º 
Volume 2550.93(7) Å3  
Z, Calculated density 4, 1.270 Mg/m3  
Absorption coefficient 0.692 mm-1  
F(000) 1040 
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Crystal Data   
   
Empirical formula C22H29BrN2  
Formula weight 401.37  
Crystal size 0.310 x 0.160 x 0.080 mm  
Crystal description  flat rod  
Crystal colour  colourless  
Crystal system Monoclinic  
Space group  P 21  
Unit cell dimensions               a = 9.3190(3) Å     α = 90º 
                                         b = 5.5464(2) Å      β = 96.756(2)º 
                                         c = 19.6979(4) Å     γ = 90º 
Volume  1011.05(5) Å^3  
Z, Calculated density  2, 1.318 Mg/m3  
Absorption coefficient  2.798 mm-1  
F(000)  420  
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5.2. Abbreviations 
 
 
abs. Absolute 
AcOH   Acetic acid   
Ac2O Acetic anhydride 
Acnc 1-aminocycloalkanecarboxylic acid 
Ac3c 1-aminocyclopropanecarboxylic acid 
Ac4c 1-aminocyclobutanecarboxylic acid 
Ac5c 1-aminocyclopentanecarboxylic acid 
Ac6c 1-aminocyclohexanecarboxylic acid 
Ac7c 1-aminocycloheptanecarboxylic acid 
Ac8c 1-aminocyclooctanecarboxylic acid 
Ac9c 1-aminocyclononanecarboxylic acid 
Ar   Aromatic  
atm Atmosphere 
Bn Benzyl 
Boc tert-Butoxycarbonyl 
Bz Benzyl 
iBu Isobutyle 
BuLi Butyl lithium 
c Concentration 
cat. Catalyst 
Cbz Carbobenzyloxy 
CD Circulardichroismus 
d Day 
c3Arg 1-amino-2-(2-guanidinoethyl)cyclopropane-1,2-dicarboxylic acid 
c3Asp 1-aminocyclopropane-1,2-dicarboxylic acid 
c3Leu   1-amino-2-isopropylcyclopropanecarboxylic acid 
c3Met   1-amino-2-methylthiomethylcyclopropanecarboxylic acid 
c3Phe   1-amino-2-phenylcyclopropanecarboxylic acid 
c6Phe   1-amino-2-phenylcyclohexanecarboxylic acid 
DCC   Dicyclohexylcarbodiimide 
DCM Dichloromethane 
DIPEA (N,N)-Diisopropyleethylamine 
DMAP Dimethylaminopyridine 
DMF N,N-Dimethylformamide 
DMSO Dimethylsulfoxide 
dr Diatereomeric ratio 
ee Enantomeric excess 
EDC N-(3-Dimethylaminopropyl)-N’-ethyl carbodiimide 
EI Electron impact (MS) 
eq Equivalent 
ESI Electrosprayionisation 
EtOH Ethanol 
EtOAc Ethylacetate 
FAB Fast Atom Bombardement 
Gly Glycine 
h Hour(s) 
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HATU 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluro phosphate 
HOAt 1-Hydroxy-7-azabenzotriazole 
HOBt 1-Hydroxybenzotriazole 
HOPAS Hydroxypyrrole amino acid (5-Aminomethyl-3-methoxy-4-
methyl-1H-pyrrole-2-carboxylic acid) 
HPLC High pressure liquid chromatography 
HRMS High resolution mass spectrum 
Ile Isoleucine (L-Isileucine) 
IR Infrared (spectrum) 
J Coupling constant 
Leu Leucine (L-Leucine) 
LAH Lithium aluminium hydride 
LDA Lithium diisopropyle amine 
M Moleculeion 
Me Methyl 
min. Minute(s) 
MS Mass spectrum 
MeOH Methanol 
NMR Nuclear magnetic resonance 
NOE Nuclear overhauser effect 
PE Petrole ethers 40/60 
PG Protecting group 
Ph Phenyl 
Phe Phenylalanine (L-Phenylalanine) 
Pro Proline (L-Proline) 
quant.  Quantitative 
ROESY Rotating frame nuclear overhauser enhanced spectroscopy 
rt Room temperature 
TBAF Tetrabutyl ammonium fluoride 
TFA Trifluroacetic acid 
UV Ultraviolate 
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